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ABSTRACT	  
Background:	  Soy	  isoflavones	  have	  been	  hypothesized	  to	  affect	  gene	  expression	  related	  
to	  prostate	  cancer	  development	  and	  progression,	  yet	  few	  studies	  have	  evaluated	  the	  
effect	  of	  this	  phytochemical	  on	  the	  transcriptome	  of	  prostate	  cancer	  cells	  in	  a	  human	  
model.	  
Objective:	  To	  determine	  if	  short-­‐term	  soy	  isoflavone	  supplementation	  influences	  gene	  
expression	  in	  men	  with	  localized	  prostate	  cancer.	  
Methods:	  Six	  men	  diagnosed	  with	  clinically	  localized	  prostate	  cancer	  were	  asked	  to	  take	  
a	  soy	  isoflavone	  supplement	  for	  up	  to	  6	  weeks	  prior	  to	  radical	  prostatectomy.	  Total	  RNA	  
was	  isolated	  and	  sequenced	  from	  tumor	  and	  adjacent	  normal	  frozen	  prostate	  tissue	  
pairs	  obtained	  from	  these	  participants.	  Gene	  expression	  profiles	  were	  determined,	  
differentially	  expressed	  genes	  were	  identified,	  and	  gene	  expression	  profiles	  were	  
mapped	  to	  molecular	  pathways	  for	  biological	  interpretation	  using	  Ingenuity	  Pathway	  
Analysis	  software	  (Ingenuity	  Systems®,	  www.ingenuity.com).	  The	  trimmed	  mean	  of	  the	  
M	  values	  method	  (TMM,	  where	  M=log2	  fold	  change)	  was	  used	  to	  calculate	  the	  
normalization	  factor.	  Quantile-­‐adjusted	  conditional	  maximum	  likelihood	  (qCML)	  method	  
was	  used	  to	  estimate	  common	  dispersion	  across	  all	  genes.	  Exact	  test	  with	  a	  negative	  
binomial	  distribution	  was	  used	  to	  calculate	  expression	  differences	  between	  groups.	  
Multiple	  test	  adjustments	  were	  carried	  out	  using	  the	  false	  discovery	  rate	  (FDR)	  using	  
Benjamini	  and	  Hochberg’s	  method.	  An	  FDR	  value	  of	  <	  0.05	  was	  considered	  statistically	  
significant.	  
	   iv	  
Results:	  All	  6	  men	  were	  included	  in	  the	  final	  analysis.	  Soy	  isoflavones	  differentially	  
expressed	  128	  genes	  in	  cancerous	  prostate	  tissue	  and	  166	  genes	  in	  normal	  prostate	  
tissue.	  Twenty	  genes	  were	  differentially	  expressed	  in	  both	  tissues,	  2	  of	  which	  were	  
differentially	  regulated	  in	  either	  tissue.	  Some	  pathways	  suggested	  a	  protective	  effect	  
(human	  embryonic	  stem	  cell	  pluripotency,	  complement	  system,	  protein	  citrullination,	  
and	  methylglyoxal	  degradation	  VI	  pathways),	  while	  others	  suggested	  harm	  (intrinsic	  and	  
extrinsic	  prothrombing	  activation	  and	  IL-­‐17A	  pathways).	  The	  following	  pathways	  were	  of	  
unknown	  relevance:	  acute	  phase	  response	  signaling,	  UDP-­‐glucuronosyltransferase,	  and	  
glutamate-­‐dependent	  acid	  resistance	  pathways.	  
Conclusion:	  Short-­‐term	  soy	  isoflavone	  supplementation	  prior	  to	  curative	  treatment	  for	  
localized	  prostate	  cancer	  was	  found	  to	  significantly	  affect	  gene	  expression	  in	  tumor	  and	  
adjacent	  normal	  tissues.	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CHATPER	  I:	  INTRODUCTION	  
	   Prostate	  cancer	  remains	  the	  most	  commonly	  diagnosed	  non-­‐cutaneous	  cancer	  
and	  the	  second	  leading	  cause	  of	  cancer	  deaths	  in	  American	  men	  (1).	  In	  2013,	  an	  
estimated	  238,590	  American	  men	  will	  receive	  a	  prostate	  cancer	  diagnosis,	  while	  
approximately	  29,720	  American	  men	  will	  die	  from	  the	  disease	  (1).	  Global	  incidence	  data	  
indicates	  that	  the	  highest	  rates	  of	  prostate	  cancer	  occur	  in	  North	  America,	  Australia,	  and	  
Northern	  and	  Western	  Europe,	  while	  the	  lowest	  rates	  occur	  in	  Asia	  and	  North	  Africa	  (2).	  
Although	  increased	  screening	  and	  health	  care	  differences	  likely	  contribute	  to	  this	  
discrepancy,	  it	  is	  possible	  that	  the	  difference	  in	  incidence	  relates	  to	  diet	  and	  lifestyle.	  
Population	  migration	  studies	  have	  shown	  that	  prostate	  cancer	  incidence	  increases	  
among	  Asian	  men	  who	  adopt	  Western	  diet	  and	  lifestyle	  patterns	  after	  relocating	  to	  
Western	  countries	  (3).	  Furthermore,	  population	  studies	  have	  shown	  that	  prostate	  
cancer	  incidence	  increases	  among	  men	  who	  adopt	  Western	  diet	  and	  lifestyle	  patterns	  
while	  in	  their	  home	  countries	  (3).	  Traditional	  Asian	  diet	  patterns	  are	  typically	  plant-­‐
based	  and	  include	  many	  foods	  found	  to	  contain	  phytochemicals,	  which	  are	  bioactive	  
compounds	  thought	  to	  play	  a	  role	  in	  cancer	  prevention.	  For	  example,	  soybeans,	  which	  
represent	  a	  major	  protein	  source	  in	  traditional	  Asian	  diets,	  contain	  bioactive	  
phytochemicals	  collectively	  referred	  to	  as	  isoflavones.	  Replacing	  the	  animal	  proteins	  
emphasized	  in	  Western	  diets	  with	  this	  plant-­‐based	  protein	  may	  explain	  the	  difference	  in	  
prostate	  cancer	  rates	  between	  Asian	  and	  Western	  countries.	  	  	  
	   The	  mechanisms	  through	  which	  soy	  isoflavones	  act	  to	  affect	  the	  development	  
and	  progression	  of	  prostate	  cancer	  have	  been	  of	  recent	  interest.	  Evidence	  from	  cell	  line	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and	  animal	  studies	  suggests	  that	  soy	  isoflavones	  can	  affect	  pathways	  associated	  with	  
cell	  growth,	  cell	  cycle	  progression,	  and	  apoptosis	  (4).	  Soy	  isoflavone	  supplementation	  in	  
both	  animal	  and	  human	  models	  seems	  to	  reduce	  the	  risk	  of	  developing	  prostate	  cancer	  
(4);	  however,	  the	  precise	  mechanism(s)	  that	  mitigate	  this	  risk	  have	  yet	  to	  be	  
determined.	  It	  is	  thought	  that	  soy	  isoflavones	  affect	  the	  transcription	  of	  certain	  genes	  as	  
well	  as	  the	  expression	  of	  proteins	  implicated	  in	  prostate	  cancer	  development	  and	  
progression	  (5,6).	  
	   The	  increasing	  use	  of	  and	  continued	  improvements	  in	  high-­‐throughput	  analysis	  
techniques,	  such	  as	  DNA	  microarrays	  and	  massively	  parallel	  next-­‐generation	  sequencing	  
(NGS),	  have	  facilitated	  the	  rapid	  discovery	  of	  many	  oncogenes	  and	  tumor	  suppressor	  
genes	  (7).	  These	  technologies	  have	  allowed	  scientists	  to	  characterize	  cancerous	  tissues,	  
identify	  differential	  gene	  expression	  between	  cancerous	  and	  normal	  tissues,	  investigate	  
the	  effects	  of	  potential	  therapies,	  and	  contribute	  to	  a	  more	  thorough	  understanding	  of	  
the	  interactions	  among	  the	  genome,	  epigenome,	  transcriptome,	  proteome,	  and	  
metabolome	  within	  the	  context	  of	  prostate	  cancer.	  NGS	  technologies	  could	  not	  only	  
help	  identify	  and	  develop	  effective	  prostate	  cancer	  treatments,	  but	  could	  also	  help	  
elucidate	  the	  potential	  chemopreventative	  effects	  of	  dietary	  components	  such	  as	  soy	  
isoflavones.	  
	  
Statement	  of	  purpose	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   Applying	  NGS	  technology	  to	  tissue	  samples	  inherited	  from	  a	  previous	  study,	  the	  
present	  study	  will	  investigate	  the	  following	  question:	  Does	  short-­‐term	  soy	  isoflavone	  
supplementation	  influence	  gene	  expression	  in	  men	  with	  localized	  prostate	  cancer?	  
	  
Objectives	  
This	  exploratory	  project	  seeks	  to	  characterize	  RNA	  sequencing	  data	  derived	  from	  
the	  NGS	  analysis	  of	  prostate	  tissue	  exposed	  to	  soy	  isoflavones	  or	  placebo	  and	  obtain	  
preliminary	  data	  for	  future	  studies.	  The	  research	  question	  will	  be	  investigated	  by	  
addressing	  the	  following	  specific	  aims:	  
	  
1. To	  identify	  the	  effect(s)	  of	  soy	  isoflavones	  on	  prostate	  cancer	  by	  comparing	  gene	  
transcripts	  found	  in	  cancerous	  prostate	  tissues	  of	  men	  supplemented	  with	  soy	  
isoflavones	  to	  those	  of	  men	  randomly	  assigned	  to	  a	  placebo	  control	  group.	  
2. To	  identify	  the	  effect(s)	  of	  soy	  isoflavones	  on	  prostate	  cancer	  by	  comparing	  gene	  
transcripts	  found	  in	  adjacent	  normal	  prostate	  tissues	  of	  men	  supplemented	  with	  
soy	  isoflavones	  to	  those	  of	  men	  randomly	  assigned	  to	  a	  placebo	  control	  group.	  
3. To	  identify	  the	  effect(s)	  of	  soy	  isoflavones	  on	  prostate	  cancer	  by	  comparing	  gene	  
transcripts	  found	  in	  cancerous	  and	  adjacent	  normal	  prostate	  tissues	  of	  men	  
supplemented	  with	  soy	  isoflavones	  to	  those	  of	  men	  randomly	  assigned	  to	  a	  
placebo	  control	  group.	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4. To	  explore	  the	  biological	  relationships	  among	  the	  most	  significant	  of	  the	  
differentially	  expressed	  gene	  transcripts	  by	  conducting	  pathway	  analyses	  using	  
Ingenuity	  Pathway	  Analysis	  (Ingenuity®	  Systems,	  www.ingenuity.com).	  
	  
The	  overall	  hypothesis	  is	  that	  short-­‐term	  soy	  isoflavone	  supplementation	  will	  
influence	  the	  expression	  of	  several	  genes	  related	  to	  prostate	  cancer	  development	  and	  
progression.	  The	  goal	  of	  the	  study	  is	  to	  gain	  insight	  into	  the	  general	  biological	  and	  
molecular	  functions	  that	  are	  altered	  as	  a	  result	  of	  soy	  isoflavone	  treatment	  in	  patients	  
with	  localized	  prostate	  cancer.	  
	  
Structure	  of	  thesis	  
	   This	  study	  seeks	  to	  explore	  the	  effects	  of	  soy	  isoflavones	  on	  the	  development	  
and	  progression	  of	  prostate	  cancer	  by	  investigating	  changes	  in	  the	  transcriptome.	  The	  
review	  of	  literature	  will	  serve	  two	  purposes:	  1)	  to	  provide	  background	  information	  on	  
soy	  isoflavones,	  nutritional	  genomics,	  and	  RNA	  sequencing	  technology,	  and	  2)	  to	  review	  
the	  published	  scientific	  literature	  on	  the	  effects	  of	  dietary	  bioactive	  interventions	  on	  the	  
transcriptome,	  while	  highlighting	  those	  that	  have	  utilized	  soy	  isoflavone	  interventions.	  
This	  will	  be	  followed	  by	  a	  discussion	  of	  the	  materials	  and	  methods	  used	  in	  the	  present	  
study,	  and	  a	  description	  of	  the	  statistical	  analyses	  employed	  to	  identify	  differentially	  
expressed	  genes.	  The	  results	  of	  the	  study	  will	  be	  presented	  and	  summarized,	  followed	  
by	  a	  thorough	  discussion	  of	  the	  significance	  of	  these	  results	  in	  the	  context	  of	  the	  
available	  literature.	  The	  thesis	  will	  conclude	  with	  an	  evaluation	  of	  the	  study’s	  overall	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strengths	  and	  weaknesses	  and	  will	  suggest	  directions	  for	  future	  research.	  All	  
supplemental	  information	  (e.g.	  tables,	  illustrations,	  charts,	  and	  graphs)	  will	  appear	  in	  
the	  appendix.	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CHAPTER	  II:	  BACKGROUND	  AND	  LITERATURE	  REVIEW	  
Prostate	  cancer	  
	   Although	  prostate	  cancer	  treatments	  have	  improved	  significantly,	  the	  disease	  
continues	  to	  claim	  the	  lives	  of	  thousands	  of	  men	  every	  year	  (1).	  When	  prostate	  cancer	  
remains	  localized	  within	  the	  prostate	  gland,	  it	  is	  surgically	  removed	  during	  a	  radical	  
prostatectomy	  procedure.	  Localized	  prostate	  cancer	  is	  also	  treated	  with	  radiation	  
therapy.	  This	  treatment	  regimen	  has	  reduced	  the	  number	  of	  prostate	  cancer	  deaths	  by	  
40%	  over	  the	  past	  twenty	  years	  and	  resulted	  in	  a	  5-­‐year	  survival	  rate	  of	  100%	  (8).	  
However,	  approximately	  35%	  of	  men	  continue	  to	  experience	  biochemical	  recurrence	  
(BCR),	  i.e.	  an	  increase	  in	  prostate-­‐specific	  antigen	  (PSA)	  values	  (the	  biochemical	  marker	  
currently	  used	  to	  screen	  for	  prostate	  cancer)	  following	  initial	  treatment,	  within	  5	  years	  
(9).	  Though	  salvage	  therapies	  exist	  to	  treat	  biochemically	  recurrent	  disease,	  they	  may	  
not	  effectively	  cure	  prostate	  cancer.	  In	  one	  study,	  68%	  of	  men	  with	  BCR	  who	  initially	  
received	  a	  prostatectomy	  and	  74%	  of	  men	  with	  BCR	  who	  initially	  received	  radiation	  
therapy	  failed	  salvage	  therapy	  at	  approximately	  3.5	  years	  (10).	  These	  men	  typically	  
develop	  metastatic	  disease,	  characterized	  by	  the	  spread	  of	  the	  initial	  prostate	  cancer	  
into	  distant	  tissues	  such	  as	  lymph	  nodes,	  adrenal	  glands,	  lungs,	  liver,	  and	  bone	  (8,11).	  
Approximately	  72%	  of	  distant	  metastatic	  cancers	  will	  result	  in	  death	  within	  5	  years	  (8).	  
	   Physicians	  lack	  the	  clinical	  tools	  that	  would	  help	  them	  recognize	  aggressive	  
prostate	  cancer	  in	  order	  to	  provide	  timely	  and	  appropriate	  therapies	  (7).	  Currently,	  
physicians	  evaluate	  a	  combination	  of	  several	  clinical	  characteristics	  (e.g.	  preoperative	  
PSA	  values,	  Gleason	  score)	  to	  detect	  prostate	  cancer	  and	  predict	  the	  likelihood	  of	  BCR	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and	  metastasis.	  Because	  this	  screening	  methodology	  lacks	  specificity	  and	  sensitivity,	  
many	  men	  remain	  undiagnosed	  and	  under-­‐treated,	  while	  others	  are	  over-­‐treated.	  A	  
more	  thorough	  understanding	  of	  the	  genetic	  mechanisms	  behind	  prostate	  cancer	  
development	  and	  progression	  is	  needed	  in	  order	  to	  identify	  biomarkers	  that	  can	  detect	  
aggressive	  prostate	  cancer	  and	  to	  apply	  appropriate	  treatments	  (7,12).	  	  
The	  development	  of,	  access	  to,	  and	  relative	  affordability	  of	  microarray	  
technologies	  as	  well	  as	  the	  accumulation	  of	  data	  from	  studies	  using	  these	  technologies	  
have	  allowed	  for	  a	  more	  comprehensive	  view	  of	  the	  genes	  and	  biochemical	  pathways	  
expressed	  in	  prostate	  cancer.	  Comparing	  gene	  expression	  profiles	  between	  normal	  and	  
diseased	  tissue	  allows	  for	  the	  identification	  of	  candidate	  biomarkers	  of	  prostate	  cancer	  
(7).	  For	  example,	  the	  evaluation	  of	  data	  obtained	  from	  high-­‐throughput	  analysis	  points	  
toward	  a	  product	  of	  a	  gene	  known	  as	  EZH2	  as	  a	  marker	  of	  advanced	  prostate	  cancer	  
(11).	  A	  similar	  methodology	  can	  be	  applied	  to	  prostate	  cancer	  tissues	  that	  have	  been	  
exposed	  to	  dietary	  bioactives	  in	  order	  to	  gain	  an	  understanding	  of	  diet’s	  effect	  on	  
genetic	  expression.	  	  
	  
Nutrigenetics	  and	  nutrigenomics	  
	   Though	  nutrigenetics	  and	  nutrigenomics	  are	  closely	  related	  fields	  and	  though	  
they	  both	  operate	  under	  the	  overarching	  hypothesis	  that	  health	  can	  be	  improved	  by	  
tailoring	  nutrition	  recommendations	  to	  an	  individual’s	  genetic	  profile,	  they	  are	  not	  
synonymous:	  the	  former	  refers	  to	  the	  study	  of	  how	  genes	  affect	  nutrient	  uptake	  and	  
metabolism,	  while	  the	  latter	  refers	  to	  the	  study	  of	  how	  bioactive	  food	  compounds	  affect	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the	  “omics”	  (13).	  The	  “omics”	  refer	  to	  the	  study	  of	  each	  stage	  of	  genetic	  replication	  
according	  to	  the	  classical	  paradigm;	  therefore,	  the	  “omics”	  include	  genomics,	  
epigenomics,	  transcriptomics,	  proteomics,	  and	  metabolomics.	  
	   When	  a	  cell	  divides,	  it	  replicates	  its	  DNA	  for	  the	  new	  cell.	  Every	  cell	  in	  the	  human	  
body	  carries	  the	  same	  DNA;	  however,	  a	  cell’s	  function	  determines	  the	  expression	  of	  
those	  genes.	  Genetic	  expression	  begins	  with	  transcription,	  a	  process	  that	  involves	  
copying	  the	  genetic	  information	  encoded	  within	  the	  DNA	  strand	  by	  generating	  
complementary	  RNA	  molecules.	  Three	  types	  of	  RNA	  are	  used	  in	  the	  process:	  messenger	  
RNA,	  ribosomal	  RNA,	  and	  transfer	  RNA.	  Molecules	  of	  mRNA	  determine	  the	  order	  of	  
amino	  acids;	  during	  translation,	  tRNA	  molecules	  use	  the	  information	  encoded	  in	  the	  
mRNA	  to	  select	  the	  correct	  amino	  acid	  for	  the	  growing	  protein	  chain,	  while	  rRNA	  fuses	  
the	  amino	  acids	  together	  to	  form	  a	  complete	  protein	  product	  (14).	  	  
	   The	  number	  and	  type	  of	  transcripts	  within	  a	  cell	  is	  termed	  the	  transcriptome,	  
and	  it	  can	  be	  used	  to	  describe	  the	  cell.	  All	  cells	  contain	  the	  same	  DNA,	  but	  the	  function	  
of	  the	  cell	  affects	  the	  transcriptome.	  Quantifying	  the	  transcripts	  present	  in	  a	  cell	  
indicates	  which	  genes	  are	  being	  expressed	  in	  that	  cell	  at	  that	  point	  in	  time	  (14).	  By	  
comparing	  the	  transcripts	  of	  normal	  and	  diseased	  cells,	  transcriptomic	  technologies	  can	  
help	  identify	  which	  genes	  are	  being	  expressed	  or	  silenced	  by	  cancerous	  processes.	  
Similarly,	  by	  comparing	  the	  transcripts	  of	  cells	  exposed	  to	  dietary	  bioactives	  to	  those	  of	  
unexposed	  cells,	  transcriptomic	  technologies	  may	  identify	  which	  protective	  genes	  are	  
being	  up-­‐regulated	  by	  the	  chemical	  or	  which	  cancer-­‐promoting	  genes	  are	  being	  down-­‐
regulated	  by	  the	  chemical.	  
	   9	  
Transcriptomics	  
	   Over	  the	  past	  several	  years,	  technology	  for	  evaluating	  the	  transcripts	  of	  cells	  has	  
evolved,	  improved,	  and	  become	  more	  financially	  feasible.	  Transcriptomic	  studies	  
characterize	  and	  quantify	  the	  RNA	  content	  of	  a	  given	  cell	  or	  tissue	  sample,	  use	  the	  data	  
to	  deduce	  gene	  expression,	  and	  determine	  the	  biological	  significance	  of	  differentially	  
expressed	  genes	  by	  interpreting	  them	  within	  the	  context	  of	  established	  molecular	  
pathways	  (15).	  Real-­‐time	  quantitative	  PCR	  (qPCR),	  microarrays,	  and	  massively	  parallel	  
next-­‐generation	  RNA	  sequencing,	  or	  RNA-­‐seq,	  are	  the	  three	  major	  techniques	  for	  
examining	  the	  transcriptome	  (16).	  The	  qPCR	  method	  is	  most	  appropriate	  for	  looking	  at	  a	  
small	  number	  of	  transcripts	  (16).	  Microarrays	  and	  RNA	  sequencing	  can	  identify	  
transcripts	  expressed	  across	  the	  entire	  genome	  (16).	  Microarrays	  can	  only	  detect	  
sequences	  already	  specified	  on	  the	  array,	  while	  RNA	  sequencing	  technologies	  can	  detect	  
all	  mRNA	  sequences	  as	  well	  as	  microRNAs,	  long	  non-­‐coding	  RNAs,	  and	  strand-­‐specificity	  
(16).	  Because	  of	  this,	  RNA	  sequencing	  technologies	  are	  best	  suited	  for	  exploratory	  
studies	  such	  as	  the	  present	  study.	  RNA	  sequencing	  applications	  include	  Illumina’s	  
TruSeq	  Stranded	  mRNA	  Sample	  Preparation	  Kit,	  Life	  Technologies’	  SOLiD®	  Total	  RNA	  Seq	  
Kit,	  and	  Agilent’s	  SureSelect	  Strand	  Specific	  RNA	  Library	  Preparation	  Kit	  (16).	  
	   	  Essentially,	  RNA-­‐seq	  consists	  of	  five	  distinct	  phases:	  1)	  isolating	  the	  RNA	  from	  
the	  sample,	  2)	  preparing	  a	  library	  of	  cDNA	  molecules,	  3)	  sequencing	  by	  synthesis,	  4)	  
aligning	  the	  raw	  reads	  to	  a	  reference	  transcriptome	  or	  genome,	  and	  5)	  determining	  
statistical	  significance	  for	  differential	  gene	  expression.	  The	  identification	  of	  differentially	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expressed	  genes	  helps	  determine	  the	  function	  of	  genes	  as	  the	  cells	  respond	  to	  different	  
treatments	  or	  conditions.	  	  
	   RNA-­‐Seq	  produces	  large,	  complex	  data	  sets.	  The	  acquisition,	  management,	  
storage,	  retrieval,	  and	  analysis	  of	  these	  data	  sets	  represent	  significant	  challenges	  when	  
working	  with	  RNA	  sequencing	  data	  (13).	  The	  high	  cost	  of	  RNA	  sequencing	  limits	  the	  
number	  of	  samples	  that	  can	  be	  analyzed;	  therefore,	  comparing	  different	  doses	  and	  
different	  time	  points	  can	  rarely	  be	  examined	  and	  only	  general	  effects	  can	  be	  identified	  
(17).	  Transcriptomic	  studies	  also	  vary	  considerably	  in	  terms	  of	  experimental	  design,	  
microarray	  technology,	  statistical	  methodology,	  patient	  characteristics,	  and	  dietary	  
bioactive	  (7,15),	  making	  it	  somewhat	  difficult	  to	  draw	  meaningful	  conclusions	  from	  the	  
available	  literature.	  The	  microarray	  technology	  itself	  further	  complicates	  matters	  as	  the	  
reliability	  of	  data	  can	  be	  compromised	  by	  the	  source	  (e.g.	  cell	  lines	  or	  human	  tissue)	  and	  
quality	  of	  mRNA	  (17,18).	  Although	  “omics”	  research	  continues	  to	  contribute	  novel	  data,	  
results	  must	  be	  placed	  within	  the	  context	  of	  the	  each	  subject’s	  nutrition	  status,	  lifestyle	  




	   Soybeans,	  a	  plant	  native	  to	  Southeast	  Asia,	  are	  legumes	  that	  represent	  a	  high-­‐
quality,	  complete	  protein	  source	  (19).	  Soybeans	  may	  be	  steamed,	  roasted,	  or	  processed	  
into	  different	  soy-­‐based	  products,	  ranging	  from	  more	  traditional	  soy	  foods	  (e.g.	  tofu,	  
miso,	  tempeh,	  and	  soy	  milk)	  to	  “second	  generation”	  soy-­‐based	  infant	  formulas,	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meatless	  soy	  burgers,	  soy	  protein	  isolate,	  soy	  flour,	  and	  various	  food	  additives	  (20).	  
Even	  though	  traditional	  soy	  products	  are	  a	  staple	  of	  Asian	  cuisine,	  North	  American	  soy	  
food	  sales	  have	  increased	  $1	  billion	  to	  $5.2	  billion	  over	  the	  past	  15	  years	  (21).	  The	  
United	  Soybean	  Board	  reported	  that	  37%	  of	  Americans	  consumed	  soy	  products	  at	  least	  
once	  a	  month	  in	  2011	  (21).	  On	  average,	  however,	  Americans	  and	  Europeans	  consume	  
less	  than	  1	  gram	  of	  soy	  protein	  per	  day.	  Conversely,	  Asian	  cultures	  consume	  much	  more	  
soy	  protein	  than	  Americans	  and	  Europeans.	  The	  Japanese	  consume	  8.7	  g	  daily;	  Koreans,	  
6.2-­‐9.6	  g;	  Indonesians,	  7.4	  g;	  and	  the	  Chinese,	  3.4	  g	  (20,22).	  	  
	   Soybeans	  contain	  several	  bioactive	  compounds,	  including	  isoflavones.	  
Isoflavones	  belong	  to	  a	  class	  of	  phytochemicals	  called	  phytoestrogens,	  a	  group	  of	  
compounds	  with	  chemical	  structures	  resembling	  that	  of	  estrogen	  (20).	  Though	  
isoflavones	  occur	  in	  other	  plants,	  soybeans	  represent	  the	  most	  commonly	  consumed	  
source	  of	  dietary	  isoflavones	  in	  the	  American	  diet.	  Soybeans	  contain	  three	  major	  
isoflavones:	  genistein,	  daidzein,	  and	  glycitein.	  Within	  unprocessed	  soybeans,	  these	  
isoflavones	  are	  bound	  to	  sugar	  molecules,	  present	  as	  the	  biologically	  inactive	  
compounds	  genistin,	  daidzin,	  and	  glycitin	  (20).	  During	  digestion,	  isoflavones	  undergo	  
separation	  from	  these	  sugars	  and	  become	  the	  biologically	  active	  isoflavones,	  usually	  
referred	  to	  as	  aglycone	  isoflavones	  (20).	  
	   The	  isoflavone	  content	  in	  soybeans	  and	  soy-­‐based	  products	  varies	  according	  to	  
their	  growing	  environment,	  the	  amount	  and	  type	  of	  food	  processing,	  and	  individual	  
variation	  in	  human	  digestion,	  among	  other	  factors.	  For	  example,	  3.3	  oz	  steamed	  
soybeans	  (i.e.	  edamame)	  contains	  ~50	  mg	  isoflavones,	  while	  the	  same	  amount	  of	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cooked	  soybeans	  contains	  ~18	  mg	  isoflavones	  (23).	  Soy	  protein	  concentrate	  produced	  
by	  alcohol	  extraction	  has	  only	  ~11.5	  mg	  isoflavones	  per	  3.3	  oz,	  while	  soy	  protein	  
concentrate	  produced	  by	  aqueous	  extraction	  has	  ~95	  mg	  isoflavones	  for	  the	  same	  
amount	  (23).	  Additionally,	  daidzein	  can	  be	  further	  metabolized	  into	  equol,	  a	  metabolite	  
that	  may	  elicit	  a	  biological	  effect	  in	  the	  intestines	  of	  approximately	  30%	  of	  Americans	  
(24).	  Because	  soy	  protein	  is	  more	  frequently	  consumed	  among	  Asian	  populations	  than	  
Western	  populations,	  it	  stands	  to	  reason	  that	  isoflavone	  intake	  is	  also	  higher	  in	  Asian	  
populations	  than	  Western	  populations.	  On	  average,	  the	  Japanese	  consume	  
approximately	  27	  mg	  isoflavones,	  or	  one	  serving	  of	  soy	  food,	  daily	  (25–27).	  In	  contrast,	  
those	  consuming	  a	  typical	  Western	  diet	  consume	  an	  average	  of	  2-­‐3	  mg	  isoflavones	  per	  
day	  (28).	  	  
	  
Potential	  mechanisms	  of	  action	  
	   Many	  in	  vitro	  and	  in	  vivo	  studies	  have	  been	  conducted	  to	  determine	  the	  
potential	  mechanisms	  of	  action	  through	  which	  soy	  isoflavones	  exert	  their	  hypothesized	  
chemopreventative	  effects;	  however,	  data	  remain	  inconclusive	  as	  study	  designs	  vary	  
widely	  in	  terms	  of	  isoflavone	  dose,	  form	  of	  administration,	  or	  timing	  and	  duration	  of	  
exposure	  (17).	  Unfortunately,	  many	  in	  vitro	  studies	  tend	  to	  supply	  isoflavones	  at	  
concentrations	  that	  exceed	  those	  that	  could	  be	  achieved	  in	  human	  plasma	  or	  tissues	  by	  
tolerable	  oral	  intake	  (29).	  Steiner	  et	  al.	  (17)	  report	  that	  isoflavone	  concentrations	  as	  
high	  as	  1-­‐2.5	  nmol/g	  can	  be	  achieved	  in	  prostate	  tissue	  after	  short-­‐term	  
supplementation.	  This	  complicates	  the	  interpretation	  of	  any	  anti-­‐carcinogenic	  effect	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produced	  by	  soy	  isoflavones	  in	  such	  studies,	  as	  any	  preventative	  effect	  seen	  would	  be	  
impossible	  to	  obtain	  through	  the	  diet	  (17).	  	  
Despite	  this	  variability,	  isoflavones	  have	  been	  shown	  to	  modulate	  steroid	  
synthesis,	  transport,	  and	  metabolism;	  inhibit	  protein	  tyrosine	  kinases;	  modify	  nuclear	  
receptor	  binding,	  hormone	  receptor	  binding,	  and	  other	  cell	  signaling	  pathways;	  induce	  
apoptosis,	  anti-­‐oxidant	  effects,	  and	  cell	  cycle	  arrest;	  and	  suppress	  metastasis	  and	  
angiogenesis	  (17,30).	  High-­‐throughput	  data	  analysis	  techniques	  are	  being	  used	  to	  
investigate	  these	  effects	  more	  closely	  by	  attempting	  to	  identify	  how	  soy	  isoflavones	  
regulate	  the	  expression	  of	  genes	  related	  to	  these	  observed	  effects	  involved	  in	  prostate	  
cancer	  prevention,	  development,	  and	  progression.	  Published	  studies	  that	  investigate	  
the	  effects	  of	  nutritional	  interventions	  on	  the	  transcriptome	  vary	  considerably	  in	  terms	  
of	  dietary	  bioactive,	  matrix,	  and	  dose;	  biological	  specimen,	  medical	  condition	  of	  
interest,	  population,	  and	  sample	  size;	  intervention	  duration;	  microarray	  platform	  (i.e.	  
RNA	  methods);	  as	  well	  as	  statistical	  techniques	  and	  software	  tools	  used	  to	  evaluate	  
biological	  significance.	  
	  
Effects	  of	  bioactive	  dietary	  components	  on	  the	  transcriptome	  
	   A	  transcriptomic	  approach	  has	  been	  used	  to	  investigate	  the	  influence	  of	  various	  
bioactives	  on	  genes	  related	  to	  various	  medical	  conditions.	  In	  addition	  to	  prostate	  
cancer,	  the	  medical	  conditions	  represented	  in	  this	  review	  include	  obesity,	  weight	  loss,	  
metabolic	  syndrome,	  hyperlipidemia,	  cardiovascular	  disease,	  osteoporosis,	  zinc	  
deficiency,	  and	  colon	  cancer.	  The	  transcripts	  of	  healthy	  individuals	  were	  also	  evaluated.	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   With	  the	  exception	  of	  soy	  isoflavones	  in	  prostate	  cancer,	  this	  review	  revealed	  
little	  consistency	  among	  the	  dietary	  bioactives	  used.	  Some	  in	  vivo	  studies	  took	  
advantage	  of	  the	  micronutrients	  and	  phytochemicals	  already	  present	  in	  or	  derived	  from	  
different	  foods,	  including	  the	  anthocyanins	  and	  flavonols	  in	  dried	  and	  pureed	  bilberries	  
(31),	  the	  zinc	  content	  of	  various	  foods	  (32),	  the	  sulforaphane	  content	  in	  broccoli	  (33),	  
and	  the	  isoflavone	  content	  of	  tofu	  (34).	  Other	  in	  vivo	  studies	  artificially	  supplemented	  
diets	  or	  provided	  dietary	  supplements	  to	  subjects.	  Rodents	  were	  typically	  supplemented	  
per	  kg	  body	  weight	  or	  per	  kg	  diet	  (35–37),	  while	  humans	  received	  capsules	  containing	  
bioactive	  substances	  (30,38–41)	  or	  oral	  dietary	  supplements	  (32).	  In	  vitro	  studies	  
exposed	  established	  cell	  lines	  or	  cells	  derived	  from	  harvested	  tissues	  to	  purified	  
concentrations	  of	  micronutrients	  or	  phytochemicals,	  including	  sulforaphane	  (33,42),	  
curcumin	  (43),	  kuguacin-­‐J	  (44),	  genistein	  (41,45–49),	  daidzein	  (30),	  and	  equol	  (30).	  	  
The	  studies	  that	  implemented	  soy	  isoflavone	  interventions	  in	  prostate	  cancer	  (n	  
=	  6)	  used	  purified	  isoflavone	  solutions	  (30,41,46–49)	  or	  isoflavone-­‐containing	  capsules	  
(30,41).	  The	  isoflavone	  solutions	  used	  for	  in	  vitro	  studies	  ranged	  in	  concentration	  from	  
0.0075	  µM	  to	  100	  µM	  per	  liter	  (30,41,46–49).	  In	  one	  of	  the	  human	  studies,	  participants	  
consumed	  a	  pill	  containing	  27.2	  mg	  mixed	  isoflavone	  aglycones	  three	  times	  daily,	  or	  
approximately	  82	  mg	  mixed	  isoflavones	  daily	  (30).	  In	  the	  other	  human	  study,	  
participants	  consumed	  a	  capsule	  containing	  150	  mg	  genistein	  only	  (40).	  	  	  
Though	  the	  attempt	  was	  made	  to	  focus	  on	  human	  interventions,	  this	  literature	  
review	  also	  included	  in	  vitro	  studies	  and	  rodent	  models	  when	  needed.	  Studies	  of	  various	  
bioactives	  in	  various	  medical	  conditions	  (n	  =	  5)	  focused	  exclusively	  on	  human	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interventions.	  Sample	  sizes	  were	  generally	  limited,	  ranging	  from	  3	  (31,38,42)	  to	  16	  
participants	  (39).	  The	  source	  of	  the	  biospecimen	  obtained	  from	  these	  participants	  also	  
varied,	  including	  tumor	  and	  adjacent	  normal	  colon	  tissue	  (42),	  cheek	  cells	  (32),	  and	  
blood	  (31,32,38,39).	  Notably,	  the	  majority	  of	  these	  studies	  used	  biospecimens	  that	  were	  
relatively	  non-­‐invasive	  and	  easy	  to	  obtain	  from	  human	  participants.	  	  
Studies	  of	  various	  bioactives	  on	  the	  prostate	  cancer	  transcriptome	  used	  LNCaP	  
cells	  (33,43),	  PC-­‐3	  cells	  (44),	  C4-­‐3B	  cells	  (43),	  and	  cells	  derived	  from	  the	  tumor	  tissue	  of	  
Copenhagen	  rats	  with	  MatLyLu	  Dunning-­‐induced	  prostate	  cancer	  (35).	  Studies	  that	  
investigated	  the	  effect	  of	  soy	  isoflavones	  on	  the	  transcriptome	  of	  various	  tissue	  types	  
employed	  both	  rodent	  (34,36,37,45,50)	  and	  human	  models	  (40),	  including	  female	  
Zucker	  rats,	  male	  and	  female	  Sprague-­‐Dawley	  rats,	  and	  healthy	  post-­‐menopausal	  
women.	  Prostate	  cancer	  cell	  lines,	  specifically	  LNCaP	  cells	  (30,47,49),	  PC-­‐3	  cells	  
(30,41,46,48,49),	  PC-­‐3-­‐M	  cells	  (41),	  DU-­‐145	  cells	  (48),	  1532-­‐NPTX	  (41),	  1542-­‐NPTX	  (41),	  
1532-­‐CPTX	  (41),	  1542-­‐CPTX	  (41),	  and	  RWPE-­‐1	  cells	  (49),	  were	  used	  in	  studies	  of	  soy	  
isoflavones	  on	  the	  prostate	  cancer	  transcriptome.	  The	  two	  studies	  with	  human	  
participants	  (30,41)	  used	  prostatectomy	  tissue	  samples	  obtained	  from	  male	  prostate	  
cancer	  patients	  who	  consumed	  a	  soy	  isoflavone	  supplement	  prior	  to	  surgery.	  	  
	   Although	  the	  duration	  of	  the	  nutritional	  interventions	  varied	  considerably,	  the	  
majority	  were	  relatively	  short.	  The	  majority	  of	  rodent	  studies	  provided	  dietary	  
intervention	  for	  2	  weeks	  (34,37,51),	  while	  others	  continued	  for	  4	  weeks	  (41),	  6	  weeks	  
(35),	  12	  weeks	  (36,45),	  or	  40	  weeks	  (50).	  Prostate	  cancer	  cell	  lines	  were	  exposed	  to	  
various	  bioactive	  dietary	  supplements	  for	  2	  to	  96	  hours,	  and	  at	  regular	  time	  points	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within	  this	  range	  (30,33,41–44,46–49).	  Human	  dietary	  interventions	  ranged	  from	  2	  
weeks	  (30,38,41)	  to	  11	  weeks	  (40).	  The	  in	  vitro	  studies	  that	  implemented	  soy	  isoflavone	  
interventions	  in	  prostate	  cancer	  lasted	  between	  6	  (46)	  and	  96	  hours	  (47),	  while	  both	  
human	  studies	  lasted	  between	  2	  and	  6	  weeks	  (30,41).	  All	  reviewed	  studies	  reported	  
statistically	  significant	  results,	  suggesting	  that	  dietary	  supplementation	  can	  effect	  a	  
change	  in	  genetic	  expression	  in	  a	  relatively	  short	  time	  period.	  	  
	   None	  of	  the	  studies	  reviewed	  used	  massively	  parallel	  next-­‐generation	  
sequencing	  techniques	  to	  evaluate	  the	  effects	  of	  dietary	  bioactives	  on	  the	  
transcriptome.	  Many	  used	  qPCR	  to	  evaluate	  the	  transcriptome,	  some	  of	  which	  
correlated	  microarray	  data	  with	  the	  results	  of	  the	  more	  established	  qPCR	  technique	  
(30–32,34,36,37,39,41,44–47,49,51).	  Many	  others	  used	  microarrays	  
(33,35,38,40,42,43,46,48,50,51).	  The	  most	  common	  microarray	  used	  was	  Affymetrix	  
GeneChip®	  Gene	  Expression	  (35,38,42,43,48,50,51).	  Because	  the	  present	  study	  uses	  
next-­‐gen	  technology,	  it	  will	  be	  able	  to	  more	  thoroughly	  evaluate	  the	  transcriptomic	  
response	  of	  prostate	  cancer	  to	  soy	  isoflavones.	  
	  
Summary	  
A	  review	  of	  the	  relevant	  published	  literature	  indicates	  that	  micronutrient	  and	  
other	  dietary	  bioactive	  compounds	  can	  induce	  a	  change	  in	  the	  transcriptome	  of	  cells	  
derived	  from	  various	  tissues	  in	  as	  little	  as	  2	  weeks.	  These	  studies	  illustrate	  how	  
evaluating	  the	  transcriptome	  of	  various	  cells	  can	  be	  used	  to	  investigate	  the	  effects	  of	  
micronutrients	  and	  other	  dietary	  bioactives.	  Importantly,	  significant	  results	  were	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discovered	  despite	  the	  fact	  that	  many	  of	  these	  studies	  used	  physiological	  doses	  of	  their	  
respective	  supplements.	  Human	  transcriptomic	  studies	  are	  few,	  especially	  when	  
focusing	  specifically	  on	  soy	  isoflavones	  and	  prostate	  cancer,	  and	  most	  of	  these	  had	  a	  
very	  limited	  sample	  size.	  	  
The	  present	  study	  seeks	  to	  explore	  the	  effect	  of	  soy	  isoflavones	  on	  gene	  
expression	  in	  prostate	  cancer	  using	  the	  insights	  provided	  by	  RNA	  sequencing	  
applications.	  Gene	  expression	  profiles	  will	  be	  obtained	  by	  isolating	  and	  sequencing	  the	  
RNA	  of	  fresh	  frozen	  prostate	  tissue	  collected	  from	  6	  participants	  who	  underwent	  radical	  
prostatectomy	  for	  the	  treatment	  of	  localized	  prostate	  cancer.	  These	  participants	  
received	  either	  a	  soy	  isoflavone	  supplement	  that	  provided	  51	  mg	  total	  aglycone	  
equivalents	  per	  day	  or	  a	  matching	  placebo	  capsule	  for	  up	  to	  6	  weeks	  before	  the	  
operation.	  The	  transcripts	  of	  normal	  and	  tumor	  tissue	  from	  each	  participant	  will	  be	  
quantified	  and	  subsequently	  mapped	  to	  known	  genes.	  Differentially	  expressed	  genes	  
will	  be	  identified.	  The	  biological	  relationships	  among	  these	  genes	  will	  be	  evaluated	  and	  
interpreted	  using	  Ingenuity	  Pathway	  Analysis	  software	  (Ingenuity	  Systems	  ®,	  
www.ingenuity.com).	  The	  list	  of	  highly	  expressed	  genes	  will	  be	  used	  to	  further	  explore	  
the	  effect	  of	  soy	  isoflavones	  on	  genetic	  expression	  in	  prostate	  cancer.	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CHAPTER	  III:	  MATERIALS	  AND	  METHODS	  
Study	  overview	  
Under	  a	  protocol	  approved	  by	  the	  Institutional	  Review	  Boards	  at	  the	  University	  
of	  Kansas	  (KUH)	  and	  the	  Kansas	  City	  Veterans	  Affairs	  Medical	  Center	  (VAMC),	  86	  men	  
diagnosed	  with	  prostate	  cancer	  who	  were	  scheduled	  to	  undergo	  prostatectomy	  were	  
enrolled	  in	  the	  study	  after	  providing	  informed	  consent.	  Eligibility	  criteria	  included:	  
histologically	  confirmed	  prostate	  adenocarcinoma,	  clinically	  localized	  disease	  (stage	  T1	  
or	  T2),	  and	  medical	  clearance	  for	  surgery.	  Exclusion	  criteria	  included:	  concurrent	  
chemotherapy,	  radiation,	  or	  hormone	  therapy,	  consumption	  of	  soy	  foods	  within	  90	  days	  
prior	  to	  enrollment	  or	  during	  the	  study,	  initiation	  of	  any	  new	  vitamin,	  mineral,	  or	  herbal	  
supplement	  during	  the	  study,	  and	  a	  known	  history	  of	  soy	  allergy	  or	  intolerance.	  The	  
study	  was	  a	  double-­‐blinded,	  randomized,	  placebo-­‐controlled	  trial	  in	  which	  participants	  
were	  asked	  to	  take	  study	  capsules	  for	  up	  to	  6	  weeks	  before	  operation.	  Participants	  were	  
randomized	  to	  receive	  either	  a	  soy	  isoflavone	  supplement	  (n	  =	  42)	  or	  a	  matching	  
placebo	  (n	  =	  44).	  Between	  April	  2006	  and	  May	  2009,	  each	  participant	  provided	  
biological	  specimens	  for	  future	  analysis,	  including	  urine	  samples	  and	  snap	  frozen	  
prostate	  tissue	  (both	  normal	  and	  tumor	  samples),	  which	  were	  subsequently	  banked	  at	  
the	  VAMC.	  	  
The	  current	  study	  focused	  on	  a	  subsample	  (n	  =	  6)	  of	  the	  original	  86	  participants,	  
and	  analyzed	  and	  sequenced	  total	  RNA	  isolated	  from	  tumor	  and	  adjacent	  normal	  frozen	  
prostate	  tissue	  obtained	  from	  these	  participants	  (Figure	  1).	  From	  the	  RNA	  sequencing	  
data,	  gene	  expression	  profiles	  were	  determined,	  differentially	  expressed	  genes	  were	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Soy	  isoflavone	  and	  placebo	  capsules	  
The	  treatment	  group	  received	  a	  commercially	  available,	  soy	  isoflavone	  capsule	  
(Flav-­‐ein,	  3	  B’S	  Ltd.,	  Lenexa,	  KS)	  derived	  from	  soy	  germ	  that	  provided	  51	  mg	  total	  
isoflavone	  aglycone	  equivalents	  per	  day,	  with	  an	  average	  distribution	  of	  55%	  daidzein,	  
30%	  glycitein,	  and	  15%	  genistein	  as	  analyzed	  by	  an	  independent	  laboratory	  (NP	  
Analytical	  Laboratories,	  St.	  Louis,	  MO).	  The	  placebo	  pills	  were	  manufactured	  to	  appear	  
identical	  to	  the	  isoflavone	  capsules	  and	  provided	  <0.06	  mg	  isoflavones	  per	  day	  (NP	  
Analytical	  Laboratories,	  St.	  Louis,	  MO).	  	  
	  
Methods	  
Urine	  sample	  collection	  and	  analysis	  for	  compliance	  
Urine	  samples	  were	  collected	  at	  baseline,	  2	  weeks,	  and	  immediately	  prior	  to	  
prostatectomy.	  Samples	  were	  stored	  at	  -­‐80˚C	  without	  preservative.	  Urine	  samples	  
collected	  between	  2	  and	  4	  weeks	  from	  baseline	  were	  selected	  for	  isoflavone	  analysis.	  
Frozen	  urine	  samples	  were	  thawed	  overnight,	  aliquoted	  into	  2-­‐mL	  tubes,	  packed	  in	  dry	  
ice,	  and	  shipped.	  The	  urinary	  concentration	  of	  3	  isoflavones	  and	  3	  isoflavone	  
metabolites	  (genistein,	  daidzein,	  glycitein,	  equol,	  dihydrodaidzein,	  and	  O-­‐
desmethylangolensin)	  were	  measured	  at	  the	  University	  of	  Minnesota	  using	  a	  high	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pressure	  liquid	  chromatography-­‐tandem	  mass	  spectrometry	  (LC-­‐MS/MS)	  method	  based	  
on	  a	  previously	  used	  method	  (52).	  Urinary	  creatinine	  was	  used	  to	  normalize	  the	  urinary	  
isoflavone	  data	  because	  24-­‐hour	  urinary	  excretion	  volume	  was	  unknown.	  The	  Kansas	  
City	  VAMC	  determined	  urinary	  creatinine	  excretion	  using	  a	  kinetic	  alkaline	  picrate	  
method	  (Abbott	  8200,	  Abbott	  Laboratories,	  Abbott	  Park,	  IL).	  	  
Because	  the	  isoflavone	  supplement	  provided	  proportionally	  more	  daidzein	  than	  
isoflavone	  supplements	  derived	  from	  whole	  soybeans,	  urinary	  daidzein	  concentrations	  
were	  used	  to	  determine	  intervention	  compliance.	  Those	  consuming	  placebo	  capsules	  
were	  considered	  non-­‐compliant	  if	  their	  adjusted	  urinary	  daidzein	  concentration	  
exceeded	  10	  nM/mL.	  This	  level	  was	  chosen	  based	  on	  a	  natural	  cutoff-­‐point	  as	  well	  as	  
normal	  concentrations	  found	  in	  the	  United	  States.	  Those	  consuming	  soy	  supplement	  
capsules	  that	  had	  low	  urinary	  daidzein	  levels	  were	  considered	  compliant	  as	  these	  
reduced	  levels	  were	  likely	  related	  to	  non	  per	  os	  (NPO),	  or	  nothing	  by	  mouth,	  status	  prior	  
to	  surgery.	  Equol	  producer	  status	  was	  classified	  according	  to	  a	  published	  method	  (53).	  
	  
Prostate	  tissue	  collection	  and	  analysis	  
Prostate	  tissue	  samples	  were	  obtained	  from	  patients	  at	  the	  Kansas	  City	  VAMC.	  	  
The	  urological	  surgeon	  obtained	  core	  samples	  of	  both	  tumor	  and	  adjacent	  normal	  
prostate	  tissue	  during	  the	  prostatectomy	  procedure.	  The	  samples	  were	  immediately	  
snap-­‐frozen,	  stored	  in	  liquid	  nitrogen,	  and	  transferred	  to	  KUMC	  by	  the	  KUMC	  
biospecimen	  repository	  team,	  where	  Dr.	  Ossama	  Tawfik	  (University	  of	  Kansas	  Medical	  
Center,	  Kansas	  City,	  KS)	  reviewed	  and	  graded	  each	  core	  specimen	  in	  order	  to	  ensure	  the	  
	   21	  
presence	  of	  tumor	  or	  normal	  tissue.	  Samples	  were	  stored	  at	  -­‐80˚C	  and	  were	  transferred	  
to	  liquid	  nitrogen	  prior	  to	  RNA	  isolation	  and	  sequencing.	  
	  
RNA	  sequencing	  
Total	  RNA	  was	  isolated	  from	  6	  normal/tumor	  pairs	  of	  flash-­‐frozen	  prostate	  tissue	  
samples	  from	  6	  participants	  at	  KUMC	  using	  TRIzol®	  reagent	  with	  Phase	  Lock	  GelHeavy	  
(54).	  These	  6	  participants	  were	  chosen	  because	  they	  had	  normal/tumor	  pairs	  in	  
inventory	  (Table	  1).	  Depending	  on	  the	  amount	  of	  biopsy	  available,	  between	  20-­‐50	  mg	  of	  
tissue	  were	  used	  for	  total	  RNA	  isolation.	  The	  tissue	  was	  homogenized	  with	  0.8-­‐1	  ml	  
TRIzol®	  reagent	  (50-­‐100	  mg	  tissue).	  The	  cell	  lysate	  was	  added	  to	  pre-­‐spun	  Phase	  Lock	  
GelHeavy	  tubes	  and	  incubated	  for	  5	  minutes	  at	  25˚C.	  Chloroform	  was	  added	  to	  the	  
tubes	  at	  0.2	  ml	  chloroform	  per	  1	  ml	  TRIzol®	  reagent	  and	  tubes	  were	  centrifuged	  at	  no	  
more	  than	  12,000	  x	  g	  for	  10	  minutes	  at	  4˚C.	  The	  aqueous	  phase	  containing	  the	  RNA	  was	  
transferred	  to	  a	  fresh	  tube.	  RNA	  was	  precipitated	  by	  adding	  0.5	  ml	  isopropyl	  alcohol	  per	  
1	  ml	  TRIzol®	  reagent	  used	  initially.	  Samples	  were	  mixed	  by	  repeated	  inversion,	  
incubated	  at	  25˚C	  for	  10	  minutes,	  and	  centrifuged	  for	  10	  minutes	  at	  no	  more	  than	  
12,000	  x	  g	  at	  4˚C.	  The	  supernatant	  was	  decanted,	  and	  1	  ml	  75%	  ethanol	  per	  1	  ml	  TRIzol®	  
reagent	  was	  added	  to	  wash	  the	  RNA	  pellet.	  The	  samples	  were	  mixed	  to	  dislodge	  the	  
pellet	  and	  were	  centrifuged	  at	  no	  more	  than	  7,500	  x	  g	  for	  5	  minutes	  at	  4˚C.	  The	  
supernatant	  was	  again	  decanted.	  The	  RNA	  pellets	  were	  air-­‐dried	  for	  5-­‐10	  minutes	  to	  
remove	  any	  residual	  ethanol,	  dissolved	  in	  molecular	  biology	  grade	  water,	  and	  incubated	  
at	  55˚C	  for	  10	  minutes	  to	  facilitate	  dissolution.	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Total	  RNA	  extracted	  from	  the	  samples	  was	  multiplexed	  (3	  samples	  per	  lane)	  and	  
sequenced	  at	  a	  50	  bp	  paired-­‐end	  resolution	  using	  Illumina®	  HiSeq®	  2500	  Sequencing	  
System	  (University	  of	  Kansas	  Medical	  Center	  Genomics	  Core,	  Kansas	  City,	  KS).	  Total	  RNA	  
(0.5	  µg)	  was	  used	  to	  initiate	  the	  RNA	  sequencing	  library	  preparation	  protocol	  (55).	  The	  
mRNA	  fraction	  was	  enriched,	  sized,	  reverse-­‐transcribed	  into	  cDNA	  and	  ligated	  with	  the	  
appropriate	  indexed	  adaptors	  using	  Illumina®	  TruSeq™	  RNA	  Sample	  Preparation	  Kit	  v2	  
(Illumina	  RS-­‐122-­‐2001/2002).	  Following	  Agilent	  2100	  Bioanalyzer	  QC,	  the	  libraries	  were	  
adjusted	  to	  a	  2	  nM	  concentration	  and	  pooled	  for	  multiplexed	  sequencing.	  Libraries	  were	  
denatured	  and	  diluted	  to	  13	  pM	  followed	  by	  clonal	  clustering	  onto	  the	  sequencing	  flow	  
cell	  using	  the	  TruSeq™	  Paired-­‐End	  (PE)	  Cluster	  Kit	  v3-­‐cBOT-­‐HS	  (Illumina	  PE401-­‐3001).	  
The	  clonal	  clustering	  procedure	  was	  automated	  using	  the	  Illumina®	  cBOT	  Cluster	  
Station.	  The	  clustered	  flow	  cell	  was	  sequenced	  on	  the	  Illumina®	  HiSeq®	  2500	  
Sequencing	  System	  using	  the	  TruSeq™	  SBS	  Kit	  v3-­‐HS	  (Illumina	  FC401-­‐3002).	  	  
Following	  collection,	  RNA	  sequencing	  data	  were	  converted	  from	  .bcl	  file	  format	  
to	  FastQ	  files	  and	  de-­‐multiplexed	  into	  individual	  sequences	  (University	  of	  Kansas	  
Medical	  Center	  Bioinformatics	  Core,	  Kansas	  City,	  KS).	  A	  secure	  FTP	  site	  was	  created	  and	  
the	  data	  were	  made	  available	  for	  download.	  Short	  reads	  were	  quality	  assessed	  using	  
FastQC	  (Version	  0.10.1,	  Babraham	  Bioinformatics,	  Cambridge,	  United	  Kingdom)	  (56),	  a	  
quality	  control	  tool	  for	  raw	  high	  throughput	  sequence	  data.	  Short	  reads	  were	  mapped	  
to	  the	  GRCh37	  assembly	  (UCSC	  name:	  hg19)	  using	  TopHat	  (Version	  2.0.8b,	  Center	  for	  
Bioinformatics	  and	  Computational	  Biology,	  College	  Park,	  MD)	  (57),	  a	  fast	  splice	  junction	  
mapper	  for	  RNA-­‐Seq	  reads	  that	  aligns	  RNA-­‐Seq	  reads	  to	  mammalian-­‐sized	  genomes	  and	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analyzes	  mapping	  results	  to	  identify	  splice	  junctions	  between	  exons.	  Read	  alignments	  
were	  quality	  assessed	  using	  sam-­‐stats	  (October	  2012)	  (58),	  a	  tool	  used	  for	  computing	  
statistics	  from	  SAM	  or	  BAM	  files,	  and	  RNA-­‐SeQC	  (Version	  1.1.7)	  (59),	  a	  program	  that	  
computes	  a	  series	  of	  quality	  control	  metrics	  for	  RNA-­‐seq	  data.	  Read	  counting	  was	  
performed	  using	  htseq-­‐count	  (Version	  0.5.4p2)	  (60).	  Gene	  annotation	  files	  were	  
downloaded	  from	  Ensembl	  70	  (Feb	  2013	  release)	  (61).	  
	  
Statistical	  Analysis	  
Separate	  analyses	  were	  carried	  out	  for	  tumor	  data	  and	  normal	  data.	  The	  results	  
of	  the	  two	  analyses	  were	  further	  summarized	  using	  the	  set	  of	  differentially	  expressed	  
genes	  commonly	  expressed	  in	  both	  normal	  and	  tumor	  tissues.	  Any	  gene	  that	  had	  zero	  
mapped	  reads	  for	  all	  six	  samples	  were	  removed.	  Because	  RNA	  sequencing	  data	  is	  count	  
data,	  discrete	  probability	  distribution	  based	  models	  were	  used	  to	  analyze	  the	  data.	  
Because	  one	  of	  the	  characteristics	  of	  RNA	  sequencing	  data	  is	  that	  observed	  variation	  is	  
greater	  than	  the	  mean,	  negative	  binomial	  distribution	  was	  used.	  	  
Normalization	  was	  performed	  to	  adjust	  for	  varying	  sequencing	  depths	  and	  
potentially	  other	  technical	  effects	  across	  replicates.	  The	  trimmed	  mean	  of	  the	  M	  values	  
method	  (TMM,	  where	  M=log2	  fold	  change)	  was	  used	  to	  calculate	  the	  normalization	  
factor.	  Quantile-­‐adjusted	  conditional	  maximum	  likelihood	  (qCML)	  method	  was	  used	  for	  
estimating	  common	  dispersion	  across	  all	  genes.	  Then,	  exact	  test	  with	  a	  negative	  
binomial	  distribution	  was	  used	  to	  calculate	  expression	  differences	  between	  the	  soy	  and	  
placebo	  groups.	  Multiple	  test	  adjustments	  were	  carried	  out	  using	  the	  false	  discovery	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rate	  (FDR)	  using	  Benjamini	  and	  Hochberg’s	  method.	  The	  analyses	  were	  carried	  out	  using	  
R	  version	  3.0.	  Bioconductor	  Package	  edgeR	  (R	  Core	  Team,	  Vienna,	  Austria)	  was	  used	  to	  
complete	  the	  analyses	  (62).	  An	  FDR	  value	  of	  <	  0.05	  was	  considered	  statistically	  
significant.	  Statistical	  analysis	  was	  conducted	  by	  Dr.	  Prabhakar	  Chalise	  (University	  of	  
Kansas	  Medical	  Center	  Department	  of	  Biostatistics,	  Kansas	  City,	  KS).	  	  
	  
Bioinformatics	  
Pathway	  analysis	  used	  Ingenuity	  Pathway	  Analysis	  (IPA)	  (Ingenuity®	  Systems,	  
www.ingenuity.com)	  for	  all	  differentially	  expressed	  genes	  (FDR	  <	  0.05).	  To	  determine	  if	  
differentially	  expressed	  genes	  were	  relevant	  to	  the	  prostate	  cancer	  disease	  process,	  
each	  set	  of	  differentially	  expressed	  genes	  (genes	  in	  tumor	  and	  normal	  tissue	  and	  the	  
common	  genes	  shared	  between	  normal	  and	  tumor	  samples)	  were	  uploaded	  into	  IPA.	  
The	  canonical	  pathways	  and	  molecules	  for	  each	  set	  of	  differentially	  expressed	  genes	  
were	  downloaded	  from	  IPA.	  The	  top	  canonical	  pathways	  and	  molecules	  for	  comparison	  
analyses	  were	  also	  downloaded	  from	  IPA.	  
	  
Electronic	  medical	  record	  abstraction	  
Clinical	  outcome	  data	  were	  abstracted	  from	  electronic	  medical	  records	  (EMR)	  at	  
the	  Kansas	  City	  VAMC.	  Patient	  charts	  were	  reviewed	  for	  demographic	  information,	  
treatment	  modalities	  and	  complications,	  clinical	  and	  pathological	  staging,	  Gleason	  score,	  
comorbidities,	  PSA,	  biochemical	  recurrence,	  follow-­‐up	  status,	  and	  survival	  status.	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Data	  collection	  
Baseline	  demographic	  information,	  clinical	  outcome	  data,	  and	  the	  results	  of	  
subsequent	  biospecimen	  analyses	  have	  already	  been	  collected	  and	  reported	  on	  this	  
sample	  (63).	  All	  data	  received	  from	  urinalysis,	  tissue	  analysis,	  and	  EMR	  abstraction	  were	  
collected	  and	  maintained	  using	  Research	  Electronic	  Data	  Capture	  (REDCap	  version	  5.3.4)	  
hosted	  on	  a	  HIPAA-­‐certified	  server	  at	  the	  University	  of	  Kansas.	  RNA	  sequencing	  results	  
were	  de-­‐identified,	  exported	  into	  Microsoft©	  Excel	  spreadsheets,	  and	  stored	  on	  a	  
secure	  drive	  on	  the	  KUMC	  campus.	  IPA	  results	  were	  de-­‐identified,	  exported	  into	  
Microsoft©	  Excel	  spreadsheets	  and	  jpeg	  files,	  and	  stored	  on	  secure	  computers.	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Figure	  1.	  Participant	  flow	  diagram.	  The	  figure	  shows	  the	  current	  study’s	  participants	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CHAPTER	  IV:	  RESULTS	  
Subject	  characteristics	  
Of	  the	  86	  men	  originally	  randomized	  in	  the	  parent	  study,	  42	  were	  allocated	  to	  
receive	  soy	  isoflavone	  supplementation	  and	  44	  were	  allocated	  to	  receive	  the	  matching	  
placebo	  capsule.	  Of	  the	  42	  men	  supplemented	  with	  soy	  isoflavones,	  30	  men	  (71%)	  
underwent	  radical	  prostatectomy;	  29	  men	  (66%)	  underwent	  radical	  prostatectomy	  in	  
the	  placebo	  group.	  Two	  men,	  one	  from	  each	  treatment	  group,	  chose	  active	  surveillance	  
in	  lieu	  of	  surgery	  or	  radiation	  therapy.	  Tissue	  was	  collected	  from	  14	  of	  the	  59	  men	  who	  
chose	  surgery.	  In	  some	  cases,	  the	  tumor	  was	  too	  small	  or	  the	  KUMC	  biospecimen	  
repository	  team	  missed	  the	  tumor	  in	  collection.	  Out	  of	  the	  14	  tissue	  samples,	  only	  6	  had	  
adequate	  normal/tumor	  pairs	  (Table	  1,	  Table	  2).	  	  
Therefore,	  only	  6	  prostate	  tissue	  samples	  were	  used	  for	  analysis:	  4	  from	  men	  
who	  received	  isoflavone	  supplementation,	  and	  2	  from	  men	  who	  received	  placebo.	  
Baseline	  characteristics	  of	  the	  subset	  (n	  =	  6)	  appear	  in	  Table	  3.	  	  
	  
Urinary	  isoflavone	  levels	  
Urine	  samples	  from	  all	  6	  participants	  were	  analyzed	  for	  urinary	  isoflavone	  and	  
isoflavone	  metabolite	  concentrations	  to	  indicate	  compliance	  with	  the	  supplementation	  
protocol	  (Table	  4).	  All	  6	  participants	  were	  compliant	  with	  the	  protocol.	  Data	  on	  equol	  
production	  were	  known	  for	  all	  6	  participants	  included	  in	  the	  analysis.	  Out	  of	  the	  4	  
participants	  taking	  soy	  supplements,	  only	  Patient	  No.	  2	  was	  an	  equol	  producer	  
according	  to	  the	  equol-­‐to-­‐daidzein	  ratio	  >0.018	  definition	  (53).	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Differential	  gene	  expression	  
A	  total	  of	  62,069	  genes	  were	  obtained	  from	  the	  RNA	  sequencing	  data.	  In	  the	  6	  
tumor	  tissue	  samples,	  20,209	  genes	  had	  zero	  mapped	  reads	  for	  all	  samples.	  These	  were	  
removed	  from	  analysis,	  leaving	  41,860	  genes	  for	  analysis.	  Of	  these,	  128	  genes	  were	  
found	  to	  be	  differentially	  expressed	  between	  soy	  and	  placebo	  in	  the	  tumor	  tissue	  
samples.	  Out	  of	  the	  128	  differentially	  expressed	  genes,	  93	  were	  down-­‐regulated	  and	  35	  
were	  up-­‐regulated	  in	  the	  soy	  group	  when	  compared	  to	  the	  placebo	  group	  (Table	  5,	  
Table	  6).	  Of	  these	  128	  differentially	  expressed	  genes,	  108	  were	  expressed	  only	  in	  tumor	  
tissue	  (Table	  7,	  Table	  8).	  
In	  the	  6	  normal	  tissue	  samples,	  16,471	  genes	  had	  zero	  mapped	  reads	  for	  all	  
samples,	  leaving	  45,598	  genes	  for	  the	  analysis.	  Of	  these,	  186	  were	  found	  to	  be	  
differentially	  expressed	  between	  soy	  and	  placebo	  groups	  in	  the	  normal	  tissue	  samples.	  
Out	  of	  the	  186	  differentially	  expressed	  genes,	  147	  were	  down-­‐regulated	  and	  39	  were	  
up-­‐regulated	  in	  the	  soy	  group	  when	  compared	  to	  the	  placebo	  group	  (Table	  9,	  Table	  10).	  
Of	  these	  186	  differentially	  expressed	  genes,	  166	  were	  expressed	  only	  in	  normal	  tissue	  
(Table	  11,	  Table	  12).	  	  
A	  comparison	  of	  the	  128	  differentially	  expressed	  genes	  in	  tumor	  tissue	  samples	  
to	  the	  186	  differentially	  expressed	  genes	  in	  normal	  tissue	  samples	  revealed	  20	  genes	  in	  
common	  between	  the	  two	  groups	  (Table	  13).	  Of	  the	  20	  genes	  expressed	  in	  both	  tissues,	  
11	  were	  down-­‐regulated	  and	  9	  were	  up-­‐regulated	  in	  normal	  tissue.	  Similarly,	  11	  were	  
down-­‐regulated	  and	  9	  were	  up-­‐regulated	  in	  tumor	  tissue.	  The	  regulation	  direction	  of	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only	  2	  of	  the	  20	  genes	  differed	  between	  normal	  and	  tumor	  tissue	  (Table	  14,	  Table	  15,	  




	   The	  top	  five	  canonical	  pathways	  enriched	  for	  the	  128	  differentially	  expressed	  
genes	  in	  tumor	  tissue	  were:	  extrinsic	  prothrombin	  activation	  pathway	  (2	  of	  the	  128	  
genes	  were	  in	  the	  list	  of	  16	  genes	  within	  the	  pathway;	  p	  =	  2.56x10-­‐3	  for	  enrichment	  of	  
pathway),	  human	  embryonic	  stem	  cell	  pluripotency	  (4	  of	  the	  128	  genes	  were	  in	  the	  list	  
of	  the	  149	  genes	  within	  the	  pathway;	  p	  =	  3.6x10-­‐3	  for	  enrichment	  of	  pathway),	  intrinsic	  
prothrombin	  activation	  pathway	  (2	  of	  the	  128	  genes	  were	  in	  the	  list	  of	  32	  genes	  within	  
the	  pathway;	  p	  =	  7.78x10-­‐3	  for	  enrichment	  of	  pathway),	  acute	  phase	  response	  signaling	  
(4	  of	  the	  128	  genes	  were	  in	  the	  list	  of	  173	  genes	  within	  the	  pathway;	  p	  =	  8.39x10-­‐3	  for	  
enrichment	  of	  pathway),	  and	  the	  complement	  system	  (2	  of	  the	  128	  genes	  were	  in	  the	  
list	  of	  33	  genes	  within	  the	  pathway;	  p	  =	  1.01x10-­‐2	  for	  enrichment	  of	  pathway)	  (Table	  17,	  
Figure	  2).	  	  
The	  2	  differentially	  expressed	  genes	  up-­‐regulated	  by	  soy	  isoflavones	  within	  
extrinsic	  prothrombin	  activation	  and	  intrinsic	  prothrombin	  activation	  were	  FGA	  (p	  =	  
4.28x10-­‐5)	  and	  FGB	  (p	  =	  2.78x10-­‐7)	  (Figure	  3).	  The	  4	  differentially	  expressed	  genes	  within	  
human	  embryonic	  stem	  cell	  pluripotency	  were	  BMP5	  (down-­‐regulated;	  p	  =	  6.66x10-­‐16),	  
NANOG	  (down-­‐regulated;	  p	  =	  1.40x10-­‐4),	  WNT2	  (down-­‐regulated;	  p	  =	  9.60x10-­‐6),	  and	  
ZIC3	  (up-­‐regulated;	  p	  =	  1.29x10-­‐4)	  (Figure	  3).	  The	  4	  differentially	  expressed	  genes	  within	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acute	  phase	  signaling	  were	  FGA	  (up-­‐regulated;	  p	  =	  4.28x10-­‐5),	  FGB	  (up-­‐regulated;	  p	  =	  
2.78x10-­‐7),	  LBP	  (down-­‐regulated;	  p	  =	  1.07x10-­‐4),	  and	  RBP4	  (down-­‐regulated;	  p	  =	  1.46x10-­‐
6)	  (Figure	  3).	  The	  2	  differentially	  expressed	  genes	  within	  the	  complement	  system	  were	  
CFD	  (down-­‐regulated;	  p	  9.99x10-­‐5)	  and	  CR2	  (down-­‐regulated;	  2.54x10-­‐8)	  (Figure	  3).	  
	  
Normal	  tissue	  
	   The	  top	  five	  canonical	  pathways	  enriched	  for	  the	  186	  differentially	  expressed	  
genes	  in	  normal	  tissue	  were:	  the	  role	  of	  IL-­‐17A	  in	  psoriasis	  (2	  of	  the	  186	  genes	  were	  in	  
the	  list	  of	  13	  genes	  within	  the	  pathway;	  p	  =	  1.10x10-­‐3	  for	  enrichment	  of	  pathway),	  the	  
methylglyoxal	  degradation	  VI	  pathway	  (1	  of	  the	  186	  genes	  were	  in	  the	  list	  of	  1	  gene	  
within	  the	  pathway;	  p	  =	  3.84x10-­‐3	  for	  enrichment	  of	  pathway),	  glutamate	  dependent	  
acid	  resistance	  (1	  of	  the	  186	  genes	  were	  in	  the	  list	  of	  2	  genes	  within	  the	  pathway;	  	  
p	  =	  7.67x10-­‐3	  for	  enrichment	  of	  pathway),	  GABA	  receptor	  signaling	  (2	  of	  the	  186	  genes	  
were	  in	  the	  list	  of	  46	  genes	  within	  the	  pathway;	  p	  =	  1.35x10-­‐2	  for	  enrichment	  of	  
pathway),	  and	  protein	  citrullination	  (1	  of	  the	  186	  genes	  were	  in	  the	  list	  of	  5	  genes	  within	  
the	  pathway;	  p	  =	  1.91x10-­‐2	  for	  enrichment	  of	  pathway)	  (Table	  18,	  Figure	  4).	  	  
The	  2	  differentially	  expressed	  genes	  up-­‐regulated	  by	  soy	  isoflavones	  within	  the	  
role	  of	  IL-­‐17A	  in	  psoriasis	  were	  CXCL5	  (p	  =	  3.54x10-­‐6)	  and	  S100A7	  (p	  =	  1.55x10-­‐5)	  (Figure	  
5).	  The	  differentially	  expressed	  gene	  down-­‐regulated	  by	  soy	  isoflavones	  within	  the	  
methylglyoxal	  degradation	  VI	  pathway	  was	  LDHD	  (p	  =	  6.06x10-­‐5)	  (Figure	  5).	  The	  
differentially	  expressed	  gene	  down-­‐regulated	  by	  soy	  isoflavones	  within	  glutamate	  
dependent	  acid	  resistance	  was	  GAD2	  (p	  =	  2.92x10-­‐14)	  (Figure	  5).	  The	  2	  differentially	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expressed	  genes	  down-­‐regulated	  by	  soy	  isoflavones	  within	  GABA	  receptor	  signaling	  
were	  GABRA4	  (p	  =	  7.79x10-­‐5)	  and	  GAD2	  (p	  =	  2.92x10-­‐14)	  (Figure	  5).	  The	  differentially	  
expressed	  gene	  down-­‐regulated	  by	  soy	  isoflavones	  within	  protein	  citrullination	  was	  
PADI3	  (p	  =	  1.04x10-­‐4)	  (Figure	  5).	  	  
	  
Overlapping	  pathways	  
	   The	  top	  five	  canonical	  pathways	  enriched	  for	  the	  20	  differentially	  expressed	  
genes	  in	  common	  between	  normal	  and	  tumor	  tissue	  were:	  extrinsic	  prothrombin	  
activation	  pathway	  (1	  of	  the	  20	  genes	  were	  in	  the	  list	  of	  16	  genes	  within	  the	  pathway;	  p	  
=	  7.28x10-­‐3	  for	  enrichment	  of	  pathway),	  thyroid	  hormone	  metabolism	  II	  (1	  of	  the	  20	  
genes	  were	  in	  the	  list	  of	  26	  genes	  within	  the	  pathway;	  p	  =	  1.18x10-­‐2	  for	  enrichment	  of	  
pathway),	  intrinsic	  prothrombin	  activation	  pathway	  (1	  of	  the	  20	  genes	  were	  in	  the	  list	  of	  
32	  genes	  within	  the	  pathway;	  p	  =	  1.27x10-­‐2	  for	  enrichment	  of	  pathway),	  the	  coagulation	  
system	  (1	  of	  the	  20	  genes	  were	  in	  the	  list	  of	  35	  genes	  within	  the	  pathway;	  p	  =	  1.59x10-­‐2	  
for	  enrichment	  of	  pathway),	  and	  nicotine	  degradation	  III	  (1	  of	  the	  20	  genes	  were	  in	  the	  
list	  of	  45	  genes	  within	  the	  pathway;	  p	  =	  2.03x10-­‐2	  for	  enrichment	  of	  pathway)	  (Table	  19,	  
Figure	  6).	  	  
The	  2	  differentially	  expressed	  genes	  up-­‐regulated	  by	  soy	  isoflavones	  were	  FGB	  
and	  UGT2B4	  (Table	  20).	  The	  differentially	  expressed	  gene	  up-­‐regulated	  by	  soy	  
isoflavones	  within	  the	  extrinsic	  prothrombin	  activation	  pathway	  was	  FGB	  (p	  =	  2.78x10-­‐7	  
in	  tumor	  tissue;	  p	  =	  1.11x10-­‐6	  in	  normal	  tissue).	  The	  differentially	  expressed	  gene	  up-­‐
regulated	  by	  soy	  isoflavones	  within	  the	  thyroid	  hormone	  metabolism	  II	  pathway	  was	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UGT2B4	  (p	  =	  4.06x10-­‐5	  in	  tumor	  tissue;	  p	  =	  1.68x10-­‐6	  in	  normal	  tissue).	  The	  differentially	  
expressed	  gene	  up-­‐regulated	  by	  soy	  isoflavones	  in	  the	  intrinsic	  prothrombin	  activation	  
pathway	  was	  FGB	  (p	  =	  2.78x10-­‐7	  in	  tumor	  tissue;	  p	  =	  1.11x10-­‐6	  in	  normal	  tissue).	  The	  
differentially	  expressed	  gene	  up-­‐regulated	  by	  soy	  isoflavones	  within	  the	  coagulation	  
system	  was	  FGB	  (p	  =	  2.78x10-­‐7	  in	  tumor	  tissue;	  p	  =	  1.11x10-­‐6	  in	  normal	  tissue).	  The	  
differentially	  expressed	  gene	  up-­‐regulated	  by	  soy	  isoflavones	  within	  the	  nicotine	  
degradation	  III	  was	  UGT2B4	  (p	  =	  4.06x10-­‐5	  in	  tumor	  tissue;	  p	  =	  1.68x10-­‐6	  in	  normal	  
tissue).	  	  
	  
Electronic	  medical	  record	  data	  
Clinical	  follow-­‐up	  data	  abstracted	  from	  electronic	  medical	  records	  appears	  in	  
Table	  21.	  Pathological	  staging	  indicated	  T2A	  to	  T3A	  (IIA	  to	  III)	  prostate	  cancer.	  Only	  one	  
subject	  had	  invasion	  of	  the	  lymph	  nodes.	  No	  subjects	  experienced	  metastatic	  disease.	  
No	  patient	  experienced	  biochemical	  recurrence,	  though	  one	  patient	  experienced	  
persistent	  disease.	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Table	  1.	  Biospecimen	  inventory	  of	  study	  sample	  
	   	   	   Frozen	  tissue	   	  
Patient	   ID	  No.	   Treatment	   Normal	   Tumor	   Urine	  
1	   07	   SOY	   X	   X	   X	  
2	   34	   SOY	   X	   X	   X	  
3	   36	   PLACEBO	   X	   X	   X	  
4	   37	   SOY	   BPH	   X	   X	  
5	   38	   PLACEBO	   X	   X	   X	  
6	   50	   SOY	   X	   X	   X	  
Patient	  No.	  4	  (ID	  #37):	  normal	  tissue	  contained	  benign	  prostatic	  hyperplasia	  (BPH)	  cells,	  a	  
benign	  condition.	  




Table	  2.	  Frozen	  prostate	  tissue	  in	  total	  inventory	  
	   ID	  No.	   Treatment	  	   Normal	   Tumor	   Normal/tumor	  tissue	  pairs	  
1	   01	   PLACEBO	   0	   LYSATE	   No,	  lysate	  only	  
2	   02	   PLACEBO	   0	   0	   No,	  no	  samples	  in	  inventory	  
3	   04	   SOY	   0	   0	   No,	  no	  samples	  in	  inventory	  
4	   06	   SOY	   0	   0	   No,	  no	  samples	  in	  inventory	  
5	   07	   SOY	   1	   1	   Yes	  
6	   08	   PLACEBO	   0	   0	   No,	  no	  samples	  in	  inventory	  
7	   11	   PLACEBO	   0	   0	   No,	  no	  samples	  in	  inventory	  
8	   31	   SOY	   2	   0	   No,	  no	  normal	  tissue	  in	  inventory	  
9	   33	   PLACEBO	   LYSATE	  	   LYSATE	  	   No,	  lysate	  only	  
10	   34	   SOY	   1	   1	   Yes	  
11	   36	   PLACEBO	   1	   1	   Yes	  
12	   37	   SOY	   BPH	  	   1	  	   Yes,	  BPH	  is	  a	  benign	  condition	  
13	   38	   PLACEBO	   1	   1	   Yes	  
14	   50	   SOY	   1	   1	   Yes	  
BPH,	  benign	  prostatic	  hyperplasia	  




Table	  3.	  Baseline	  characteristics	  of	  study	  sample	  
Patient,	  No.	   1	   2	   3	   4	   5	   6	  
ID	  No.	   07	   34	   36	   37	   38	   50	  
Treatment	   SOY	   SOY	   PLACEBO	   SOY	   PLACEBO	   SOY	  
Age,	  yr	   69	   75	   62	   61	   63	   59	  













Weight,	  lbs	   182	   148	   209	   152	   216	   245	  
Height,	  in	   68	   68	   71	   68	   70	   67	  
BMI,	  kg/m2	   27.7	   22.5	   29.2	   23.1	   30.8	   38.4	  
PSA,	  ng/mL	   10.9	   5.6	   4.1	   21.6	   7.3	   9.5	  
Clinical	  stage	   T2A	   T2A	   T2C	   T2A	   T2A	   T1C	  
Gleason	  score	   7	   9	   7	   7	   6	   7	  
Approach	   RRP	   RRP	   RRP	   RRP	   RRP	   RRP	  
Concurrent	  
ADT	  
NO	   NO	   NO	   YES	   NO	   NO	  
Complications	   NO	   NO	   NO	   NO	   NO	   NO	  
Compliant	   YES	   YES	   YES	   YES	   YES	   YES	  
Equol	  
producer	  
YES	   NO	   PLACEBO	   NO	   PLACEBO	   NO	  
BMI,	  body	  mass	  index;	  PSA,	  prostate	  specific	  antigen;	  RRP,	  radical	  retropubic	  prostatectomy	  





Table	  4.	  Urinary	  isoflavone	  concentrations	  (nmol/L)	  of	  study	  sample	  
Patient	   1	   2	   3	   4	   5	   6	  
ID	  No.	   07	   34	   36	   37	   38	   50	  
Treatment	   SOY	   SOY	   PLACEBO	   SOY	   PLACEBO	   SOY	  
Genistein	   2.551	   5.843	   0.112	   1.370	   0.029	   12.533	  
Adjusted	  
genistein	  
2.278	   5.745	   0.093	   2.630	   0.027	   ND	  
Daidzein	   19.091	   44.402	   0.291	   12.839	   0.042	   98.164	  
Adjusted	  daidzein	   17.046	   43.660	   0.241	   24.642	   0.039	   ND	  
Glycitein	   4.617	   17.350	   0.124	   10.240	   0.029	   ND	  
Adjusted	  glycitein	   4.122	   17.350	   0.124	   10.240	   0.029	   22.276	  
ODMA	   0.184	   12.307	   0.011	   2.969	   ND	   1.158	  
Adjusted	  ODMA	   0.164	   12.307	   0.009	   5.700	   ND	   ND	  
DHD	   6.560	   10.252	   0.117	   4.835	   0.026	   4.577	  
Adjusted	  DHD	   5.858	   10.081	   0.097	   9.280	   0.024	   ND	  
Equol	  	   24.073	   0.028	   0.011	   0.018	   ND	   ND	  
Equol:daidzein	   1.261	   0.001	   0.039	   0.001	   ND	   ND	  
Equol	  producer	   YES	   NO	   PLACEBO	   NO	   PLACEBO	   NO	  
Creatinine	  
(mg/dL)	  
112	   101.7	   120.6	   52.1	   107.8	   ND	  
ND,	  no	  data;	  ODMA,	  O-­‐desmethylangolensin;	  DHD,	  dihydrodaizein	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Table	  5.	  Differentially	  expressed	  genes	  (FDR	  <	  0.05)	  down-­‐regulated	  by	  soy	  isoflavone	  
supplementation	  of	  the	  128	  differentially	  expressed	  genes	  from	  tumor	  tissue	  obtained	  from	  4	  men	  
who	  consumed	  soy	  isoflavones	  and	  2	  who	  consumed	  placebo	  (n	  =	  6)	  
	   Gene	  ID	  
Gene	  
abbreviation	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
change	   p-­‐value	   FDR	  
1	   ENSG00000112175	   BMP5	   Bone	  morphogenetic	  
protein	  5	  
6	   55618443	   55740362	   234	   6.66E-­‐16	   2.79E-­‐11	  
2	   ENSG00000170290	   SLN	   Sarcolipin	   11	   107578104	   107590419	   269	   2.37E-­‐14	   4.72E-­‐10	  
3	   ENSG00000156234	   CXCL13	   Chemokine	  (C-­‐X-­‐C	  
motif)	  ligand	  13	  
4	   78432907	   78532988	   129	   3.39E-­‐14	   4.72E-­‐10	  
4	   ENSG00000254851	   RP11-­‐
109L13.1	  
	   11	   117006244	   117009298	   340	   4.88E-­‐14	   5.11E-­‐10	  
5	   ENSG00000181617	   FDCSP	   Follicular	  dendritic	  
cell	  secreted	  protein	  
4	   71091788	   71100969	   104	   3.68E-­‐11	   2.74E-­‐07	  
6	   ENSG00000145681	   HAPLN1	   Hyaluronan	  and	  
proteoglycan	  link	  
protein	  1	  
5	   82933624	   83017432	   60	   3.93E-­‐11	   2.74E-­‐07	  
7	   ENSG00000131094	   C1QL1	   Complement	  
component	  1,	  q	  
subcomponent-­‐like	  1	  
17	   43037061	   43045439	   49	   2.15E-­‐10	   1.12E-­‐06	  
8	   ENSG00000237250	   RP11-­‐
193H5.1	  
	   1	   238025475	   238091621	   350	   6.88E-­‐10	   3.20E-­‐06	  
9	   ENSG00000171201	   SMR3B	   Submaxillary	  gland	  
androgen	  regulated	  
protein	  3B	  
4	   71235810	   71255961	   67	   1.73E-­‐09	   7.24E-­‐06	  
10	   ENSG00000164879	   CA3	   Carbonic	  anhydrase	  
III,	  muscle	  specific	  
8	   86285665	   86361269	   35	   3.96E-­‐09	   1.51E-­‐05	  




20	   62037542	   62103993	   32	   5.51E-­‐09	   1.92E-­‐05	  
12	   ENSG00000101204	   CHRNA4	   Cholinergic	  receptor,	  
nicotinic,	  alpha	  4	  
(neuronal)	  
20	   61975420	   62009753	   56	   7.95E-­‐09	   2.56E-­‐05	  
13	   ENSG00000184374	   COLEC10	   Collectin	  sub-­‐family	  
member	  10	  (C-­‐type	  
lectin)	  
8	   120007691	   120118821	   40	   9.49E-­‐09	   2.84E-­‐05	  
14	   ENSG00000171446	   KRT27	   Keratin	  27	   17	   38933060	   38938786	   60	   1.87E-­‐08	   5.21E-­‐05	  
15	   ENSG00000258027	   RP11-­‐
597A11.1	  
	   14	   20078033	   20146082	   31	   2.20E-­‐08	   5.76E-­‐05	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16	   ENSG00000117322	   CR2	   Complement	  
component	  
(3d/Epstein	  Barr	  
virus)	  receptor	  2	  
1	   207627575	   207663240	   29	   2.54E-­‐08	   6.25E-­‐05	  
17	   ENSG00000185742	   C11orf87	   Chromosome	  11	  
open	  reading	  frame	  
87	  
11	   109292846	   109299840	   58	   3.47E-­‐08	   8.04E-­‐05	  
18	   ENSG00000197616	   MYH6	   Myosin,	  heavy	  chain	  
6,	  cardiac	  muscle,	  
alpha	  
14	   23851199	   23877486	   28	   3.68E-­‐08	   8.04E-­‐05	  
19	   ENSG00000164616	   FBXL21	   F-­‐box	  and	  leucine-­‐
rich	  repeat	  protein	  
21	  
5	   135266006	   135287280	   28	   3.84E-­‐08	   8.04E-­‐05	  
20	   ENSG00000121075	   TBX4	   T-­‐box	  4	   17	   59529765	   59562471	   23	   8.97E-­‐08	   0.00017071	  
21	   ENSG00000253400	   RP11-­‐
337A23.6	  
	   9	   26801731	   26805860	   181	   1.13E-­‐07	   0.00020532	  
22	   ENSG00000253998	   IGKV2-­‐29	   Immunoglobulin	  
kappa	  variable	  2-­‐29	  
2	   89533655	   89534393	   174	   1.35E-­‐07	   0.00023415	  
23	   ENSG00000266554	   RP11-­‐
537H14.2	  
	   18	   14946266	   14973769	   78	   1.40E-­‐07	   0.00023415	  
24	   ENSG00000185668	   POU3F1	   POU	  class	  3	  
homeobox	  1	  
1	   38509523	   38512450	   23	   1.53E-­‐07	   0.00024649	  
25	   ENSG00000184613	   NELL2	   NEL-­‐like	  2	  (chicken)	   12	   44902058	   45315631	   19	   3.99E-­‐07	   0.0005937	  
26	   ENSG00000184258	   CDR1	   Cerebellar	  
degeneration-­‐related	  
protein	  1,	  34kDa	  
X	   139865425	   139866723	   67	   4.59E-­‐07	   0.00062761	  
27	   ENSG00000188778	   ADRB3	   Adrenoceptor	  beta	  3	   8	   37820516	   37824483	   22	   4.65E-­‐07	   0.00062761	  
28	   ENSG00000104921	   FCER2	   Fc	  fragment	  of	  IgE,	  
low	  affinity	  II,	  
receptor	  for	  (CD23)	  
19	   7753644	   7767032	   22	   5.60E-­‐07	   0.00072277	  
29	   ENSG00000257357	   RP11-­‐
244H18.3	  
	   14	   20105463	   20109540	   24	   5.87E-­‐07	   0.00072277	  




11	   2016406	   2022700	   18	   6.06E-­‐07	   0.00072277	  
31	   ENSG00000257432	   RP11-­‐
244H18.4	  
	   14	   20097282	   20098616	   22	   6.22E-­‐07	   0.00072277	  
32	   ENSG00000224521	   RP11-­‐
438F14.3	  
	   1	   248712057	   248727140	   134	   9.94E-­‐07	   0.00109547	  




13	   23755091	   23899304	   17	   1.06E-­‐06	   0.00113499	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34	   ENSG00000141744	   PNMT	   Phenylethanolamine	  
N-­‐methyltransferase	  
17	   37824234	   37826728	   17	   1.19E-­‐06	   0.00124436	  
35	   ENSG00000138207	   RBP4	   Retinol	  binding	  
protein	  4,	  plasma	  
10	   95351444	   95361501	   16	   1.46E-­‐06	   0.00145278	  
36	   ENSG00000263556	   RN7SL383P	   RNA,	  7SL,	  
cytoplasmic	  383,	  
pseudogene	  
5	   44716292	   44716587	   130	   1.57E-­‐06	   0.00153224	  
37	   ENSG00000179455	   MKRN3	   Makorin	  ring	  finger	  
protein	  3	  
15	   23810454	   23873064	   23	   1.73E-­‐06	   0.00164774	  
38	   ENSG00000181072	   CHRM2	   Cholinergic	  receptor,	  
muscarinic	  2	  
7	   136553416	   136705002	   33	   1.83E-­‐06	   0.00170513	  
39	   ENSG00000260125	   RP11-­‐
31E22.1	  
	   15	   86838880	   86860404	   40	   2.03E-­‐06	   0.0018495	  
40	   ENSG00000255399	   TBX5-­‐AS1	   TBX5	  antisense	  RNA	  
1	  
12	   114845996	   114850636	   16	   2.42E-­‐06	   0.00215714	  
41	   ENSG00000170054	   SERPINA9	   Serpin	  peptidase	  





14	   94929054	   94946026	   118	   2.55E-­‐06	   0.00218999	  
42	   ENSG00000019169	   MARCO	   Macrophage	  
receptor	  with	  
collagenous	  structure	  
2	   119699742	   119752236	   15	   2.62E-­‐06	   0.00219449	  
43	   ENSG00000100427	   MLC1	   Megalencephalic	  
leukoencephalopathy	  
with	  subcortical	  cysts	  
1	  
22	   50497820	   50524331	   14	   3.78E-­‐06	   0.00304331	  
44	   ENSG00000162989	   KCNJ3	   Potassium	  inwardly-­‐
rectifying	  channel,	  
subfamily	  J,	  member	  
3	  
2	   155554811	   155714863	   14	   4.62E-­‐06	   0.00360292	  
45	   ENSG00000118231	   CRYGD	   Crystallin,	  gamma	  D	   2	   208986331	   208989225	   49	   4.79E-­‐06	   0.00364794	  
46	   ENSG00000173976	   RAX2	   Retina	  and	  anterior	  
neural	  fold	  
homeobox	  2	  
19	   3769087	   3772233	   109	   5.56E-­‐06	   0.00408458	  
47	   ENSG00000228408	   RP1-­‐111D6.3	   	   6	   149539062	   149565208	   106	   5.56E-­‐06	   0.00408458	  
48	   ENSG00000249201	   CTD-­‐
3080P12.3	  
	   5	   1173256	   1178720	   102	   7.32E-­‐06	   0.00504856	  
49	   ENSG00000185002	   RFX6	   Regulatory	  factor	  X,	  6	   6	   117198375	   117253326	   15	   7.36E-­‐06	   0.00504856	  
50	   ENSG00000105989	   WNT2	   Wingless-­‐type	  MMTV	  
integration	  site	  
family	  member	  2	  
7	   116916685	   116963343	   12	   9.60E-­‐06	   0.00648123	  
51	   ENSG00000261076	   RP11-­‐
179B15.6	  
	   10	   66085374	   60086790	   43	   1.14E-­‐05	   0.00732234	  
	   40	  
52	   ENSG00000228294	   AL589743.2	   	   14	   19670480	   19686002	   26	   1.23E-­‐05	   0.00777982	  
53	   ENSG00000257162	   RP11-­‐
244H18.2	  
	   14	   20071068	   20074896	   93	   1.30E-­‐05	   0.00814965	  
54	   ENSG00000234184	   RP5-­‐
887A10.1	  
	   1	   81001440	   81112473	   14	   1.36E-­‐05	   0.00839273	  
55	   ENSG00000181195	   PENK	   Proenkephalin	   8	   57349233	   57359293	   12	   1.51E-­‐05	   0.00916479	  
56	   ENSG00000235743	   RP11-­‐
439H9.1	  
	   6	   23337939	   23346788	   92	   1.77E-­‐05	   0.01026902	  
57	   ENSG00000238773	   AL137855.1	   	   1	   58222756	   58222848	   92	   1.77E-­‐05	   0.01026902	  
58	   ENSG00000211892	   IGHG4	   Immunoglobulin	  
heavy	  constant	  
gamma	  4	  (G4m	  
marker)	  
14	   106090687	   106092403	   11	   2.08E-­‐05	   0.0118659	  
59	   ENSG00000188176	   SMTNL2	   Smoothelin-­‐like	  2	   17	   4487294	   4511614	   12	   2.10E-­‐05	   0.0118659	  
60	   ENSG00000211670	   IGLV3-­‐9	   Immunoglobulin	  
lambda	  variable	  3-­‐9	  
22	   23161507	   23162253	   12	   2.30E-­‐05	   0.01283791	  
61	   ENSG00000174482	   LINGO2	   Leucine	  rich	  repeat	  
and	  Ig	  domain	  
containing	  2	  
9	   27948076	   28670283	   12	   2.65E-­‐05	   0.01439979	  
62	   ENSG00000123572	   NRK	   Nik	  related	  kinase	   X	   105066536	   105202602	   10	   3.94E-­‐05	   0.02086231	  
63	   ENSG00000188000	   OR7D2	   Olfactory	  receptor,	  
family	  7,	  subfamily	  D,	  
member	  2	  
19	   9296279	   9299493	   14	   4.09E-­‐05	   0.02088368	  
64	   ENSG00000139767	   SRRM4	   Serine/arginine	  
repetitive	  matrix	  4	  
12	   119419300	   119600856	   14	   4.20E-­‐05	   0.02116363	  
65	   ENSG00000171189	   GRIK1	   Glutamate	  receptor,	  
ionotropic,	  kainate	  1	  
21	   30909254	   31312351	   10	   4.36E-­‐05	   0.021459	  
66	   ENSG00000149295	   DRD2	   Dopamine	  receptor	  
D2	  
11	   113280318	   113346413	   10	   4.60E-­‐05	   0.02179889	  
67	   ENSG00000260412	   RP11-­‐
438B23.2	  
	   9	   27937615	   27944495	   15	   5.25E-­‐05	   0.02439748	  
68	   ENSG00000259384	   GH1	   Growth	  hormone	  1	   17	   61994560	   61996179	   25	   5.68E-­‐05	   0.02585888	  
69	   ENSG00000234665	   RP11-­‐
262H14.3	  
	   9	   66513488	   66553911	   14	   5.86E-­‐05	   0.0263856	  
	   41	  
70	   ENSG00000255760	   RP11-­‐
428G5.5	  
	   12	   32030013	   32040137	   13	   5.99E-­‐05	   0.02656543	  
71	   ENSG00000130700	   GATA5	   GATA	  binding	  protein	  
5	  
20	   61038553	   61051026	   10	   6.08E-­‐05	   0.02656543	  
72	   ENSG00000154016	   GRAP	   GRB2-­‐related	  
adaptor	  protein	  
17	   18923986	   18950950	   74	   6.66E-­‐05	   0.02819966	  
73	   ENSG00000186207	   LCE5A	   Late	  cornified	  
envelope	  5A	  
1	   152483320	   152484653	   71	   6.66E-­‐05	   0.02819966	  
74	   ENSG00000163534	   FCRL1	   Fc	  receptor-­‐like	  1	   1	   157764193	   157789895	   10	   6.67E-­‐05	   0.02819966	  
75	   ENSG00000101440	   ASIP	   Agouti	  signaling	  
protein	  
20	   32782375	   32857150	   10	   7.24E-­‐05	   0.03002326	  
76	   ENSG00000234931	   MARK2P15	   MAP/microtubule	  
affinity-­‐regulating	  
kinase	  2	  pseudogene	  
15	  
10	   85071384	   85074231	   29	   7.24E-­‐05	   0.03002326	  
77	   ENSG00000234224	   TMEM229A	   Transmembrane	  
protein	  229A	  
7	   123670973	   123673523	   11	   7.46E-­‐05	   0.0300731	  
78	   ENSG00000175513	   TSGA10IP	   Testis	  specific,	  10	  
interacting	  protein	  
11	   65712916	   65727434	   13	   7.54E-­‐05	   0.0300731	  
79	   ENSG00000233403	   RP11-­‐86A5.1	   	   X	   25896456	   25911661	   31	   8.60E-­‐05	   0.03387416	  
80	   ENSG00000254278	   RP11-­‐
278I4.2	  
	   8	   120075181	   120081021	   71	   9.59E-­‐05	   0.03616201	  
81	   ENSG00000231882	   F10-­‐AS1	   F10	  antisense	  RNA	  1	   13	   113782469	   113783194	   67	   9.59E-­‐05	   0.03616201	  
82	   ENSG00000229231	   FEM1AP1	   Fem-­‐1	  homolog	  a	  (C.	  
elegans)	  pseudogene	  
1	  
21	   15134659	   15136653	   67	   9.59E-­‐05	   0.03616201	  
83	   ENSG00000197766	   CFD	   Complement	  factor	  D	  
(adipsin)	  
19	   859453	   863569	   9	   9.99E-­‐05	   0.03698971	  
84	   ENSG00000100433	   KCNK10	   Potassium	  channel,	  
subfamily	  K,	  member	  
10	  
14	   88649113	   88793251	   13	   0.00010074	   0.03698971	  
85	   ENSG00000170356	   OR2A20P	   Olfactory	  receptor,	  
family	  2,	  subfamily	  A,	  
member	  20	  
pseudogene	  
7	   143947138	   143950050	   12	   0.00010074	   0.03698971	  
86	   ENSG00000129988	   LBP	   Lipopolysaccharide	  
binding	  protein	  
20	   36974759	   37005665	   11	   0.00010695	   0.038504	  
87	   ENSG00000213424	   KRT222	   Keratin	  222	   17	   38810917	   38821433	   10	   0.00010762	   0.038504	  
	   42	  
88	   ENSG00000260896	   RP11-­‐
314O13.1	  
	   16	   80862632	   80926492	   9	   0.00011354	   0.04027704	  
89	   ENSG00000230229	   RP11-­‐90J7.4	   	   10	   80112354	   80115857	   14	   0.00012331	   0.04266026	  
90	   ENSG00000110675	   ELMOD1	   ELMO/CED-­‐12	  
domain	  containing	  1	  
11	   107461817	   107537505	   9	   0.00012445	   0.04270224	  




16	   48200821	   48281479	   9	   0.00013328	   0.04499134	  
92	   ENSG00000259761	   RP11-­‐
138H10.2	  
	   15	   87585285	   87590392	   64	   0.00014028	   0.04660497	  
93	   ENSG00000111704	   NANOG	   NANOG	  homeobox	   12	   7940390	   7948655	   62	   0.00014028	   0.04660497	  
Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	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Table	  6.	  Differentially	  expressed	  genes	  (FDR	  <	  0.05)	  up-­‐regulated	  by	  soy	  isoflavone	  
supplementation	  of	  the	  128	  differentially	  expressed	  genes	  from	  tumor	  tissue	  obtained	  from	  4	  
men	  who	  consumed	  soy	  isoflavones	  and	  2	  who	  consumed	  placebo	  (n	  =	  6)	   	  
	   Gene	  ID	  
Gene	  
abbreviation	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
change	   p-­‐value	   FDR	  
1	   ENSG00000164266	   SPINK1	   Serine	  peptidase	  
inhibitor,	  Kazal	  
type	  1	  
5	   147204131	   147211349	   518	   9.04E-­‐11	   5.41E-­‐07	  
2	   ENSG00000052850	   ALX4	   ALX	  homeobox	  4	   11	   44281994	   44331716	   131	   5.59E-­‐08	   0.0001115	  
3	   ENSG00000171564	   FGB	   Fibrinogen	  beta	  
chain	  
4	   155484108	   155492238	   222	   2.78E-­‐07	   0.00043134	  
4	   ENSG00000204612	   FOXB2	   Forkhead	  box	  B2	   9	   79634571	   79635869	   662	   4.11E-­‐07	   0.0005937	  
5	   ENSG00000233760	   AC004947.2	   	  	   7	   26591441	   26596819	   68	   5.90E-­‐07	   0.00072277	  
6	   ENSG00000144355	   DLX1	   Distal-­‐less	  
homeobox	  1	  
2	   172949468	   172954405	   66	   7.26E-­‐07	   0.00082111	  




19	   42177235	   42210895	   63	   1.42E-­‐06	   0.00145162	  
8	   ENSG00000170369	   CST2	   Cystatin	  SA	   20	   23804406	   23807368	   45	   2.56E-­‐06	   0.00218999	  
9	   ENSG00000096006	   CRISP3	   Cysteine-­‐rich	  
secretory	  protein	  
3	  
6	   49695097	   49712150	   44	   3.69E-­‐06	   0.00302595	  
10	   ENSG00000226278	   PSPHP1	   Phosphoserine	  
phosphatase	  
pseudogene	  1	  
7	   55832490	   55840981	   116	   4.65E-­‐06	   0.00360292	  
11	   ENSG00000171759	   PAH	   Phenylalanine	  
hydroxylase	  
12	   103230663	   103352188	   36	   6.65E-­‐06	   0.00479909	  
12	   ENSG00000126733	   DACH2	   Dachshund	  
homolog	  2	  
(Drosophila)	  
X	   85403462	   86087607	   36	   7.24E-­‐06	   0.00504856	  
13	   ENSG00000240045	   RP11-­‐451G4.2	   	  	   3	   155008018	   155011564	   48	   1.02E-­‐05	   0.00680086	  
14	   ENSG00000227560	   RP11-­‐139K1.2	   	  	   10	   114747235	   114747624	   46	   1.12E-­‐05	   0.00732234	  
15	   ENSG00000170373	   CST1	   Cystatin	  SN	   20	   23728190	   23731905	   29	   1.67E-­‐05	   0.00996704	  
	   44	  
16	   ENSG00000153294	   GPR115	   G	  protein-­‐
coupled	  receptor	  
115	  
6	   47653600	   47689757	   40	   2.42E-­‐05	   0.01331627	  
17	   ENSG00000254349	   RP11-­‐
758M4.1	  
	  	   8	   75512010	   75735548	   29	   3.75E-­‐05	   0.02015023	  
18	   ENSG00000156096	   UGT2B4	   UDP	  
glucuronosyltran
sferase	  2	  family,	  
polypeptide	  B4	  
4	   70345883	   70391732	   28	   4.06E-­‐05	   0.02088368	  
19	   ENSG00000134443	   GRP	   Gastrin-­‐releasing	  
peptide	  
18	   56887400	   56898006	   25	   4.08E-­‐05	   0.02088368	  
20	   ENSG00000171560	   FGA	   Fibrinogen	  alpha	  
chain	  
4	   155504278	   155511918	   225	   4.28E-­‐05	   0.02134795	  
21	   ENSG00000100665	   SERPINA4	   Serpin	  peptidase	  





14	   95027428	   95036250	   63	   4.48E-­‐05	   0.02179889	  
22	   ENSG00000230327	   AC009234.1	   	  	   2	   50815828	   50816553	   39	   4.60E-­‐05	   0.02179889	  
23	   ENSG00000172238	   ATOH1	   Atonal	  homolog	  
1	  (Drosophila)	  
4	   94750042	   94751221	   216	   4.63E-­‐05	   0.02179889	  
24	   ENSG00000170426	   SDR9C7	   Short	  chain	  
dehydrogenase/r
eductase	  family	  
9C,	  member	  7	  
12	   57316938	   57328189	   25	   5.60E-­‐05	   0.02573882	  
25	   ENSG00000154975	   CA10	   Carbonic	  
anhydrase	  X	  
17	   49707674	   50237377	   36	   6.09E-­‐05	   0.02656543	  
26	   ENSG00000237567	   RP3-­‐359N14.2	   	  	   6	   106060542	   106080071	   24	   7.39E-­‐05	   0.0300731	  
27	   ENSG00000095627	   TDRD1	   Tudor	  domain	  
containing	  1	  
10	   115939029	   115992063	   23	   7.52E-­‐05	   0.0300731	  
28	   ENSG00000224099	   AC064834.1	   	  	   2	   196313256	   196343649	   31	   8.66E-­‐05	   0.03387416	  





6	   25754927	   25781419	   27	   8.89E-­‐05	   0.03447194	  
30	   ENSG00000261045	   RP11-­‐
673P17.4	  
	  	   16	   27169775	   27187908	   22	   0.0001071
4	  
0.038504	  
31	   ENSG00000247627	   MTND4P12	   MT-­‐ND4	  
pseudogene	  12	  
5	   134262350	   134263726	   18	   0.0001145
3	  
0.04028588	  
32	   ENSG00000243236	   RP1-­‐
214M20.2	  
	  	   6	   52804524	   52822319	   18	   0.0001176
8	  
0.04105023	  
33	   ENSG00000156925	   ZIC3	   ZIC	  family	  
member	  3	  
X	   136648301	   136659850	   53	   0.0001293
2	  
0.04401105	  
	   45	  
34	   ENSG00000128564	   VGF	   VGF	  nerve	  
growth	  factor	  
inducible	  
7	   100805790	   100808874	   19	   0.0001453
7	  
0.04791442	  
35	   ENSG00000187416	   LHFPL3	   Lipoma	  HMGIC	  
fusion	  partner-­‐
like	  3	  
7	   103969104	   104549001	   21	   0.0001502
1	  
0.04912182	  
Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	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Table	  7.	  Differentially	  expressed	  genes	  (FDR	  <	  0.05)	  down-­‐regulated	  by	  soy	  isoflavone	  
supplementation	  of	  the	  108	  differentially	  expressed	  genes	  from	  only	  tumor	  tissue	  obtained	  from	  
4	  men	  who	  consumed	  soy	  isoflavones	  and	  2	  who	  consumed	  placebo	  (n	  =	  6)	  
	   Gene	  ID	  
Gene	  
abbreviation	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
change	   p-­‐value	   FDR	  
1	   ENSG00000112175	   BMP5	   Bone	  
morphogenetic	  
protein	  5	  
6	   55618443	   55740362	   234	   6.66E-­‐16	   2.79E-­‐11	  
2	   ENSG00000170290	   SLN	   Sarcolipin	   11	   1.08E+08	   1.08E+08	   269	   2.37E-­‐14	   4.72E-­‐10	  
3	   ENSG00000156234	   CXCL13	   Chemokine	  (C-­‐X-­‐
C	  motif)	  ligand	  
13	  
4	   78432907	   78532988	   129	   3.39E-­‐14	   4.72E-­‐10	  
4	   ENSG00000181617	   FDCSP	   Follicular	  
dendritic	  cell	  
secreted	  protein	  
4	   71091788	   71100969	   104	   3.68E-­‐11	   2.74E-­‐07	  
5	   ENSG00000145681	   HAPLN1	   Hyaluronan	  and	  
proteoglycan	  link	  
protien	  1	  
5	   82933624	   83017432	   60	   3.93E-­‐11	   2.74E-­‐07	  
6	   ENSG00000131094	   C1QL1	   Complement	  
component	  1,	  q	  
subcomponent-­‐
like	  1	  
17	   43037061	   43045439	   49	   2.15E-­‐10	   1.12E-­‐06	  
7	   ENSG00000237250	   RP11-­‐193H5.1	   	  	   1	   238025475	   238091621	   350	   6.88E-­‐10	   3.20E-­‐06	  




4	   71235810	   71255961	   67	   1.73E-­‐09	   7.24E-­‐06	  
9	   ENSG00000164879	   CA3	   Carbonic	  
anhydrase	  III,	  
muscle	  specific	  
8	   86285665	   86361269	   35	   3.96E-­‐09	   1.51E-­‐05	  





20	   62037542	   62103993	   32	   5.51E-­‐09	   1.92E-­‐05	  
11	   ENSG00000101204	   CHRNA4	   Cholinergic	  
receptor,	  
nicotinic,	  alpha	  4	  
(neuronal)	  
20	   61975420	   62009753	   56	   7.95E-­‐09	   2.56E-­‐05	  
12	   ENSG00000184374	   COLEC10	   Collectin	  
subfamily	  
member	  10	  
8	   120007691	   120118821	   40	   9.49E-­‐09	   2.84E-­‐05	  
13	   ENSG00000171446	   KRT27	   Keratin	  27	   17	   38933060	   38938786	   60	   1.87E-­‐08	   5.21E-­‐05	  
14	   ENSG00000117322	   CR2	   Complement	  
component	  
(3d/Epstein	  Barr	  
virus)	  receptor	  2	  
1	   207627575	   207663240	   29	   2.54E-­‐08	   6.25E-­‐05	  
15	   ENSG00000185742	   C11orf87	   Chromosome	  11	  
open	  reading	  
frame	  87	  
11	   109292846	   109299840	   58	   3.47E-­‐08	   8.04E-­‐05	  
	   47	  
16	   ENSG00000197616	   MYH6	   Myosin,	  heavy	  
chain	  6,	  cardiac	  
muscle,	  alpha	  
14	   23851199	   23877486	   28	   3.68E-­‐08	   8.04E-­‐05	  




5	   135266006	   135287820	   28	   3.84E-­‐08	   8.04E-­‐05	  
18	   ENSG00000253400	   RP11-­‐
337A23.6	  
	  	   9	   26801731	   26805860	   181	   1.13E-­‐07	   0.000205318	  
19	   ENSG00000266554	   RP11-­‐
527H14.2	  
	  	   18	   14946266	   14973769	   78	   1.40E-­‐07	   0.000234152	  
20	   ENSG00000185668	   POU3F1	   POU	  class	  3	  
homeobox	  1	  
1	   38509523	   38512450	   23	   1.53E-­‐07	   0.000246492	  
21	   ENSG00000184613	   NELL2	   NEL-­‐like	  2	  
(chicken)	  
12	   44902058	   45315631	   19	   3.99E-­‐07	   0.000593697	  




X	   139865425	   139866723	   67	   4.59E-­‐07	   0.000627607	  
23	   ENSG00000188778	   ADRB3	   Adrenoreceptor	  
beta	  3	  
8	   37820516	   37824483	   22	   4.65E-­‐07	   0.000627607	  
24	   ENSG00000104921	   FCER2	   Fc	  fragment	  of	  
IgE,	  low	  affinity	  
II,	  receptor	  for	  
(CD23)	  
19	   7753644	   7767032	   22	   5.60E-­‐07	   0.00072277	  





11	   2016406	   2022700	   18	   6.06E-­‐07	   0.00072277	  
26	   ENSG00000257432	   RP11-­‐
244H18.4	  
	  	   14	   20097282	   20098616	   22	   6.22E-­‐07	   0.00072277	  
27	   ENSG00000224521	   RP11-­‐
438F14.3	  
	  	   1	   248712057	   248727140	   134	   9.94E-­‐07	   0.001095466	  





13	   23755091	   23899304	   17	   1.06E-­‐06	   0.001134986	  




17	   37824234	   37826728	   17	   1.19E-­‐06	   0.001244355	  
30	   ENSG00000138207	   RBP4	   Retinol	  binding	  
protein	  4,	  
plasma	  
10	   95351444	   95361501	   16	   1.46E-­‐06	   0.00145278	  
31	   ENSG00000263556	   RN7SL383P	   RNA,	  7SL,	  
cytoplasmic	  383,	  
pseudogene	  
5	   44716292	   44716587	   130	   1.57E-­‐06	   0.001532245	  
32	   ENSG00000179455	   MKRN3	   Makorin	  ring	  
finger	  protein	  3	  
15	   23810454	   23873064	   23	   1.73E-­‐06	   0.00164774	  
33	   ENSG00000181072	   CHRM2	   Cholinergic	  
receptor,	  
muscarinic	  2	  
7	   136553416	   136705002	   33	   1.83E-­‐06	   0.001705134	  
	   48	  
34	   ENSG00000255399	   TBX5-­‐AS1	   TBX5	  antisense	  
RNA	  1	  
12	   114845996	   114850636	   16	   2.42E-­‐06	   0.002157141	  
35	   ENSG00000170054	   SERPINA9	   Serpin	  peptidase	  





14	   94929054	   94946026	   118	   2.55E-­‐06	   0.002189989	  




2	   119699742	   119752236	   15	   2.62E-­‐06	   0.002194493	  





22	   50497820	   50524331	   14	   3.78E-­‐06	   0.003043306	  






2	   155554811	   155714863	   14	   4.62E-­‐06	   0.003602916	  
39	   ENSG00000118231	   CRYGD	   Crystallin,	  
gamma	  D	  
2	   208986331	   208989225	   49	   4.79E-­‐06	   0.003647939	  
40	   ENSG00000173976	   RAX2	   Retina	  and	  
anterior	  neural	  
fold	  homeobox	  2	  
19	   3769087	   3772233	   109	   5.56E-­‐06	   0.00408458	  
41	   ENSG00000228408	   RP1-­‐111D6.3	   	  	   6	   149539062	   149565208	   106	   5.56E-­‐06	   0.00408458	  
42	   ENSG00000249201	   CTD-­‐
3080P12.3	  
	  	   5	   1173256	   1178720	   102	   7.32E-­‐06	   0.005048563	  
43	   ENSG00000185002	   RFX6	   Regulatory	  factor	  
X,	  6	  
6	   117198375	   117253326	   15	   7.36E-­‐06	   0.005048563	  
44	   ENSG00000105989	   WNT2	   Wingless-­‐type	  
MMTV	  
integration	  site	  
family	  member	  2	  
7	   116916685	   116963343	   12	   9.60E-­‐06	   0.006481232	  
45	   ENSG00000261076	   RP11-­‐
179B15.6	  
	  	   10	   66085374	   60086790	   43	   1.14E-­‐05	   0.007322341	  
46	   ENSG00000228294	   AL589743.2	   	  	   14	   19670480	   19686002	   26	   1.23E-­‐05	   0.00777982	  
47	   ENSG00000257162	   RP11-­‐
244H18.2	  
	  	   14	   20071068	   20074896	   93	   1.30E-­‐05	   0.008149649	  
48	   ENSG00000234184	   RP5-­‐887A10.1	   	  	   1	   81001440	   81112473	   14	   1.36E-­‐05	   0.008392733	  
49	   ENSG00000181195	   PENK	   Proenkephalin	   8	   57349233	   57359293	   12	   1.51E-­‐05	   0.009164791	  
50	   ENSG00000235743	   RP11-­‐439H9.1	   	  	   6	   23337939	   23346788	   92	   1.77E-­‐05	   0.010269018	  
51	   ENSG00000238773	   AL137855.1	   	  	   1	   58222756	   58222848	   92	   1.77E-­‐05	   0.010269018	  
	   49	  
52	   ENSG00000211892	   IGHG4	   Immunoglobulin	  
heavy	  constant	  
gamma	  4	  (G4m	  
marker)	  
14	   106090687	   106092403	   11	   2.08E-­‐05	   0.011865899	  
53	   ENSG00000188176	   SMTNL2	   Smoothelin-­‐like	  
2	  
17	   4487294	   4511614	   12	   2.10E-­‐05	   0.011865899	  





22	   23161507	   23162253	   12	   2.30E-­‐05	   0.012837914	  
55	   ENSG00000174482	   LINGO2	   Leucine	  rich	  
repeat	  and	  Ig	  
domain	  
containing	  2	  
9	   27948076	   28670283	   12	   2.65E-­‐05	   0.014399793	  
56	   ENSG00000123572	   NRK	   NIK	  related	  
kinase	  
X	   105066536	   105202602	   10	   3.94E-­‐05	   0.020862314	  
57	   ENSG00000139767	   SRRM4	   Serine/arginine	  
repetitive	  matrix	  
4	  
12	   119419300	   119600856	   14	   4.20E-­‐05	   0.021163626	  




21	   30909254	   31312351	   10	   4.36E-­‐05	   0.021458998	  
59	   ENSG00000149295	   DRD2	   Dopamine	  
receptor	  D2	  
11	   113280318	   113346413	   10	   4.60E-­‐05	   0.021798893	  
60	   ENSG00000260412	   RP11-­‐
438B23.2	  
	  	   9	   27937615	   27944495	   15	   5.25E-­‐05	   0.024397483	  
61	   ENSG00000259384	   GH1	   Growth	  hormone	  
1	  
17	   61994560	   61996179	   25	   5.68E-­‐05	   0.025858877	  
62	   ENSG00000255760	   RP11-­‐428G5.5	   	  	   12	   32030013	   32040137	   13	   5.99E-­‐05	   0.02656543	  
63	   ENSG00000130700	   GATA5	   GATA	  binding	  
protein	  5	  
20	   61038553	   61051026	   10	   6.08E-­‐05	   0.02656543	  
64	   ENSG00000154016	   GRAP	   GRB2-­‐related	  
adaptor	  protein	  
17	   18923986	   18950950	   74	   6.66E-­‐05	   0.028199661	  
65	   ENSG00000186207	   LCE5A	   Late	  cornified	  
envelope	  5A	  
1	   152483320	   152484653	   71	   6.66E-­‐05	   0.028199661	  
66	   ENSG00000163534	   FCRL1	   Fc	  receptor-­‐like	  1	   1	   157764193	   157789895	   10	   6.67E-­‐05	   0.028199661	  
67	   ENSG00000101440	   ASIP	   Agouti	  signaling	  
protein	  
20	   32782375	   32857150	   10	   7.24E-­‐05	   0.030023263	  
68	   ENSG00000234224	   TMEM229A	   Transmembrane	  
protein	  229A	  
7	   123670973	   123673523	   11	   7.46E-­‐05	   0.030073102	  
69	   ENSG00000175513	   TSGA10IP	   Testis	  specific,	  10	  
interacting	  
protein	  
11	   65712916	   65727434	   13	   7.54E-­‐05	   0.030073102	  
	   50	  
70	   ENSG00000233403	   RP11-­‐86A5.1	   	  	   X	   25896456	   25911661	   31	   8.60E-­‐05	   0.033874159	  
71	   ENSG00000254278	   RP11-­‐278I4.2	   	  	   8	   120075181	   120081021	   71	   9.59E-­‐05	   0.036162015	  
72	   ENSG00000231882	   F10-­‐As1	   F10	  antisense	  
RNA	  1	  
13	   113782469	   113783194	   67	   9.59E-­‐05	   0.036162015	  
73	   ENSG00000229231	   FEM1AP1	   Fem-­‐1	  homolog	  
a	  (C.	  elegans)	  
pseudogene	  1	  
21	   15134659	   15136653	   67	   9.59E-­‐05	   0.036162015	  
74	   ENSG00000197766	   CFD	   Complement	  
factor	  D	  (adipsin)	  
19	   859453	   863569	   9	   9.99E-­‐05	   0.03698971	  




14	   88649113	   88793251	   13	   0.000100736	   0.03698971	  
76	   ENSG00000129988	   LBP	   Lipopolysacchari
de	  binding	  
protein	  
20	   36974759	   37005665	   11	   0.000106947	   0.038504	  
77	   ENSG00000213424	   KRT222	   Keratin	  222	   17	   38810917	   38821433	   10	   0.00010762	   0.038504	  
78	   ENSG00000260896	   RP11-­‐
314O13.1	  
	  	   16	   80862632	   80926492	   9	   0.000113538	   0.040277045	  
79	   ENSG00000230229	   RP11-­‐90J7.4	   	  	   10	   80112354	   80115857	   14	   0.000123313	   0.04266026	  
80	   ENSG00000110675	   ELMOD1	   ELMO/CED-­‐12	  
domain	  
containing	  1	  
11	   107461817	   107537505	   9	   0.000124455	   0.04270224	  





16	   48200821	   48281479	   9	   0.000133276	   0.044991335	  
82	   ENSG00000111704	   NANOG	   NANOG	  
homeobox	  
12	   7940390	   7948655	   62	   0.000140283	   0.046604968	  
Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	  
	  
	   51	  
	  
Table	  8.	  Differentially	  expressed	  genes	  (FDR	  <	  0.05)	  up-­‐regulated	  by	  soy	  isoflavone	  
supplementation	  of	  the	  108	  differentially	  expressed	  genes	  from	  only	  tumor	  tissue	  obtained	  from	  4	  




abbreviation	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
change	   p-­‐value	   FDR	  
1	   ENSG00000052850	   ALX4	   ALX	  homeobox	  4	   11	   44281994	   44331716	   131	   5.59E-­‐08	   0.000111501	  
2	   ENSG00000204612	   FOXB2	   Forkhead	  box	  B2	   9	   79634571	   79635869	   662	   4.11E-­‐07	   0.000593697	  
3	   ENSG00000144355	   DLX1	   Distal-­‐less	  
homeobox	  1	  
2	   172949468	   172954405	   66	   7.26E-­‐07	   0.000821114	  




19	   42177235	   42210895	   63	   1.42E-­‐06	   0.001451622	  
5	   ENSG00000171759	   PAH	   Phenylalanine	  
hydroxlyase	  
12	   103230663	   103352188	   36	   6.65E-­‐06	   0.004799086	  
6	   ENSG00000126733	   DACH2	   Dachshund	  
homolog	  2	  
(Drosophila)	  
X	   85403462	   86087607	   36	   7.24E-­‐06	   0.005048563	  
7	   ENSG00000240045	   RP11-­‐451G4.2	   	  	   3	   155008018	   155011564	   48	   1.02E-­‐05	   0.006800863	  
8	   ENSG00000227560	   RP11-­‐139K1.2	   	  	   10	   114747235	   114747624	   46	   1.12E-­‐05	   0.007322341	  
9	   ENSG00000170373	   CST1	   Cystatin	  SN	   20	   23728190	   23731905	   29	   1.67E-­‐05	   0.009967044	  
10	   ENSG00000153294	   GPR115	   G	  protein-­‐coupled	  
receptor	  115	  
6	   47653600	   47689757	   40	   2.42E-­‐05	   0.013316272	  
11	   ENSG00000254349	   RP11-­‐
758M4.1	  
	  	   8	   75512010	   75735548	   29	   3.75E-­‐05	   0.020150228	  
12	   ENSG00000134443	   GRP	   Gastrin-­‐releasing	  
peptide	  
18	   56887400	   56898006	   25	   4.08E-­‐05	   0.020883677	  
13	   ENSG00000171560	   FGA	   Fibrinogen	  alpha	  
chain	  
4	   155504278	   155511918	   225	   4.28E-­‐05	   0.021347954	  
14	   ENSG00000100665	   SERPINA4	   Serpin	  peptidase	  





14	   95027428	   95036250	   63	   4.48E-­‐05	   0.021798893	  
15	   ENSG00000230327	   AC009234.1	   	  	   2	   50815828	   50816553	   39	   4.60E-­‐05	   0.021798893	  
	   52	  
16	   ENSG00000170426	   SDR9C7	   Short	  chain	  
dehydrogenase/red
uctase	  family	  9C,	  
member	  7	  
12	   57316938	   57328189	   25	   5.60E-­‐05	   0.025738821	  
17	   ENSG00000154975	   CA10	   Carbonic	  anhydrase	  
X	  
17	   49707674	   50237377	   36	   6.09E-­‐05	   0.02656543	  
18	   ENSG00000237567	   RP3-­‐
359N14.2	  
	  	   6	   106060542	   106080071	   24	   7.39E-­‐05	   0.030073102	  
19	   ENSG00000095627	   TDRD1	   Tudor	  domain	  
containing	  1	  
10	   115939029	   115992063	   23	   7.52E-­‐05	   0.030073102	  
20	   ENSG00000224099	   AC064834.1	   	  	   2	   196313256	   196343649	   31	   8.66E-­‐05	   0.033874159	  




6	   25754927	   25781419	   27	   8.89E-­‐05	   0.034471943	  
22	   ENSG00000261045	   RP11-­‐
673P17.4	  
	  	   16	   27169775	   27187908	   22	   0.000107141	   0.038504	  
23	   ENSG00000243236	   RP1-­‐
214M20.2	  
	  	   6	   52804524	   52822319	   18	   0.000117679	   0.041050234	  
24	   ENSG00000156925	   ZIC3	   ZIC	  family	  member	  
3	  
X	   136648301	   136659850	   53	   0.000129321	   0.044011046	  
25	   ENSG00000128564	   VGF	   VGF	  nerve	  growth	  
factor	  inducible	  
7	   100805790	   100808874	   19	   0.000145369	   0.047914417	  
26	   ENSG00000187416	   LHFPL3	   Lipoma	  HMGIC	  
fusion	  partner-­‐like	  
3	  
7	   103969104	   104549001	   21	   0.000150205	   0.049121823	  
Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	  
	  
	   53	  
	  
Table	  9.	  Differentially	  expressed	  genes	  (FDR	  <	  0.05)	  down-­‐regulated	  by	  soy	  isoflavone	  
supplementation	  of	  the	  186	  differentially	  expressed	  genes	  from	  normal	  tissue	  obtained	  from	  4	  
men	  who	  consumed	  soy	  isoflavones	  and	  2	  who	  consumed	  placebo	  (n	  =	  6)	  
	   Gene	  ID	  
Gene	  
abbreviation	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
change	   p-­‐value	   FDR	  
1	   ENSG00000136750	   GAD2	   Glutamate	  
decarboxylase	  2	  
(pancreatic	  islets	  
and	  brain,	  65kDa)	  
10	   26505236	   26593487	   83	   2.92E-­‐14	   1.33E-­‐09	  




10	   85071384	   85074231	   61	   1.53E-­‐13	   3.49E-­‐09	  
3	   ENSG00000244734	   HBB	   Hemoglobin,	  beta	   11	   5246694	   5250625	   33	   2.31E-­‐13	   3.52E-­‐09	  
4	   ENSG00000205271	   RP11-­‐
152F13.4	  
	  	   15	   83128128	   83145983	   93	   3.27E-­‐13	   3.73E-­‐09	  
5	   ENSG00000257846	   RP11-­‐
597A11.3	  
	  	   10	   27035522	   27150016	   34	   3.34E-­‐12	   3.05E-­‐08	  
6	   ENSG00000235992	   GRAMD4P2	   GRAM	  domain	  
containing	  4	  
pseudogene	  2	  
22	   16227138	   16228807	   25	   1.17E-­‐11	   8.93E-­‐08	  
7	   ENSG00000260125	   RP11-­‐
31E22.1	  
	  	   15	   86838880	   86860404	   44	   5.47E-­‐11	   3.56E-­‐07	  
8	   ENSG00000168824	   NSG1	   Neuron-­‐specific	  
protein	  family	  
member	  1	  
4	   4349867	   4420785	   21	   8.87E-­‐11	   5.06E-­‐07	  
9	   ENSG00000244342	   LINC00698	   Long	  intergenic	  
non-­‐protein	  coding	  
RNA	  698	  
10	   27399383	   27444195	   40	   1.87E-­‐10	   9.47E-­‐07	  
10	   ENSG00000225960	   RP11-­‐
360A18.1	  
	  	   9	   122735372	   122736600	   53	   3.31E-­‐10	   1.44E-­‐06	  
11	   ENSG00000259278	   RP11-­‐62C7.2	   	  	   15	   39311434	   39317119	   25	   3.49E-­‐10	   1.44E-­‐06	  
12	   ENSG00000259379	   RP11-­‐
925D8.5	  
	  	   15	   58444805	   58446606	   88	   5.08E-­‐10	   1.93E-­‐06	  
13	   ENSG00000254861	   RP11-­‐
945A11.2	  
	  	   11	   23782876	   23826144	   18	   2.44E-­‐09	   7.41E-­‐06	  
14	   ENSG00000112280	   COL9A1	   Collagen,	  type	  IX,	  
alpha	  1	  
6	   70924764	   71012786	   16	   2.66E-­‐09	   7.58E-­‐06	  




12	   75433857	   75603648	   15	   3.42E-­‐09	   9.18E-­‐06	  
	   54	  
2	  
16	   ENSG00000258590	   NBEAP1	   Neurobeachin	  
pseudogene	  1	  
15	   20862967	   20893737	   15	   3.87E-­‐09	   9.80E-­‐06	  
17	   ENSG00000024526	   DEPDC1	   DEP	  domain	  
containing	  1	  
1	   68939835	   68962904	   15	   7.13E-­‐09	   1.71E-­‐05	  
18	   ENSG00000257751	   RP11-­‐
536C10.21	  
	  	   10	   22045466	   22292698	   66	   1.10E-­‐08	   2.39E-­‐05	  
19	   ENSG00000223609	   HBD	   Hemoglobin,	  delta	   11	   5253908	   5256600	   151	   1.38E-­‐08	   2.86E-­‐05	  
20	   ENSG00000259472	   RP13-­‐
996F3.3	  
	  	   15	   83141718	   83182928	   147	   1.84E-­‐08	   3.64E-­‐05	  
21	   ENSG00000264063	   MIR3687	   MicroRNA	  3687	   21	   9826203	   9826263	   14	   2.04E-­‐08	   3.87E-­‐05	  
22	   ENSG00000002726	   ABP1	   Amiloride	  binding	  
protein	  1	  (amine	  
oxidase	  (copper	  
containing))	  
7	   150521715	   150558592	   13	   2.81E-­‐08	   5.13E-­‐05	  
23	   ENSG00000213727	   LA16c-­‐
60G3.7	  
	  	   22	   16404698	   16405874	   22	   2.98E-­‐08	   5.23E-­‐05	  
24	   ENSG00000170893	   TRH	   Thyrotropin-­‐
releasing	  hormone	  
3	   129693148	   129696781	   30	   4.03E-­‐08	   6.81E-­‐05	  
25	   ENSG00000258027	   RP11-­‐
597A11.1	  
	  	   14	   20078033	   20146082	   22	   4.68E-­‐08	   7.63E-­‐05	  




9	   35657751	   35658014	   13	   5.10E-­‐08	   8.02E-­‐05	  
27	   ENSG00000223542	   RP1-­‐
283K11.3	  
	  	   6	   133756215	   133760602	   21	   5.41E-­‐08	   8.23E-­‐05	  
28	   ENSG00000096006	   CRISP3	   Cysteine-­‐rich	  
secretory	  protein	  3	  
6	   49695097	   49712150	   12	   6.41E-­‐08	   9.40E-­‐05	  
29	   ENSG00000257395	   RP11-­‐
597A11.2	  
	  	   14	   20149579	   20152898	   24	   6.60E-­‐08	   9.40E-­‐05	  
30	   ENSG00000258363	   RP11-­‐
146E13.6	  
	  	   14	   19959517	   19961162	   12	   7.14E-­‐08	   9.78E-­‐05	  
31	   ENSG00000121742	   GJB6	   Gap	  junction	  
protein,	  beta	  6,	  
30kDa	  
9	   20796110	   20806534	   13	   7.29E-­‐08	   9.78E-­‐05	  
	   55	  
32	   ENSG00000184115	   RP13-­‐
1039J1.2	  
	  	   2	   111143988	   111192743	   23	   7.89E-­‐08	   0.00010277	  
33	   ENSG00000237754	   RP11-­‐
521C10.1	  
	  	   7	   67706624	   67707254	   17	   1.11E-­‐07	   0.000140766	  
34	   ENSG00000225255	   LA16c-­‐
83F12.6	  
	  	   22	   16199666	   16231333	   11	   1.45E-­‐07	   0.000169403	  
35	   ENSG00000265971	   RP11-­‐
269G24.6	  
	  	   17	   61532354	   61533178	   15	   1.49E-­‐07	   0.000169403	  
36	   ENSG00000259761	   RP11-­‐
138H10.2	  
	  	   15	   87585285	   87590392	   119	   1.65E-­‐07	   0.000183268	  
37	   ENSG00000257731	   RP11-­‐
536C10.11	  
	  	   14	   19421521	   19422698	   14	   1.82E-­‐07	   0.00019736	  
38	   ENSG00000254851	   RP11-­‐
109L13.1	  
	  	   11	   117006244	   117009298	   16	   1.90E-­‐07	   0.000201776	  
39	   ENSG00000157884	   CIB4	   Calcium	  and	  
integrin	  binding	  
family	  member	  4	  
2	   26804070	   26864236	   12	   2.15E-­‐07	   0.000222688	  
40	   ENSG00000217889	   RP11-­‐
66N11.5	  
	  	   X	   152869952	   152870803	   25	   2.57E-­‐07	   0.000260106	  
41	   ENSG00000100121	   GGTLC2	   Gamma-­‐
glutamyltransferase	  
light	  chain	  2	  
22	   22988780	   22990368	   12	   2.90E-­‐07	   0.000287678	  
42	   ENSG00000259671	   RP11-­‐
925D8.6	  
	  	   15	   58447159	   58448260	   46	   4.25E-­‐07	   0.000412623	  
43	   ENSG00000257357	   RP11-­‐
244H18.3	  
	  	   14	   20105463	   20109540	   23	   5.50E-­‐07	   0.000522509	  
44	   ENSG00000232783	   AC073135.3	   	  	   3	   197836983	   197838749	   37	   6.65E-­‐07	   0.000594735	  
45	   ENSG00000234665	   RP11-­‐
262H14.3	  
	  	   9	   66513488	   66553911	   19	   6.65E-­‐07	   0.000594735	  
46	   ENSG00000225383	   SFTA1P	   Surfactant	  
associated	  1,	  
pseudogene	  
10	   10826400	   10836943	   23	   7.16E-­‐07	   0.000627728	  
47	   ENSG00000224371	   RP11-­‐
235G24.1	  
	  	   9	   161293920	   161339681	   18	   8.21E-­‐07	   0.000701696	  
48	   ENSG00000224758	   RP13-­‐
137A17.5	  
	  	   10	   134774844	   134775741	   17	   8.31E-­‐07	   0.000701696	  
49	   ENSG00000203697	   CAPN8	   Calpain	  8	   1	   223711349	   223853436	   9	   8.99E-­‐07	   0.000745586	  
	   56	  
50	   ENSG00000257504	   RP11-­‐
536C10.7	  
	  	   9	   19406795	   19410111	   10	   1.02E-­‐06	   0.000818554	  
51	   ENSG00000188536	   HBA2	   Hemoglobin,	  alpha	  
2	  
16	   222846	   223709	   9	   1.02E-­‐06	   0.000818554	  
52	   ENSG00000236045	   RP3-­‐
467K16.7	  
	  	   9	   15660662	   15661960	   10	   1.59E-­‐06	   0.001178183	  
53	   ENSG00000238245	   MYO5BP2	   Myosin	  VB	  
pseudogene	  2	  
9	   66513032	   66514308	   29	   1.63E-­‐06	   0.001178183	  
54	   ENSG00000228897	   CTD-­‐
2021A8.2	  
	  	   7	   51454060	   51454798	   28	   1.63E-­‐06	   0.001178183	  
55	   ENSG00000257608	   CTD-­‐
2311B13.6	  
	  	   9	   19614216	   19615884	   9	   1.66E-­‐06	   0.001178363	  
56	   ENSG00000267242	   AC069278.4	   	  	   19	   44978645	   44979403	   9	   1.73E-­‐06	   0.001193033	  
57	   ENSG00000183091	   NEB	   Nebulin	   9	   152341850	   152591001	   9	   1.84E-­‐06	   0.001232515	  
58	   ENSG00000222375	   RN7SKP127	   RNA,	  7SK	  small	  
nuclear	  
pseudogene	  127	  
16	   29742372	   29742725	   9	   1.84E-­‐06	   0.001232515	  
59	   ENSG00000234567	   RP1-­‐
283K11.2	  
	  	   6	   133773995	   133777743	   12	   1.87E-­‐06	   0.001232515	  
60	   ENSG00000202198	   RN7SK	   RNA,	  7SK	  small	  
nuclear	  
9	   52860418	   52860748	   9	   2.18E-­‐06	   0.001422985	  
61	   ENSG00000233845	   AC093732.1	   	  	   2	   47262418	   47267663	   16	   2.26E-­‐06	   0.001449668	  
62	   ENSG00000230223	   ATXN8OS	   ATXN8	  opposite	  
strand	  (non-­‐protein	  
coding)	  
13	   70681345	   70705678	   13	   2.69E-­‐06	   0.001704723	  
63	   ENSG00000206172	   HBA1	   Hemoglobin,	  alpha	  
1	  
16	   226679	   227521	   9	   2.93E-­‐06	   0.001829279	  
64	   ENSG00000237674	   GSTA7P	   Glutathione	  S-­‐
transferase	  alpha	  7,	  
pseudogene	  
6	   52604388	   52609454	   16	   3.12E-­‐06	   0.001923142	  
65	   ENSG00000163618	   CADPS	   Ca++-­‐dependent	  
secretion	  activator	  
3	   62384022	   62861054	   8	   3.27E-­‐06	   0.001963106	  
66	   ENSG00000226958	   RNA28S5	   RNA,	  28S	  ribosomal	  
5	  
X	   108297361	   108297792	   8	   3.41E-­‐06	   0.002012606	  
67	   ENSG00000260581	   CTB-­‐
113P19.4	  
	  	   5	   151031836	   151035010	   9	   3.44E-­‐06	   0.002012606	  
	   57	  
68	   ENSG00000253998	   IGKV2-­‐29	   Immunoglobulin	  
kappa	  variable	  2-­‐29	  
2	   89533655	   89534393	   40	   3.89E-­‐06	   0.002192593	  
69	   ENSG00000225649	   AC064875.2	   	  	   2	   13106910	   13147138	   8	   4.36E-­‐06	   0.002426373	  
70	   ENSG00000150361	   KLHL1	   Kelch-­‐like	  family	  
member	  1	  
13	   70274726	   70682591	   9	   4.84E-­‐06	   0.002632142	  
71	   ENSG00000261760	   RP11-­‐
1223D19.1	  
	  	   2	   110988683	   111043433	   82	   5.22E-­‐06	   0.002802477	  
72	   ENSG00000233306	   TRGV2	   T	  cell	  receptor	  
gamma	  variable	  2	  
7	   38402465	   38403119	   10	   5.31E-­‐06	   0.00281554	  
73	   ENSG00000233408	   LA16c-­‐
23H5.4	  
	  	   22	   16417269	   16420386	   12	   5.47E-­‐06	   0.002868297	  
74	   ENSG00000170356	   OR2A20P	   Olfactory	  receptor,	  
family	  2,	  subfamily	  
A,	  member	  20	  
pseudogene	  
7	   143947138	   143950050	   11	   6.71E-­‐06	   0.003474592	  
75	   ENSG00000162344	   FGF19	   Fibroblast	  growth	  
factor	  19	  
11	   69513000	   69519410	   14	   8.28E-­‐06	   0.004103311	  
76	   ENSG00000238881	   SCARNA2	   Small	  Cajal	  body-­‐
specific	  RNA	  2	  
1	   109642815	   109643234	   8	   9.34E-­‐06	   0.004580364	  
77	   ENSG00000258730	   ITPK1-­‐AS1	   ITPK1	  antisense	  
RNA	  1	  
14	   93533797	   93538497	   17	   9.87E-­‐06	   0.004788171	  
78	   ENSG00000211699	   TRGV3	   T	  cell	  receptor	  
gamma	  variable	  3	  
7	   38398113	   38398763	   10	   1.01E-­‐05	   0.004855999	  
79	   ENSG00000260555	   RP11-­‐
728K20.2	  
	  	   7	   149697841	   149702213	   9	   1.12E-­‐05	   0.005311565	  
80	   ENSG00000251060	   U66061.31	   	  	   7	   142413074	   142426272	   10	   1.33E-­‐05	   0.006074933	  
81	   ENSG00000225210	   AL589743.1	   	  	   14	   19650018	   19718563	   7	   1.40E-­‐05	   0.006338535	  
82	   ENSG00000211688	   TRGJP2	   T	  cell	  receptor	  
gamma	  joining	  P2	  
7	   38295938	   38295997	   10	   1.46E-­‐05	   0.006544322	  
83	   ENSG00000244067	   GSTA2	   Glutathione	  S-­‐
transferase	  alpha	  2	  
6	   52614897	   52628367	   7	   1.53E-­‐05	   0.00673148	  
84	   ENSG00000249170	   RP11-­‐1J11.1	   	  	   4	   72165975	   72166952	   12	   1.66E-­‐05	   0.007148469	  
85	   ENSG00000232079	   AL035610.1	   	  	   21	   29420733	   29509930	   13	   1.77E-­‐05	   0.007533531	  
	   58	  
86	   ENSG00000250984	   CTD-­‐
2011G17.1	  
	  	   5	   29796045	   29796375	   15	   1.90E-­‐05	   0.008028562	  
87	   ENSG00000258265	   CTD-­‐
2311B13.2	  
	  	   14	   19529958	   19530898	   69	   2.07E-­‐05	   0.008578552	  
88	   ENSG00000225258	   AC009478.1	   	  	   2	   181436439	   181557181	   10	   2.19E-­‐05	   0.008898036	  
89	   ENSG00000180532	   ZSCAN4	   Zinc	  finger	  and	  
SCAN	  domain	  
containing	  4	  
19	   58180303	   58190520	   7	   2.43E-­‐05	   0.00978666	  
90	   ENSG00000138100	   TRIM54	   Tripartite	  motif	  
containing	  54	  
2	   27505260	   27530307	   7	   2.59E-­‐05	   0.010378663	  
91	   ENSG00000231565	   NEK2P2	   NEK2	  pseudogene	  2	   22	   16364867	   16366204	   7	   2.66E-­‐05	   0.010533754	  
92	   ENSG00000227195	   RP3-­‐410C9.1	   	  	   20	   26167556	   26232162	   6	   3.07E-­‐05	   0.012076346	  
93	   ENSG00000164093	   PITX2	   Paired-­‐like	  
homeodomain	  2	  
4	   111538579	   111563279	   8	   3.11E-­‐05	   0.012115254	  
94	   ENSG00000169856	   ONECUT1	   One	  cut	  homeobox	  
1	  
15	   53049186	   53083273	   65	   3.38E-­‐05	   0.012962553	  
95	   ENSG00000214976	   VDAC2P1	   Voltage-­‐dependent	  
anion	  channel	  2	  
pseudogene	  1	  
21	   17466735	   17467692	   62	   3.38E-­‐05	   0.012962553	  
96	   ENSG00000117154	   IGSF21	   Immunoglobulin	  
superfamily,	  
member	  21	  
1	   18434240	   18704977	   6	   3.77E-­‐05	   0.014250253	  
97	   ENSG00000166748	   AGBL1	   ATP/GTP	  binding	  
protein-­‐like	  1	  
15	   86685227	   87572283	   8	   3.78E-­‐05	   0.014250253	  




19	   42106090	   42112339	   20	   3.82E-­‐05	   0.014262985	  
99	   ENSG00000204038	   AL359195.1	   	  	   10	   82009466	   82013395	   27	   3.99E-­‐05	   0.014672388	  
100	   ENSG00000206177	   HBM	   Hemoglobin,	  mu	   16	   203891	   216767	   27	   3.99E-­‐05	   0.014672388	  
101	   ENSG00000267614	   AC138472.6	   	  	   19	   45040251	   45040599	   11	   4.45E-­‐05	   0.01622454	  
102	   ENSG00000259425	   RP11-­‐
566K19.5	  
	  	   15	   23096869	   23105332	   7	   4.99E-­‐05	   0.017634483	  
103	   ENSG00000228477	   RP3-­‐
342P20.2	  
	  	   1	   40428352	   40429076	   9	   5.34E-­‐05	   0.018747218	  
	   59	  
104	   ENSG00000254127	   IGLCOR22-­‐1	   Immunoglobulin	  
lambda	  
constant/OR22-­‐1	  
22	   32595906	   32596221	   14	   5.40E-­‐05	   0.018800627	  
105	   ENSG00000169427	   KCNK9	   Potassium	  channel,	  
subfamily	  K,	  
member	  9	  
8	   140613081	   140715299	   58	   5.63E-­‐05	   0.019274052	  
106	   ENSG00000261426	   AC144833.1	   	  	   15	   27607456	   27611544	   58	   5.63E-­‐05	   0.019274052	  
107	   ENSG00000236714	   AC005592.1	   	  	   5	   142125165	   142140563	   6	   5.99E-­‐05	   0.020239635	  
108	   ENSG00000166816	   LDHD	   Lactate	  
dehydrogenase	  D	  
16	   75145758	   75150669	   6	   6.06E-­‐05	   0.020334552	  
109	   ENSG00000178934	   LGALS7B	   Lectin,	  galactoside-­‐
binding,	  soluble,	  7B	  
19	   39279851	   39282389	   7	   6.35E-­‐05	   0.021030946	  
110	   ENSG00000148826	   NKX6-­‐2	   NK6	  homeobox	  2	   10	   134598297	   134599556	   20	   6.37E-­‐05	   0.021030946	  
111	   ENSG00000244280	   ECEL1P2	   Endothelin	  
converting	  enzyme-­‐
like	  1,	  pseudogene	  
2	  
2	   233250460	   233252167	   7	   6.41E-­‐05	   0.021030946	  
112	   ENSG00000259344	   RP11-­‐
566K19.6	  
	  	   15	   23095170	   23115256	   6	   6.57E-­‐05	   0.021387892	  
113	   ENSG00000253988	   RP11-­‐
489O18.1	  
	  	   8	   139075511	   139085483	   8	   6.99E-­‐05	   0.022605697	  
114	   ENSG00000255193	   RP11-­‐
945A11.1	  
	  	   11	   23752134	   23818516	   7	   7.06E-­‐05	   0.022683372	  
115	   ENSG00000256642	   LINC00273	   Long	  intergenic	  
non-­‐protein	  coding	  
RNA	  273	  
16	   33961052	   33962503	   6	   7.40E-­‐05	   0.023114368	  
116	   ENSG00000173809	   TDRD12	   Tudor	  domain	  
containing	  12	  
19	   33210659	   33320483	   6	   7.63E-­‐05	   0.023665842	  
117	   ENSG00000248408	   RP11-­‐
452C8.1	  
	  	   4	   80584915	   80617991	   6	   7.72E-­‐05	   0.023667538	  
118	   ENSG00000109158	   GABRA4	   Gamma-­‐
aminobutyric	  aicd	  
(GABA)	  A	  receptor,	  
alpha	  4	  
4	   46920917	   46996424	   13	   7.79E-­‐05	   0.023667538	  
119	   ENSG00000261467	   RP11-­‐
731K22.1	  
	  	   7	   73400322	   73403097	   13	   7.79E-­‐05	   0.023667538	  
120	   ENSG00000234232	   RP11-­‐
353N4.5	  
	  	   1	   149691432	   149698605	   24	   9.34E-­‐05	   0.028201554	  




4	   6027926	   6202318	   6	   9.95E-­‐05	   0.029754851	  
	   60	  
122	   ENSG00000257898	   	   	   	   	  	   	  	   6	   9.98E-­‐05	   0.029754851	  
123	   ENSG00000142619	   PADI3	   Peptidyl	  arginine	  
deiminase,	  type	  III	  
1	   17575593	   17610728	   6	   0.000104146	   0.030836563	  
124	   ENSG00000264462	   MIR3648	   MicroRNA	  3648	   21	   9825832	   9826011	   6	   0.000105754	   0.031110755	  
125	   ENSG00000260284	   TPSP2	   Tryptase	  
pseudogene	  2	  
16	   1336352	   1338838	   6	   0.000106571	   0.031150138	  
126	   ENSG00000236138	   RP11-­‐
413E6.7	  
	  	   3	   75718082	   75719336	   7	   0.000111474	   0.032375703	  




19	   45051045	   45124119	   6	   0.000115579	   0.03314582	  
128	   ENSG00000257884	   RP11-­‐
587A11.4	  
	  	   14	   20145996	   20148263	   6	   0.000122949	   0.034617353	  
129	   ENSG00000235994	   RP3-­‐
470B24.5	  
	  	   6	   168376604	   168380456	   11	   0.000122988	   0.034617353	  
130	   ENSG00000205076	   LGALS7	   Lectin,	  galactoside-­‐
binding,	  souble,	  7	  
19	   39261611	   39264132	   11	   0.000122988	   0.034617353	  
131	   ENSG00000252139	   SCARNA18	   Small	  Cajal	  body-­‐
specific	  RNA	  18	  
18	   47340731	   47340813	   15	   0.00012697	   0.035518933	  
132	   ENSG00000180383	   DEFB124	   Defensin,	  beta	  124	   20	   30053309	   30064560	   7	   0.000128563	   0.035745202	  
133	   ENSG00000170509	   HSD17B13	   Hydroxysteroid	  (17-­‐
beta)	  
dehydrogenase	  13	  
4	   88224941	   88244058	   6	   0.000132806	   0.036480179	  
134	   ENSG00000132204	   LINC00470	   Long	  intergenic	  
non-­‐protein	  coding	  
RNA	  470	  
18	   1254384	   1408345	   7	   0.000137231	   0.037469935	  
135	   ENSG00000237686	   RP5-­‐
1120P11.1	  
	  	   6	   43963460	   44042389	   6	   0.000143964	   0.039074183	  
136	   ENSG00000253326	   RP11-­‐
261C10.7	  
	  	   1	   243218163	   243219696	   23	   0.000145771	   0.039330509	  
137	   ENSG00000259600	   RP11-­‐
925D8.3	  
	  	   15	   58443232	   58444712	   8	   0.000152739	   0.04072871	  
138	   ENSG00000206195	   AP000525.9	   	  	   22	   16147979	   16193004	   6	   0.000154801	   0.041038475	  
139	   ENSG00000266998	   RP11-­‐
936I5.1	  
	  	   17	   75369900	   75373318	   9	   0.00016348	   0.042841205	  
	   61	  
140	   ENSG00000221673	   U3	   Small	  nucleolar	  
RNA	  U3	  
1	   220136028	   220136206	   49	   0.000165955	   0.042995614	  
141	   ENSG00000240881	   RP11-­‐
713P14.1	  
	  	   11	   23541868	   23542748	   49	   0.000165955	   0.042995614	  
142	   ENSG00000170423	   KRT78	   Keratin	  78	   12	   53231588	   53242876	   10	   0.000168481	   0.043159648	  
143	   ENSG00000166268	   MYRFL	   Myelin	  regulatory	  
factor-­‐like	  
12	   70219084	   70352877	   6	   0.000170898	   0.043533352	  
144	   ENSG00000259787	   CTB-­‐85P21.2	   	  	   5	   143861871	   143865249	   10	   0.000172198	   0.043533352	  
145	   ENSG00000263015	   RP5-­‐
1029F21.3	  
	  	   17	   406411	   414587	   11	   0.000172804	   0.043533352	  
146	   ENSG00000188000	   OR7D2	   Olfactory	  receptor,	  
family	  7,	  subfamily	  
D,	  member	  2	  
19	   9296279	   9299493	   7	   0.000182463	   0.045464119	  
147	   ENSG00000223764	   RP11-­‐
54O7.3	  
	  	   1	   852250	   855072	   5	   0.000195371	   0.048154249	  
Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	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Table	  10.	  Differentially	  expressed	  genes	  (FDR	  <	  0.05)	  up-­‐regulated	  by	  soy	  isoflavone	  
supplementation	  of	  the	  186	  differentially	  expressed	  genes	  from	  normal	  tissue	  obtained	  from	  4	  
men	  who	  consumed	  soy	  isoflavones	  and	  2	  who	  consumed	  placebo	  (n	  =	  6)	  
	   Gene	  ID	  
Gene	  
abbreviation	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
change	   p-­‐value	   FDR	  
1	   ENSG00000206073	   SERPINB4	   Serpin	  peptidase	  
inhibitor,	  clade	  B	  
(ovalbumin),	  
member	  4	  
18	   61304493	   61311532	   69	   7.13E-­‐10	   2.50E-­‐06	  
2	   ENSG00000164266	   SPINK1	   Serine	  peptidase	  
inhibitor,	  Kazal	  type	  
1	  
5	   147204131	   147211349	   63	   1.01E-­‐09	   3.28E-­‐06	  
3	   ENSG00000226278	   PSPHP1	   Phosphoserine	  
phosphatase	  
pseudogene	  1	  
7	   55832490	   55840981	   100	   8.43E-­‐09	   1.92E-­‐05	  
4	   ENSG00000170369	   CST2	   Cystatin	  SA	   20	   23804406	   23807368	   27	   1.15E-­‐07	   0.000141837	  
5	   ENSG00000057149	   SERPINB3	   Serpin	  peptidase	  
inhibitor,	  clade	  B	  
(ovalbumin),	  
member	  3	  
18	   61322431	   61329197	   32	   1.33E-­‐07	   0.000158996	  
6	   ENSG00000264209	   AC104448.1	   	  	   3	   48529745	   48529838	   266	   6.30E-­‐07	   0.000586159	  
7	   ENSG00000171564	   FGB	   Fibrinogen	  beta	  
chain	  
9	   155484108	   155492236	   67	   1.11E-­‐06	   0.000869858	  
8	   ENSG00000247627	   MTND4P12	   MT-­‐ND4	  
pseudogene	  12	  
5	   134262350	   134263726	   19	   1.13E-­‐06	   0.000869858	  
9	   ENSG00000267056	   AC005336.4	   	  	   19	   16021393	   16022634	   18	   1.49E-­‐06	   0.001134641	  
10	   ENSG00000156096	   UGT2B4	   UDP	  
glucuronosyltransfe
rase	  2	  family,	  
polypeptide	  B4	  
4	   70345883	   70391732	   26	   1.68E-­‐06	   0.001178363	  
11	   ENSG00000175445	   LPL	   Lipoprotein	  lipase	   9	   19759228	   19824769	   16	   3.25E-­‐06	   0.001963106	  
12	   ENSG00000163735	   CXCL5	   Chemokine	  (C-­‐X-­‐C	  
motif)	  ligand	  5	  
4	   74861359	   74864496	   16	   3.54E-­‐06	   0.002038721	  
13	   ENSG00000182816	   KRTAP13-­‐2	   Keratin	  associated	  
protein	  13-­‐2	  
21	   31743709	   31744557	   40	   3.58E-­‐06	   0.002038721	  
14	   ENSG00000163209	   SPRR3	   Small	  proline-­‐rich	  
protein	  3	  
1	   152974223	   152976332	   29	   4.85E-­‐06	   0.002632142	  
15	   ENSG00000000005	   TNMD	   Tenomodulin	   X	   99839799	   99854882	   18	   7.34E-­‐06	   0.003746265	  
	   63	  
16	   ENSG00000184937	   WT1	   Wilms	  tumor	  1	   11	   32409321	   32457176	   15	   7.39E-­‐06	   0.003746265	  
17	   ENSG00000251165	   RP11-­‐
215A19.1	  
	  	   4	   187207248	   187422151	   49	   7.58E-­‐06	   0.003795706	  
18	   ENSG00000134339	   SAA2	   Serum	  amyloid	  A2	   11	   18260770	   18270190	   13	   1.14E-­‐05	   0.005357755	  
19	   ENSG00000172238	   ATOH1	   Atonal	  homolog	  1	  
(Drosophila)	  
4	   94750042	   94751221	   22	   1.15E-­‐05	   0.005357755	  
20	   ENSG00000227063	   RPL41P1	   Ribosomal	  protein	  
L41	  pseudogene	  1	  
20	   21735866	   21736171	   17	   1.20E-­‐05	   0.005515008	  
21	   ENSG00000243063	   IGKV3-­‐7	   Immunoglobulin	  
kappa	  variable	  3-­‐7	  
(non-­‐functional)	  
2	   89277987	   89278600	   161	   1.55E-­‐05	   0.00673148	  
22	   ENSG00000143556	   S100A7	   S100	  calcium	  
binding	  protein	  A7	  
1	   153430220	   153433177	   155	   1.55E-­‐05	   0.00673148	  
23	   ENSG00000211974	   IGHV2-­‐70	   Immunoglobulin	  
heavy	  variable	  2-­‐70	  
14	   107178820	   107179338	   13	   1.93E-­‐05	   0.008055596	  
24	   ENSG00000198535	   C2CD4A	   C2	  calcium-­‐
dependent	  domain	  
containing	  4A	  
15	   62359176	   62363116	   12	   2.17E-­‐05	   0.008898036	  
25	   ENSG00000099290	   FAM21A	   Family	  with	  
sequence	  similarity	  
21,	  member	  A	  
10	   51827648	   51893269	   11	   4.90E-­‐05	   0.017634483	  
26	   ENSG00000231083	   AC011747.6	   	  	   2	   8741022	   8763072	   36	   4.93E-­‐05	   0.017634483	  
27	   ENSG00000196427	   NBPF4	   Neuroblastoma	  
breakpoint	  family,	  
member	  4	  
1	   108765087	   108786689	   130	   4.98E-­‐05	   0.017634483	  
28	   ENSG00000104267	   CA2	   Carbonic	  anhydrase	  
II	  
8	   86376081	   86393722	   10	   5.66E-­‐05	   0.019274052	  
29	   ENSG00000198178	   CLEC4C	   C-­‐type	  lectin	  
domain	  family	  4,	  
member	  C	  
12	   7882011	   7904201	   116	   7.22E-­‐05	   0.023032885	  
30	   ENSG00000233760	   AC004947.2	   	  	   7	   26591441	   26596819	   11	   7.32E-­‐05	   0.023114368	  
31	   ENSG00000229403	   RP4-­‐
718N17.2	  
	  	   7	   51681947	   51698566	   15	   7.36E-­‐05	   0.023114368	  
32	   ENSG00000069206	   ADAM7	   ADAM	  
metallopeptidase	  
domain	  7	  
8	   24298443	   24384483	   13	   0.00011541	   0.03314582	  
33	   ENSG00000104760	   FGL1	   Fibrinogen-­‐like	  1	   8	   17721889	   17767874	   12	   0.00013199	   0.036475647	  
	   64	  
34	   ENSG00000095917	   TPSD1	   Tryptase	  delta	  1	   16	   1306060	   1308532	   10	   0.000149058	   0.039980789	  
35	   ENSG00000166396	   SERPINB7	   Serpin	  peptidase	  
inhibitor,	  clade	  B	  
(ovalbumin),	  
member	  7	  
18	   61420169	   61472604	   10	   0.00015935	   0.042000137	  
36	   ENSG00000119913	   TECTB	   Tectorin	  beta	   10	   114043493	   114064793	   11	   0.000168324	   0.043159648	  
37	   ENSG00000121075	   TBX4	   T-­‐box	  4	   17	   59529765	   59562471	   9	   0.000180519	   0.045226933	  




8	   117962512	   118188953	   17	   0.000185505	   0.045970975	  
39	   ENSG00000244921	   CTB-­‐36O1.7	   	  	   5	   134258993	   134259739	   9	   0.000201827	   0.049478048	  
Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	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Table	  11.	  Differentially	  expressed	  genes	  (FDR	  <0.05)	  down-­‐regulated	  by	  soy	  isoflavone	  
supplementation	  of	  the	  166	  differentially	  expressed	  genes	  from	  only	  normal	  tissue	  obtained	  from	  4	  
men	  who	  consumed	  soy	  isoflavones	  and	  2	  who	  consumed	  placebo	  (n	  =	  6)	  
	   Gene	  ID	  
Gene	  
abbreviation	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
change	   p-­‐value	   FDR	  
1	   ENSG00000136750	   GAD2	   Glutamate	  
decarboxylase	  
2	  (pancreatic	  
islets	  and	  brain,	  
65kDa)	  
10	   26505236	   26593487	   83	   2.92E-­‐14	   1.33E-­‐09	  
2	   ENSG00000244734	   HBB	   Hemoglobin,	  
beta	  
11	   5246694	   5250625	   33	   2.31E-­‐13	   3.52E-­‐09	  
3	   ENSG00000205271	   RP11-­‐
152F13.4	  
	  	   15	   83128128	   83145983	   93	   3.27E-­‐13	   3.73E-­‐09	  
4	   ENSG00000257846	   RP11-­‐
597A11.3	  
	  	   14	   20136988	   20138162	   34	   3.34E-­‐12	   3.05E-­‐08	  
5	   ENSG00000235992	   GRAMD4P2	   GRAM	  domain	  
containing	  4	  
pseudogene	  2	  
22	   16227138	   16228807	   25	   1.17E-­‐11	   8.93E-­‐08	  
6	   ENSG00000168824	   NSG1	   Neuron-­‐specific	  
protein	  family	  
member	  1	  
4	   4349867	   4420785	   21	   8.87E-­‐11	   5.06E-­‐07	  
7	   ENSG00000244342	   LINC00698	   Long	  intergenic	  
non-­‐protein	  
coding	  RNA	  698	  
3	   62936105	   63110738	   40	   1.87E-­‐10	   9.47E-­‐07	  
8	   ENSG00000225960	   RP11-­‐
360A18.1	  
	  	   9	   122735372	   122736600	   53	   3.31E-­‐10	   1.44E-­‐06	  
9	   ENSG00000259278	   RP11-­‐62C7.2	   	  	   15	   39311434	   39317119	   25	   3.49E-­‐10	   1.44E-­‐06	  
10	   ENSG00000259379	   RP11-­‐925D8.5	   	  	   15	   58444805	   58446606	   88	   5.08E-­‐10	   1.93E-­‐06	  
11	   ENSG00000254861	   RP11-­‐
945A11.2	  
	  	   11	   23782876	   23826144	   18	   2.44E-­‐09	   7.41E-­‐06	  
12	   ENSG00000112280	   COL9A1	   Collagen,	  type	  
IX,	  alpha	  1	  
6	   70924764	   71012786	   16	   2.66E-­‐09	   7.58E-­‐06	  






12	   75433857	   75603648	   15	   3.42E-­‐09	   9.18E-­‐06	  
14	   ENSG00000258590	   NBEAP1	   Neurobeachin	  
pseudogene	  1	  
15	   20862967	   20893737	   15	   3.87E-­‐09	   9.80E-­‐06	  
15	   ENSG00000024526	   DEPDC1	   DEP	  domain	  
containing	  1	  
1	   68939835	   68962904	   15	   7.13E-­‐09	   1.71E-­‐05	  
	   66	  
16	   ENSG00000257751	   RP11-­‐
536C10.21	  
	  	   14	   20136701	   20137215	   66	   1.10E-­‐08	   2.39E-­‐05	  
17	   ENSG00000223609	   HBD	   Hemoglobin,	  
delta	  
11	   5253908	   5256600	   151	   1.38E-­‐08	   2.86E-­‐05	  
18	   ENSG00000259472	   RP13-­‐996F3.3	   	  	   15	   83141718	   83182928	   147	   1.84E-­‐08	   3.64E-­‐05	  
19	   ENSG00000264063	   MIR3687	   MicroRNA	  3687	   21	   9826203	   9826263	   14	   2.04E-­‐08	   3.87E-­‐05	  






7	   150521715	   150558592	   13	   2.81E-­‐08	   5.13E-­‐05	  
21	   ENSG00000213727	   LA16c-­‐60G3.7	   	  	   22	   16404698	   16405874	   22	   2.98E-­‐08	   5.23E-­‐05	  
22	   ENSG00000170893	   TRH	   Thyrotropin-­‐
releasing	  
hormone	  
3	   129693148	   129696781	   30	   4.03E-­‐08	   6.81E-­‐05	  






9	   35657751	   35658014	   13	   5.10E-­‐08	   8.02E-­‐05	  
24	   ENSG00000223542	   RP1-­‐283K11.3	   	  	   6	   133756215	   133760602	   21	   5.41E-­‐08	   8.23E-­‐05	  
25	   ENSG00000257395	   RP11-­‐
597A11.2	  
	  	   14	   20149579	   20152898	   24	   6.60E-­‐08	   9.40E-­‐05	  
26	   ENSG00000258363	   RP11-­‐
146E13.6	  
	  	   14	   19959517	   19961162	   12	   7.14E-­‐08	   9.78E-­‐05	  
27	   ENSG00000121742	   GJB6	   Gap	  junction	  
protein,	  beta	  6,	  
30kDa	  
13	   20796110	   20806534	   13	   7.29E-­‐08	   9.78E-­‐05	  
28	   ENSG00000184115	   RP13-­‐
1039J1.2	  
	  	   2	   111143988	   111192743	   23	   7.89E-­‐08	   0.00010277	  
29	   ENSG00000237754	   RP11-­‐
521C10.1	  
	  	   7	   67706624	   67707254	   17	   1.11E-­‐07	   0.00014077	  
30	   ENSG00000225255	   LA16c-­‐
83F12.6	  
	  	   22	   16199666	   16231333	   11	   1.45E-­‐07	   0.0001694	  
31	   ENSG00000265971	   RP11-­‐
269G24.6	  
	  	   17	   61532354	   61533178	   15	   1.49E-­‐07	   0.0001694	  
32	   ENSG00000257731	   RP11-­‐
536C10.11	  
	  	   14	   19421521	   19422698	   14	   1.82E-­‐07	   0.00019736	  
	   67	  




2	   26804070	   26864236	   12	   2.15E-­‐07	   0.00022269	  
34	   ENSG00000217889	   RP11-­‐66N11.5	   	  	   X	   152869952	   152870803	   25	   2.57E-­‐07	   0.00026011	  
35	   ENSG00000100121	   GGTLC2	   Gamma-­‐
glutamyltransfe
rase	  light	  chain	  
2	  
22	   22988780	   22990368	   12	   2.90E-­‐07	   0.00028768	  
36	   ENSG00000259671	   RP11-­‐925D8.6	   	  	   15	   58447159	   58448260	   46	   4.25E-­‐07	   0.00041262	  
37	   ENSG00000232783	   AC073135.3	   	  	   3	   197836983	   197838749	   37	   6.65E-­‐07	   0.00059474	  
38	   ENSG00000225383	   SFTA1P	   Surfactant	  
associated	  1,	  
pseudogene	  
10	   10826400	   10836943	   23	   7.16E-­‐07	   0.00062773	  
39	   ENSG00000224371	   RP11-­‐
235G24.1	  
	  	   6	   161293920	   161339681	   18	   8.21E-­‐07	   0.0007017	  
40	   ENSG00000224758	   RP13-­‐
137A17.5	  
	  	   10	   134774844	   134775741	   17	   8.31E-­‐07	   0.0007017	  
41	   ENSG00000203697	   CAPN8	   Calpain	  8	   1	   223711349	   223853436	   9	   8.99E-­‐07	   0.00074559	  
42	   ENSG00000257504	   RP11-­‐
536C10.7	  
	  	   9	   111899167	   111929571	   10	   1.02E-­‐06	   0.00081855	  
43	   ENSG00000188536	   HBA2	   Hemoglobin,	  
alpha	  2	  
16	   222846	   223709	   9	   1.02E-­‐06	   0.00081855	  
44	   ENSG00000236045	   RP3-­‐467K16.7	   	  	   9	   113006091	   113018920	   10	   1.59E-­‐06	   0.00117818	  
45	   ENSG00000238245	   MYO5BP2	   Myosin	  VB	  
pseudogene	  2	  
9	   131217466	   131263239	   29	   1.63E-­‐06	   0.00117818	  
46	   ENSG00000228897	   CTD-­‐2021A8.2	   	  	   7	   51454060	   51454798	   28	   1.63E-­‐06	   0.00117818	  
47	   ENSG00000257608	   CTD-­‐
2311B13.6	  
	  	   9	   114122972	   114247025	   9	   1.66E-­‐06	   0.00117836	  
48	   ENSG00000267242	   AC069278.4	   	  	   19	   44978645	   44979403	   9	   1.73E-­‐06	   0.00119303	  
49	   ENSG00000183091	   NEB	   Nebulin	   9	   132565432	   132573560	   9	   1.84E-­‐06	   0.00123251	  
	   68	  




16	   29742372	   29742725	   9	   1.84E-­‐06	   0.00123251	  
51	   ENSG00000234567	   RP1-­‐283K11.2	   	  	   6	   133773995	   133777743	   12	   1.87E-­‐06	   0.00123251	  
52	   ENSG00000202198	   RN7SK	   RNA,	  7SK	  small	  
nuclear	  
9	   132589569	   132598142	   9	   2.18E-­‐06	   0.00142299	  
53	   ENSG00000233845	   AC093732.1	   	  	   2	   47262418	   47267663	   16	   2.26E-­‐06	   0.00144967	  
54	   ENSG00000230223	   ATXN8OS	   ATXN8	  opposite	  
strand	  (non-­‐
protein	  coding)	  
13	   70681345	   70705678	   13	   2.69E-­‐06	   0.00170472	  
55	   ENSG00000206172	   HBA1	   Hemoglobin,	  
alpha	  1	  
16	   226679	   227521	   9	   2.93E-­‐06	   0.00182928	  




6	   52604388	   52609454	   16	   3.12E-­‐06	   0.00192314	  




3	   62384022	   62861054	   8	   3.27E-­‐06	   0.00196311	  
58	   ENSG00000226958	   RNA28S5	   RNA,	  28S	  
ribosomal	  5	  
X	   108297361	   108297792	   8	   3.41E-­‐06	   0.00201261	  
59	   ENSG00000260581	   CTB-­‐113P19.4	   	  	   5	   151031836	   151035010	   9	   3.44E-­‐06	   0.00201261	  
60	   ENSG00000225649	   AC064875.2	   	  	   2	   13106910	   13147138	   8	   4.36E-­‐06	   0.00242637	  
61	   ENSG00000150361	   KLHL1	   Kelch-­‐like	  
family	  member	  
1	  
13	   70274726	   70682591	   9	   4.84E-­‐06	   0.00263214	  
62	   ENSG00000261760	   RP11-­‐
1223D19.1	  
	  	   2	   110988683	   111043433	   82	   5.22E-­‐06	   0.00280248	  
63	   ENSG00000233306	   TRGV2	   T	  cell	  receptor	  
gamma	  variable	  
2	  
7	   38402465	   38403119	   10	   5.31E-­‐06	   0.00281554	  
64	   ENSG00000233408	   LA16c-­‐23H5.4	   	  	   22	   16417269	   16420386	   12	   5.47E-­‐06	   0.0028683	  
65	   ENSG00000162344	   FGF19	   Fibroblast	  
growth	  factor	  
19	  
11	   69513000	   69519410	   14	   8.28E-­‐06	   0.00410331	  
66	   ENSG00000238881	   SCARNA2	   Small	  Cajal	  
body-­‐specific	  
RNA	  2	  
1	   109642815	   109643234	   8	   9.34E-­‐06	   0.00458036	  
67	   ENSG00000258730	   ITPK1-­‐AS1	   ITPK1	  antisense	  
RNA	  1	  
14	   93533797	   93538497	   17	   9.87E-­‐06	   0.00478817	  
	   69	  
68	   ENSG00000211699	   TRGV3	   T	  cell	  receptor	  
gamma	  variable	  
3	  
7	   38398113	   38398763	   10	   1.01E-­‐05	   0.004856	  
69	   ENSG00000260555	   RP11-­‐
728K20.2	  
	  	   7	   149697841	   149702213	   9	   1.12E-­‐05	   0.00531157	  
70	   ENSG00000251060	   U66061.31	   	  	   7	   142413074	   142426272	   10	   1.33E-­‐05	   0.00607493	  
71	   ENSG00000225210	   AL589743.1	   	  	   14	   19650018	   19718563	   7	   1.40E-­‐05	   0.00633854	  
72	   ENSG00000211688	   TRGJP2	   T	  cell	  receptor	  
gamma	  joining	  
P2	  
7	   38295938	   38295997	   10	   1.46E-­‐05	   0.00654432	  
73	   ENSG00000244067	   GSTA2	   Glutathione	  S-­‐
transferase	  
alpha	  2	  
6	   52614897	   52628367	   7	   1.53E-­‐05	   0.00673148	  
74	   ENSG00000249170	   RP11-­‐IJ11.1	   	  	   4	   72165975	   72166952	   12	   1.66E-­‐05	   0.00714847	  
75	   ENSG00000232079	   AL035610.1	   	  	   21	   29420733	   29509930	   13	   1.77E-­‐05	   0.00753353	  
76	   ENSG00000250984	   CTD-­‐
2011G17.1	  
	  	   5	   29796045	   29796375	   15	   1.90E-­‐05	   0.00802856	  
77	   ENSG00000258265	   CTD-­‐
2311B13.2	  
	  	   14	   19529958	   19530898	   69	   2.07E-­‐05	   0.00857855	  
78	   ENSG00000225258	   AC009478.1	   	  	   2	   181436439	   181557181	   10	   2.19E-­‐05	   0.00889804	  
79	   ENSG00000180532	   ZSCAN4	   Zinc	  finger	  and	  
SCAN	  domain	  
containing	  4	  
19	   58180303	   58190520	   7	   2.43E-­‐05	   0.00978666	  
80	   ENSG00000138100	   TRIM54	   Tripartite	  motif	  
containing	  54	  
2	   27505260	   27530307	   7	   2.59E-­‐05	   0.01037866	  
81	   ENSG00000231565	   NEK2P2	   NEK2	  
pseudogene	  2	  
22	   16364867	   16366204	   7	   2.66E-­‐05	   0.01053375	  
82	   ENSG00000227195	   RP3-­‐410C9.1	   	  	   20	   26167556	   26232162	   6	   3.07E-­‐05	   0.01207635	  
83	   ENSG00000164093	   PITX2	   Paired-­‐like	  
homeodomain	  
2	  
4	   111538579	   111563279	   8	   3.11E-­‐05	   0.01211525	  
84	   ENSG00000169856	   ONECUT1	   One	  cut	  
homeobox	  1	  
15	   53049186	   53083273	   65	   3.38E-­‐05	   0.01296255	  
	   70	  
85	   ENSG00000214976	   VDAC2P1	   Voltage-­‐
dependent	  
anion	  channel	  2	  
pseudogene	  1	  
21	   17466735	   17467692	   62	   3.38E-­‐05	   0.01296255	  
86	   ENSG00000117154	   IGSF21	   Immunoglobuli
n	  superfamily,	  
member	  21	  
1	   18434240	   18704977	   6	   3.77E-­‐05	   0.01425025	  
87	   ENSG00000166748	   AGBL1	   ATP/GTP	  
binding	  
protein-­‐like	  1	  
15	   86685227	   87572283	   8	   3.78E-­‐05	   0.01425025	  






19	   42106090	   42112339	   20	   3.82E-­‐05	   0.01426299	  
89	   ENSG00000204038	   AL359195.1	   Uncharacterize




10	   82009466	   82013395	   27	   3.99E-­‐05	   0.01467239	  
90	   ENSG00000206177	   HBM	   Hemoglobin,	  
mu	  
16	   203891	   216767	   27	   3.99E-­‐05	   0.01467239	  
91	   ENSG00000267614	   AC138472.6	   	  	   19	   45040251	   45040599	   11	   4.45E-­‐05	   0.01622454	  
92	   ENSG00000259425	   RP11-­‐
566K19.5	  
	  	   15	   23096869	   23105332	   7	   4.99E-­‐05	   0.01763448	  
93	   ENSG00000228477	   RP3-­‐342P20.2	   	  	   1	   40428352	   40429076	   9	   5.34E-­‐05	   0.01874722	  




22	   32595906	   32596221	   14	   5.40E-­‐05	   0.01880063	  




8	   140613081	   140715299	   58	   5.63E-­‐05	   0.01927405	  
96	   ENSG00000261426	   AC144833.1	   	  	   15	   27607456	   27611544	   58	   5.63E-­‐05	   0.01927405	  
97	   ENSG00000236714	   AC005592.1	   	  	   5	   142125165	   142140563	   6	   5.99E-­‐05	   0.02023964	  
98	   ENSG00000166816	   LDHD	   Lactate	  
dehydrogenase	  
D	  
16	   75145758	   75150669	   6	   6.06E-­‐05	   0.02033455	  




19	   39279851	   39282389	   7	   6.35E-­‐05	   0.02103095	  
100	   ENSG00000148826	   NKX6-­‐2	   NK6	  homeobox	  
2	  
10	   134598297	   134599556	   20	   6.37E-­‐05	   0.02103095	  




2	   233250460	   233252167	   7	   6.41E-­‐05	   0.02103095	  
	   71	  
102	   ENSG00000259344	   RP11-­‐
566K19.6	  
	  	   15	   23095170	   23115256	   6	   6.57E-­‐05	   0.02138789	  
103	   ENSG00000253988	   RP11-­‐
489O18.1	  
	  	   8	   139075511	   139085483	   8	   6.99E-­‐05	   0.0226057	  
104	   ENSG00000255193	   RP11-­‐
945A11.1	  
	  	   11	   23752134	   23818516	   7	   7.06E-­‐05	   0.02268337	  
105	   ENSG00000256642	   LINC00273	   Long	  intergenic	  
non-­‐protein	  
coding	  RNA	  273	  
16	   33961052	   33962503	   6	   7.40E-­‐05	   0.02311437	  
106	   ENSG00000173809	   TDRD12	   Tudor	  domain	  
containing	  12	  
19	   33210659	   33320483	   6	   7.63E-­‐05	   0.02366584	  
107	   ENSG00000248408	   RP11-­‐452C8.1	   	  	   4	   80584915	   80617991	   6	   7.72E-­‐05	   0.02366754	  
108	   ENSG00000109158	   GABRA4	   Gamma-­‐
aminobutyric	  
acid	  (GABA)	  A	  
receptor,	  alpha	  
4	  
4	   46920917	   46996424	   13	   7.79E-­‐05	   0.02366754	  
109	   ENSG00000261467	   RP11-­‐
731K22.1	  
	  	   7	   73400322	   73403097	   13	   7.79E-­‐05	   0.02366754	  
110	   ENSG00000234232	   RP11-­‐353N4.5	   	  	   1	   149691432	   149698605	   24	   9.34E-­‐05	   0.02820155	  





4	   6027926	   6202318	   6	   9.95E-­‐05	   0.02975485	  
112	   ENSG00000257898	   	  	   	  	   	  	   	  	   	  	   6	   9.98E-­‐05	   0.02975485	  




1	   17575593	   17610728	   6	   0.00010415	   0.03083656	  
114	   ENSG00000264462	   MIR3648	   MicroRNA	  3648	   21	   9825832	   9826011	   6	   0.00010575	   0.03111075	  
115	   ENSG00000260284	   TPSP2	   Tryptase	  
pseudogene	  2	  
16	   1336352	   1338838	   6	   0.00010657	   0.03115014	  
116	   ENSG00000236138	   RP11-­‐413E6.7	   	  	   3	   75718082	   75719336	   7	   0.00011147	   0.0323757	  






19	   45051045	   45124119	   6	   0.00011558	   0.03314582	  
118	   ENSG00000257884	   RP11-­‐
597A11.4	  
	  	   14	   20145996	   20148263	   6	   0.00012295	   0.03461735	  
119	   ENSG00000235994	   RP3-­‐470B24.5	   	  	   6	   169376604	   168380456	   11	   0.00012299	   0.03461735	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19	   39261611	   39264132	   11	   0.00012299	   0.03461735	  
121	   ENSG00000252139	   SCARNA18	   Small	  Cajal	  
body-­‐specific	  
RNA	  18	  
18	   47340731	   47340813	   15	   0.00012697	   0.03551893	  
122	   ENSG00000180383	   DEFB124	   Defensin,	  beta	  
124	  
20	   30053309	   30064560	   7	   0.00012856	   0.0357452	  




4	   88224941	   88244058	   6	   0.00013281	   0.03648018	  
124	   ENSG00000132204	   LINC00470	   Long	  intergenic	  
non-­‐protein	  
coding	  RNA	  470	  
18	   1254384	   1408345	   7	   0.00013723	   0.03746994	  
125	   ENSG00000237686	   RP5-­‐
1120P11.1	  
	  	   6	   43963460	   44042389	   6	   0.00014396	   0.03907418	  
126	   ENSG00000253326	   RP11-­‐
261C10.7	  
	  	   1	   243218163	   243219696	   23	   0.00014577	   0.03933051	  
127	   ENSG00000259600	   RP11-­‐925D8.3	   	  	   15	   58443232	   58444712	   8	   0.00015274	   0.04072871	  
128	   ENSG00000206195	   AP000525.9	   	  	   22	   16147979	   16193004	   6	   0.0001548	   0.04103847	  
129	   ENSG00000266998	   RP11-­‐936I5.1	   	  	   17	   75369900	   75373318	   9	   0.00016348	   0.04284121	  
130	   ENSG00000221673	   U3	   Small	  nucleolar	  
RNA	  U3	  
1	   220136028	   220136206	   49	   0.00016596	   0.04299561	  
131	   ENSG00000240881	   RP11-­‐
713P14.1	  
	  	   11	   23541868	   23542748	   49	   0.00016596	   0.04299561	  
132	   ENSG00000170423	   KRT78	   Keratin	  78	   12	   53231588	   53242876	   10	   0.00016848	   0.04315965	  
133	   ENSG00000166268	   MYRFL	   Myelin	  
regulatory	  
factor-­‐like	  
12	   70219084	   70352877	   6	   0.0001709	   0.04353335	  
134	   ENSG00000259787	   CTB-­‐85P21.2	   	  	   5	   143861871	   143865249	   10	   0.0001722	   0.04353335	  
135	   ENSG00000263015	   RP5-­‐
1029F21.3	  
	  	   17	   406411	   414587	   11	   0.0001728	   0.04353335	  
136	   ENSG00000223764	   RP11-­‐54O7.3	   	  	   1	   852250	   855072	   5	   0.00019537	   0.04815425	  
Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	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Table	  12.	  Differentially	  expressed	  genes	  (FDR	  <	  0.05)	  up-­‐regulated	  by	  soy	  isoflavone	  
supplementation	  of	  the	  166	  differentially	  expressed	  genes	  from	  only	  normal	  tissue	  obtained	  from	  4	  




abbreviation	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
change	   p-­‐value	   FDR	  
1	   ENSG00000206073	   SERPINB4	   Serpin	  peptidase	  
inhibitor,	  clade	  B	  
(ovalbumin),	  
member	  4	  
18	   61304493	   61311532	   69	   7.13E-­‐10	   2.50E-­‐06	  
2	   ENSG00000057149	   SERPINB3	   Serpin	  peptidase	  
inhibitor,	  clade	  B	  
(ovalbumin),	  
member	  3	  
18	   61322431	   61329197	   32	   1.33E-­‐07	   0.000158996	  
3	   ENSG00000264209	   AC104448.1	   	  	   3	   48529745	   48529838	   266	   6.30E-­‐07	   0.000586159	  
4	   ENSG00000267056	   AC005336.4	   	  	   19	   16021393	   16022634	   18	   1.49E-­‐06	   0.001134641	  
5	   ENSG00000175445	   LPL	   Lipoprotein	  
lipase	  
9	   19759228	   19824769	   16	   3.25E-­‐06	   0.001963106	  
6	   ENSG00000163735	   CXCL5	   Chemokine	  (C-­‐X-­‐
C	  motif)	  ligand	  5	  
4	   74861359	   74864496	   16	   3.54E-­‐06	   0.002038721	  
7	   ENSG00000182816	   KRTAP13-­‐2	   Keratin	  
associated	  
protein	  13-­‐2	  
21	   31743709	   31744557	   40	   3.58E-­‐06	   0.002038721	  
8	   ENSG00000163209	   SPRR3	   Small	  proline-­‐rich	  
protein	  3	  
1	   152974223	   152976332	   29	   4.85E-­‐06	   0.002632142	  
9	   ENSG00000000005	   TNMD	   Tenomodulin	   X	   99839799	   99854882	   18	   7.34E-­‐06	   0.003746265	  
10	   ENSG00000184937	   WT1	   Wilms	  tumor	  1	   11	   32409321	   32457176	   15	   7.39E-­‐06	   0.003746265	  
11	   ENSG00000251165	   RP11-­‐
215A19.1	  
	  	   4	   187207248	   187422151	   49	   7.58E-­‐06	   0.003795706	  
12	   ENSG00000134339	   SAA2	   Serum	  amyloid	  
A2	  
11	   18260770	   18270190	   13	   1.14E-­‐05	   0.005357755	  
13	   ENSG00000227063	   RPL41P1	   Ribosomal	  
protein	  L41	  
pseudogene	  1	  
20	   21735866	   21736171	   17	   1.20E-­‐05	   0.005515008	  




2	   89277987	   89278600	   161	   1.55E-­‐05	   0.00673148	  
15	   ENSG00000143556	   S100A7	   S100	  calcium	  
binding	  protein	  
A7	  
1	   153430220	   153433177	   155	   1.55E-­‐05	   0.00673148	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16	   ENSG00000211974	   IGHV2-­‐70	   Immunoglobulin	  
heavy	  variable	  2-­‐
70	  
14	   107178820	   107179338	   13	   1.93E-­‐05	   0.008055596	  




15	   62359176	   62363116	   12	   2.17E-­‐05	   0.008898036	  




10	   51827648	   51893269	   11	   4.90E-­‐05	   0.017634483	  
19	   ENSG00000231083	   AC011747.6	   	  	   2	   8741022	   8763072	   36	   4.93E-­‐05	   0.017634483	  
20	   ENSG00000196427	   NBPF4	   Neuroblastoma	  
breakpoint	  
family,	  member	  4	  
1	   108765087	   108786689	   130	   4.98E-­‐05	   0.017634483	  
21	   ENSG00000104267	   CA2	   Carbonic	  
anhydrase	  II	  
8	   86376081	   86393722	   10	   5.66E-­‐05	   0.019274052	  
22	   ENSG00000198178	   CLEC4C	   C-­‐type	  lectin	  
domain	  family	  4,	  
member	  C	  
12	   7882011	   7904201	   116	   7.22E-­‐05	   0.023032885	  
23	   ENSG00000229403	   RP4-­‐
718N17.2	  
	  	   7	   51681947	   51698566	   15	   7.36E-­‐05	   0.023114368	  
24	   ENSG00000069206	   ADAM7	   ADAM	  
metallopeptidase	  
domain	  7	  
8	   24298443	   24384483	   13	   0.00011541	   0.03314582	  
25	   ENSG00000104760	   FGL1	   Fibrinogen-­‐like	  1	   8	   17721889	   17767874	   12	   0.00013199	   0.036475647	  
26	   ENSG00000095917	   TPSD1	   Tryptase	  delta	  1	   16	   1306060	   1308532	   10	   0.000149058	   0.039980789	  
27	   ENSG00000166396	   SERPINB7	   Serpin	  peptidase	  
inhibitor,	  clade	  B	  
(ovalbumin),	  
member	  7	  
18	   61420169	   61472604	   10	   0.00015935	   0.042000137	  
28	   ENSG00000119913	   TECTB	   Tectorin	  beta	   10	   114043493	   114064793	   11	   0.000168324	   0.043159648	  
29	   ENSG00000164756	   SLC30A8	   Solute	  carrier	  
family	  30	  (zinc	  
transporter),	  
member	  8	  
8	   117962512	   118188953	   17	   0.000185505	   0.045970975	  
30	   ENSG00000244921	   CTB-­‐36O1.7	   	  	   5	   134258993	   134259739	   9	   0.000201827	   0.049478048	  
Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	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Table	  13.	  Differentially	  expressed	  genes	  (FDR	  <	  0.05)	  present	  in	  both	  normal	  and	  tumor	  tissues	  
obtained	  from	  4	  men	  who	  consumed	  soy	  isoflavones	  and	  2	  who	  consumed	  placebo	  (n	  =	  6)	  	  
	   	   	   	   	   	   	   Normal	  tissue	   Tumor	  tissue	  
	   Gene	  ID	  
Gene	  
abbreviatio
n	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
change	   p-­‐value	   FDR	  
Fold	  





	  	   11	   117006244	   117009298	   -­‐16	   1.90E-­‐07	   0.000201776	   -­‐340	   4.88E-­‐14	   5.11E-­‐10	  
2	   ENSG0000016426
6	  









	  	   14	   20078033	   20146082	   -­‐22	   4.68E-­‐08	   7.63E-­‐05	   -­‐31	   2.20E-­‐08	   5.76E-­‐05	  
4	   ENSG0000012107
5	  
TBX4	   T-­‐box	  4	   17	   59529765	   59562471	   9	   0.000180
519	  




n	  kappa	  variable	  
2-­‐29	  
2	   89533655	   89534393	   -­‐40	   3.89E-­‐06	   0.002192593	   -­‐174	   1.35E-­‐07	   0.000234152	  
6	   ENSG0000017156
4	  
FGB	   Fibrinogen	  beta	  
chain	  





	  	   14	   20105463	   20109540	   -­‐23	   5.50E-­‐07	   0.000522509	   -­‐24	   5.87E-­‐07	   0.00072277	  
8	   ENSG0000023376
0	  





	  	   15	   86838880	   86860404	   -­‐44	   5.47E-­‐11	   3.56E-­‐07	   -­‐40	   2.03E-­‐06	   0.0018495	  
10	   ENSG0000017036
9	  
CST2	   Cystatin	  SA	   20	   23804406	   23807368	   27	   1.15E-­‐07	   0.000141837	   45	   2.56E-­‐06	   0.002189989	  
11	   ENSG0000009600
6	  
CRISP3	   Cysteine-­‐rich	  
secretory	  
protein	  3	  
6	   49695097	   49712150	   -­‐12	   6.41E-­‐08	   9.40E-­‐05	   44	   3.69E-­‐06	   0.00302595	  
12	   ENSG0000022627
8	  
PSPHP1	   Phosphoserine	  
phosphatase	  
pseudogene	  1	  
7	   55832490	   55840981	   100	   8.43E-­‐09	   1.92E-­‐05	   116	   4.65E-­‐06	   0.003602916	  
13	   ENSG0000015609
6	  
UGT2B4	   UDP	  
glucurosyltransf
erase	  2	  family,	  
polypeptide	  B4	  
4	   70345883	   70391732	   26	   1.68E-­‐06	   0.001178363	   28	   4.06E-­‐05	   0.020883677	  
14	   ENSG0000018800
0	  
OR7D2	   Olfactory	  
receptor,	  family	  
7,	  subfamily	  D,	  
member	  2	  
19	   9296279	   9299493	   -­‐7	   0.000182
463	  
0.045464119	   -­‐14	   4.09E-­‐05	   0.020883677	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15	   ENSG0000017223
8	  
ATOH1	   Atonal	  homolog	  
1	  (Drosophila)	  













10	   85071384	   85074231	   -­‐61	   1.53E-­‐13	   3.49E-­‐09	   -­‐29	   7.24E-­‐05	   0.030023263	  
18	   ENSG0000017035
6	  
OR2A20P	   Olfactory	  
receptor,	  family	  
2,	  subfamily	  A,	  
member	  20	  
pseudogene	  
7	   143947138	   143950050	   -­‐11	   6.71E-­‐06	   0.003474592	   -­‐12	   0.000100736	   0.03698971	  
19	   ENSG0000024762
7	  
MTND4P12	   MT-­‐ND4	  
pseudogene	  12	  





	  	   15	   87585285	   87590392	   -­‐119	   1.65E-­‐07	   0.000183268	   -­‐64	   0.000140283	   0.046604968	  
Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	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Table	  14.	  Differentially	  expressed	  genes	  (FDR	  <	  0.05)	  present	  in	  and	  differentially	  regulated	  by	  soy	  
isoflavone	  supplementation	  in	  normal	  tissue	  compared	  to	  tumor	  tissues	  obtained	  from	  4	  men	  
who	  consumed	  soy	  isoflavones	  and	  2	  who	  consumed	  placebo	  (n	  =	  6)	  
	   	   	   	   	   	   	   Normal	  tissue	   Tumor	  tissue	  
	   Gene	  ID	  
Gene	  
abbreviation	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
change	   p-­‐value	   FDR	  
Fold	  
change	   p-­‐value	   FDR	  
1	   ENSG00000121075	   TBX4	   T-­‐box	  4	   17	   59529765	   59562471	   9	   0.000180519	   0.045226933	   -­‐23	   8.97E-­‐08	   0.000170712	  
2	   ENSG00000096006	   CRISP3	   Cysteine-­‐rich	  
secretory	  
protein	  3	  
6	   49695097	   49712150	   -­‐12	   6.41E-­‐08	   9.40E-­‐05	   44	   3.69E-­‐06	   0.00302595	  
Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	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Table	  15.	  Differentially	  expressed	  genes	  (FDR	  <	  0.05)	  down-­‐regulated	  by	  soy	  isoflavone	  
supplementation	  of	  the	  20	  differentially	  expressed	  genes	  present	  in	  both	  normal	  and	  tumor	  
tissues	  obtained	  from	  4	  men	  who	  consumed	  soy	  isoflavones	  and	  2	  who	  consumed	  placebo	  (n	  =	  6)	  
	   	   	   	   	   	   	   Normal	  tissue	   Tumor	  tissue	  
	   Gene	  ID	  
Gene	  
abbreviation	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
chang
e	   p-­‐value	   FDR	  
Fold	  
change	   p-­‐value	   FDR	  
1	   ENSG0000016426
6	  
SPINK1	   Serine	  
peptidase	  
inhibitor,	  
Kazal	  type	  1	  
5	   147204131	   147211349	   63	   1.01E-­‐09	   3.28E-­‐06	   518	   9.04E-­‐11	   5.41E-­‐07	  
2	   ENSG0000017156
4	  
FGB	   Fibrinogen	  
beta	  chain	  
4	   155484108	   155492238	   67	   1.11E-­‐06	   0.00086985
8	  
222	   2.78E-­‐07	   0.000431338	  
3	   ENSG0000023376
0	  
AC004947.2	   	  	   7	   26591441	   26596819	   11	   7.32E-­‐05	   0.02311436
8	  
68	   5.90E-­‐07	   0.00072277	  
4	   ENSG0000017036
9	  
CST2	   Cystatin	  SA	   20	   23804406	   23807368	   27	   1.15E-­‐07	   0.00014183
7	  







7	   55832490	   55840981	   100	   8.43E-­‐09	   1.92E-­‐05	   116	   4.65E-­‐06	   0.003602916	  
6	   ENSG0000015609
6	  






4	   70345883	   70391732	   26	   1.68E-­‐06	   0.00117836
3	  
28	   4.06E-­‐05	   0.020883677	  
7	   ENSG0000017223
8	  
ATOH1	   Atonal	  
homolog	  1	  
(Drosophila)	  
4	   94750042	   94751221	   22	   1.15E-­‐05	   0.00535775
5	  
216	   4.63E-­‐05	   0.021798893	  
8	   ENSG0000024762
7	  
MNTD4P12	   MT-­‐ND4	  
pseudogene	  
12	  





Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	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Table	  16.	  Differentially	  expressed	  genes	  (FDR	  <	  0.05)	  up-­‐regulated	  by	  soy	  isoflavone	  
supplemention	  of	  the	  20	  differentially	  expressed	  genes	  present	  in	  both	  normal	  and	  tumor	  tissues	  
obtained	  from	  4	  men	  who	  consumed	  soy	  isoflavones	  and	  2	  who	  consumed	  placebo	  (n	  =	  6)	  




abbreviation	   Gene	  name	   Chr	   BP	  Start	   BP	  End	  
Fold	  
chang
e	   p-­‐value	   FDR	  
Fold	  





	  	   11	   117006244	   117009298	   -­‐16	   1.90E-­‐07	   0.00020177
6	  









n	  kappa	  variable	  
2-­‐29	  
2	   89533655	   89534393	   -­‐40	   3.89E-­‐06	   0.00219259
3	  






	  	   14	   20105463	   20109540	   -­‐23	   5.50E-­‐07	   0.00052250
9	  
-­‐24	   5.87E-­‐07	   0.00072277	  
5	   ENSG0000026012
5	  
RP11-­‐31E22.1	   	  	   15	   86838880	   86860404	   -­‐44	   5.47E-­‐11	   3.56E-­‐07	   -­‐40	   2.03E-­‐06	   0.0018495	  
6	   ENSG0000018800
0	  
OR7D2	   Olfactory	  
receptor,	  family	  
7,	  subfamily	  D,	  
member	  2	  










	  	   9	   66513488	   66553911	   -­‐19	   6.65E-­‐07	   0.00059473
5	  













OR2A20P	   Olfactory	  
receptor,	  family	  
2,	  subfamily	  A,	  
member	  20	  
pseudogene	  















Chr,	  chromosome;	  BP,	  base	  pair;	  FDR,	  false	  discovery	  rate	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Table	  17.	  Top	  5	  significantly	  enriched	  canonical	  pathways	  expressed	  in	  tumor	  tissue	  
	   Canonical	  Pathways	  
-­‐log(p-­‐
value)	   Ratio	   Molecules	  









NANOG,	  BMP5,	  ZIC3,	  
WNT2	  





4	   Acute	  phase	  response	  signaling	   2.08E00	   2.31E-­‐
02	  
FGB,	  LBP,	  FGA,	  RBP4	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Table	  18.	  Top	  5	  significantly	  enriched	  canonical	  pathways	  expressed	  in	  normal	  tissue	  
	   Canonical	  Pathways	   -­‐log(p-­‐value)	   Ratio	   Molecules	  
1	   Role	  of	  IL-­‐17A	  in	  psoriasis	   2.96E00	   1.54E-­‐01	   S100A7,	  CXCL5	  
2	   Methylglyoxal	  degradation	  VI	   2.42E00	   1E00	   LDHD	  
3	   Glutamate	  dependent	  acid	  resistance	   2.12E00	   5E-­‐01	   GAD2	  
4	   GABA	  receptor	  signaling	   1.87E00	   4.35E-­‐02	   GAD2,	  GABRA4	  
5	   Protein	  citrullination	   1.72E00	   2E-­‐01	   PADI3	  




Table	  19.	  Top	  5	  significantly	  enriched	  canonical	  pathways	  expressed	  in	  both	  normal	  and	  
tumor	  tissues	  
	   Canonical	  Pathways	   -­‐log(p-­‐value)	   Ratio	   Molecules	  
1	   Extrinsic	  prothrombin	  activation	  pathway	   2.14E00	   6.25E-­‐02	   FGB	  
2	   Thyroid	  hormone	  metabolism	  II	   1.93E00	   2.85E-­‐02	   UGT2B4	  
3	   Intrinisic	  prothrombin	  activation	  pathway	   1.9E00	   3.12E-­‐02	   FGB	  
4	   Coagulation	  system	   1.8E00	   2.86E-­‐02	   FGB	  
5	   Nicotine	  degradation	  pathway	  III	   1.69E00	   2.22E-­‐02	   UGT2B4	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Table	  20.	  Specific	  genes	  expressed	  within	  the	  top	  5	  significantly	  enriched	  canonical	  pathways	  
expressed	  in	  normal	  tissue,	  tumor	  tissue,	  and	  both	  tissues	  
	   	   Normal	  tissue	   Tumor	  tissue	  
Genes	   Canonical	  pathways	   Log	  ratio	   p-­‐value	   FDR	   Log	  ratio	   p-­‐value	   FDR	  
UGT2B4	   Thyroid	  hormone	  metabolism	  II	  
Nicotine	  degradation	  III	  
+	  4.717	   1.68E-­‐06	   1.18E-­‐03	   +	  4.784	   4.06E-­‐05	   2.09E-­‐02	  
FGB	   Extrinsic	  prothrombin	  activation	  	  
Intrinsic	  prothrombin	  activation	  	  
Acute	  phase	  response	  signaling	  
Coagulation	  system	  
+	  6.076	   1.11E-­‐06	   8.70E-­‐04	   +	  7.795	   2.78E-­‐07	   4.31E-­‐04	  
S100A7	   Role	  of	  IL-­‐17A	  in	  psoriasis	   +7.276	   1.55E-­‐05	   6.73E-­‐03	   	   	   	  
CXCL5	   Role	  of	  IL-­‐17A	  in	  psoriasis	   +3.972	   3.54E-­‐06	   2.04E-­‐03	   	   	   	  
LDHD	   Methylglyoxal	  degradation	  VI	   -­‐2.592	   6.06E-­‐05	   2.03E-­‐02	   	   	   	  
GAD2	   Glutamate	  dependent	  acid	  
resistance	  
GABA	  receptor	  signaling	  
-­‐6.378	   2.92E-­‐14	   1.33E-­‐09	   	   	   	  
GABRA4	   GABA	  receptor	  signaling	   -­‐3.731	   7.79E-­‐05	   2.37E-­‐02	   	   	   	  
PADI3	   Protein	  citrullination	   -­‐2.546	   1.04E-­‐04	   3.08E-­‐02	   	   	   	  
FGA	   Extrinsic	  prothrombin	  activation	  	  
Intrinsic	  prothrombin	  activation	  	  
Acute	  phase	  response	  signaling	  
	   	   	   +7.814	   4.28E-­‐05	   2.13E-­‐02	  
ZIC3	   Human	  embryonic	  stem	  cell	  
pluripotency	  
	   	   	   +5.719	   1.29E-­‐04	   4.40E-­‐02	  
NANOG	   Human	  embryonic	  stem	  cell	  
pluripotency	  
	   	   	   -­‐5.962	   1.40E-­‐04	   4.66E-­‐02	  
BMP5	   Human	  embryonic	  stem	  cell	  
pluripotency	  
	   	   	   -­‐7.872	   6.66E-­‐16	   2.79E-­‐11	  
WNT2	   Human	  embryonic	  stem	  cell	  
pluripotency	  
	   	   	   -­‐3.640	   9.60E-­‐06	   6.48E-­‐03	  
LBP	   Acute	  phase	  response	  signaling	   	   	   	   -­‐3.466	   1.07E-­‐04	   3.85E-­‐02	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RBP4	   Acute	  phase	  response	  signaling	   	   	   	   -­‐4.010	   1.46E-­‐06	   1.45E-­‐03	  
CFD	   Complement	  system	   	   	   	   -­‐3.151	   9.99E-­‐05	   6.28E-­‐04	  
CR2	   Complement	  system	   	   	   	   -­‐4.850	   2.54E-­‐08	   6.25E-­‐05	  
FDR,	  false	  discovery	  rate	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Table	  21.	  Clinical	  outcomes	  for	  study	  sample	  
	   Patient	   1	   2	   3	   4	   5	   6	  
	   ID	   07	   34	   36	   37	   38	   50	  
	   Treatment	   SOY	   SOY	   PLACEBO	   SOY	   PLACEBO	   SOY	  
	   Gleason	  score	   7	   9	   7	   7	   7	   7	  
Stage	   T2C	  N0	  
M0	  
T3A	  N0	  M0	   T2C	  N0	  M0	  
T2A	  N1	  
M0	  
T2C	  N0	  M0	  
T2C	  N0	  
M0	  
AJCC	   IIB	   III	   IIB	   IIA	   IIB	   IIB	  
Margins	   NEG	   NEG	   NEG	   NEG	   NEG	   POS	  
Seminal	  vesicle	  
invasion	  








NEG	   POS	   NEG	   NEG	   NEG	   NEG	  
PSA	  (ng/mL)	   <0.04	   821.3	   0.00	   0.04	   0.00	   0.00	  
BCR	   NO	   NO	   NO	   NO	   NO	   NO	  
Adjuvant	  
treatment	  
NONE	   ADT/CHEMO	   NONE	   NONE	   NONE	   NONE	  
Salvage	  treatment	   NONE	   NONE	   NONE	   NONE	   NONE	   NONE	  













UNKNOWN	   ALIVE	   ALIVE	   ALIVE	  
AJCC,	  American	  Joint	  Committee	  on	  Cancer;	  PSA,	  prostate	  specific	  antigen;	  BCR,	  biochemical	  recurrence	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Figure	  3.	  Percentage	  of	  genes	  expressed	  in	  the	  dataset	  within	  the	  top	  5	  significantly	  enriched	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Figure	  5.	  Percentage	  of	  genes	  expressed	  in	  the	  dataset	  with	  in	  the	  top	  5	  significantly	  enriched	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Figure	  7.	  Percentage	  of	  genes	  expressed	  in	  the	  dataset	  within	  the	  top	  13	  significantly	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CHAPTER	  V:	  DISCUSSION	  
Potentially	  harmful	  effects	  of	  soy	  isoflavones	  
Normal	  and	  tumor	  tissue	  
	   Canonical	  pathway	  analysis	  revealed	  that	  genes	  within	  the	  extrinsic	  and	  intrinsic	  
prothrombin	  activation	  pathways	  –	  specifically	  the	  fibrinogen	  alpha	  chain	  (FGA)	  and	  the	  
fibrinogen	  beta	  chain	  (FGB)	  genes	  –	  were	  significantly	  up-­‐regulated	  by	  soy	  isoflavones	  in	  
tumor	  tissue.	  FGA	  codes	  for	  the	  alpha	  component	  of	  fibrinogen	  (64);	  FGB	  codes	  for	  the	  
beta	  component	  of	  fibrinogen	  (65).	  One	  study	  identified	  significantly	  up-­‐regulated	  
coagulation	  pathways	  in	  prostate	  cancer	  and	  benign	  prostate	  hyperplasic	  (BPH)	  tissue	  
samples	  (66).	  The	  activation	  of	  the	  extrinsic	  prothrombin	  pathway	  was	  found	  in	  the	  
plasma	  of	  106	  patients	  with	  solid	  tumors	  compared	  with	  72	  healthy	  volunteers,	  and	  
modest	  intrinsic	  prothrombin	  activation	  was	  seen	  only	  in	  those	  cancer	  patients	  with	  
advanced	  disease	  or	  in	  chemotherapy	  patients	  (67).	  Additionally,	  FGA	  and	  FGB	  were	  
found	  to	  be	  significantly	  expressed	  in	  cancerous	  tissue	  of	  mice	  with	  lung	  cancer	  (68).	  
Increased	  FGB	  expression	  has	  been	  associated	  with	  increased	  tumor	  stage	  in	  bladder	  
cancer	  (69).	  These	  two	  genes	  were	  up-­‐regulated	  in	  tumor	  tissue	  after	  exposure	  to	  soy	  
isoflavones,	  suggesting	  a	  potentially	  harmful	  effect	  of	  soy	  isoflavones	  in	  prostate	  cancer.	  
The	  FGB	  gene	  was	  also	  expressed	  and	  up-­‐regulated	  in	  normal	  tissue.	  This	  pathway	  and	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Normal	  tissue	  
Canonical	  pathway	  analysis	  also	  revealed	  that	  the	  role	  of	  IL-­‐17A	  in	  psoriasis	  
pathway	  –	  specifically	  the	  S100	  calcium	  binding	  protein	  (S100A7)	  and	  chemokine,	  C-­‐X-­‐C	  
motif	  (CXCL5)	  genes	  –	  was	  significantly	  up-­‐regulated	  by	  soy	  isoflavones	  in	  normal	  
prostate	  tissue.	  The	  exact	  function	  of	  the	  S100A7	  molecule	  has	  not	  yet	  been	  determined	  
(70);	  however,	  over-­‐expression	  of	  S100A7	  was	  associated	  with	  cell	  survival	  in	  prostate	  
cancer	  cells	  derived	  from	  tumor	  tissue,	  as	  well	  as	  in	  vitro	  invasion	  in	  PC-­‐3	  cells	  (71).	  The	  
CXCL5	  gene	  codes	  for	  chemokines	  that	  may	  promote	  cancer	  cell	  proliferation,	  migration,	  
and	  invasion	  (72).	  CXCL5	  expression	  was	  found	  to	  correlate	  with	  prostate	  cancer	  
progression	  (73).	  The	  up-­‐regulation	  of	  these	  two	  genes	  in	  normal	  prostate	  tissue	  
suggests	  a	  potentially	  harmful	  effect,	  though	  neither	  gene	  was	  present	  in	  actual	  tumor	  
tissue.	  This	  pathway	  and	  these	  genes	  have	  not	  been	  correlated	  with	  the	  effect	  of	  soy	  
isoflavones.	  
	  
Potentially	  beneficial	  effects	  of	  soy	  isoflavones	  
Tumor	  tissue	  
The	  human	  embryonic	  stem	  cell	  pluripotency	  pathway	  was	  significantly	  
modulated	  by	  soy	  isoflavones	  in	  tumor	  tissue.	  The	  ZIC	  family	  member	  3	  (ZIC3)	  gene	  was	  
up-­‐regulated	  by	  soy	  isoflavones	  in	  tumor	  tissue,	  while	  the	  Nanog	  homeobox	  (NANOG),	  
the	  bone	  morphogenetic	  protein	  5	  (BMP5),	  and	  the	  wingless-­‐type	  MMTV	  integration	  
site	  family	  member	  2	  (WNT2)	  genes	  were	  down-­‐regulated	  by	  soy	  isoflavones	  in	  tumor	  
tissue.	  None	  of	  these	  genes	  were	  expressed	  in	  normal	  prostate	  tissue	  (Table	  19).	  The	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human	  embryonic	  stem	  cell	  pluripotency	  pathway	  has	  not	  been	  implicated	  in	  prostate	  
cancer	  specifically;	  however,	  markers	  of	  this	  pathway	  have	  been	  found	  to	  correlate	  with	  
aggressive	  tumors	  (74).	  Mathieu	  et	  al.	  (74)	  found	  a	  significant	  correlation	  between	  
NANOG	  expression	  and	  increased	  Gleason	  score	  in	  primary	  prostate	  tumors.	  BMP5	  and	  
members	  of	  the	  WNT	  gene	  family	  have	  been	  implicated	  in	  tumor	  formation	  (75,76).	  The	  
ZIC	  gene	  family	  has	  been	  found	  to	  be	  significantly	  expressed	  in	  brain	  tumors	  (77).	  
Although	  soy	  isoflavones	  up-­‐regulated	  the	  ZIC3	  gene,	  suggesting	  a	  potentially	  harmful	  
effect,	  they	  also	  down-­‐regulated	  the	  NANOG,	  BMP5,	  and	  WNT2	  genes	  in	  prostate	  tumor	  
tissue,	  suggesting	  a	  potentially	  beneficial	  effect.	  This	  pathway	  and	  these	  genes	  have	  not	  
been	  correlated	  with	  the	  effect	  of	  soy	  isoflavones.	  
The	  complement	  system	  pathway	  –	  specifically	  the	  complement	  factor	  D	  (CFD)	  
and	  the	  complement	  component	  receptor	  2	  (CR2)	  genes	  –	  were	  significantly	  down-­‐
regulated	  by	  soy	  isoflavones	  in	  tumor	  tissue.	  These	  genes	  were	  not	  expressed	  in	  normal	  
tissue	  (Table	  19).	  CFD	  codes	  for	  a	  serine	  protease	  secreted	  by	  adipocytes	  and	  belongs	  to	  
an	  alternative	  complement	  pathway	  known	  for	  its	  role	  in	  humoral	  suppression	  of	  
infectious	  agents	  (78).	  One	  study	  explored	  the	  role	  of	  adipose	  tissue	  as	  a	  source	  of	  
tumor	  progenitor	  cells,	  and	  found	  over-­‐expression	  of	  CFD	  in	  periprostatic	  adipose	  tissue	  
in	  prostate	  cancer	  patients	  (79).	  	  Soy	  isoflavone	  supplementation	  down-­‐regulated	  this	  
gene	  in	  tumor	  tissue,	  suggesting	  a	  beneficial	  effect	  of	  soy.	  CR2	  codes	  for	  an	  Epstein-­‐Barr	  
virus	  receptor	  on	  B	  and	  T	  lymphocytes	  (80).	  The	  expression	  of	  CR2	  and	  other	  genes	  
related	  to	  Epstein-­‐Barr	  virus	  infection	  has	  been	  found	  in	  tumor	  tissues	  of	  patients	  with	  
brain	  cancer,	  breast	  cancer,	  colon	  cancer,	  cervical	  cancer,	  prostate	  cancer,	  and	  EBV-­‐
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negative	  Hodgkin’s	  lymphoma	  (81).	  These	  two	  genes	  have	  been	  implicated	  in	  cancer	  
development,	  appeared	  only	  in	  prostate	  tumor	  tissue,	  and	  were	  down-­‐regulated	  by	  soy	  
isoflavones.	  This	  suggests	  a	  potentially	  beneficial	  effect	  of	  soy.	  This	  pathway	  and	  these	  
genes	  have	  not	  been	  correlated	  with	  the	  effect	  of	  soy	  isoflavones.	  
	  
Normal	  tissue	  
The	  protein	  citrullination	  pathway	  –	  specifically	  peptidyl	  arginine	  deiminase,	  type	  
3	  (PADI3)	  gene	  –	  was	  significantly	  down-­‐regulated	  by	  soy	  isoflavones	  in	  normal	  prostate	  
tissue.	  Protein	  citrullination	  involves	  converting	  arginine	  into	  citrullines	  (82).	  Although	  
protein	  citrullination	  and	  the	  PADI4	  gene	  have	  been	  implicated	  in	  tumor	  growth	  (83,84),	  
the	  PADI3	  gene	  has	  been	  related	  to	  skin	  and	  hair	  formation	  (82).	  The	  down-­‐regulation	  of	  
this	  gene	  in	  prostate	  cancer	  tissue	  samples	  suggests	  a	  potentially	  beneficial	  effect	  of	  soy	  
isoflavones.	  This	  pathway	  and	  this	  gene	  have	  not	  been	  correlated	  with	  the	  effect	  of	  soy	  
isoflavones.	  
The	  methylglyoxal	  degradation	  VI	  pathway	  was	  highly	  significant,	  specifically	  the	  
lactate	  dehydrogenase	  D	  (LDHD)	  gene.	  One	  study	  revealed	  that	  this	  pathway	  was	  up-­‐
regulated	  in	  prostate	  cancer	  cells,	  and	  suggested	  that	  it	  favored	  cancer	  cell	  viability	  and	  
proliferation	  (85).	  Genistein	  at	  12	  mg/kg	  diet	  was	  found	  to	  inhibit	  methylglyoxal-­‐induced	  
apoptosis	  in	  the	  mononuclear	  cells	  of	  female	  Wistar	  rats	  (86).	  The	  LDHD	  gene	  was	  
down-­‐regulated	  by	  soy	  isoflavones	  in	  normal	  prostate	  tissue,	  suggesting	  a	  potentially	  
beneficial	  effect	  of	  soy	  isoflavones	  on	  prostate	  cancer	  progression.	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Unknown	  role	  in	  prostate	  cancer	  
Tumor	  tissue	  
The	  acute	  phase	  response	  signaling	  pathway	  –	  specifically	  the	  FGB,	  FGA,	  
lipopolysaccharide	  binding	  protein	  (LBP),	  and	  retinol	  binding	  protein	  4	  (RBP4)	  genes	  –	  
were	  significantly	  modulated	  by	  soy	  isoflavones	  in	  tumor	  tissue.	  The	  acute	  phase	  
response	  signaling	  canonical	  pathway	  was	  found	  to	  be	  significantly	  up-­‐regulated	  in	  
prostate	  cancer	  and	  benign	  prostate	  hyperplasic	  (BPH)	  tissue	  samples	  (66).	  As	  
mentioned	  previously,	  the	  FGB	  gene	  was	  significantly	  up-­‐regulated	  by	  soy	  isoflavones	  in	  
both	  normal	  and	  tumor	  tissues.	  The	  FGA	  gene	  was	  up-­‐regulated	  only	  in	  tumor	  tissue,	  
and	  was	  not	  present	  in	  normal	  tissue.	  The	  LBP	  and	  RBP4	  genes	  were	  both	  down-­‐
regulated	  by	  soy	  isoflavones	  in	  prostate	  tumor	  tissue.	  Neither	  LBP	  or	  RBP4	  have	  been	  
implicated	  in	  oncogenesis,	  but	  they	  are	  both	  involved	  in	  the	  inflammatory	  response	  
(87,88).	  The	  inflammatory	  response	  has	  been	  linked	  to	  cancer	  development	  and	  
progression.	  Because	  LBP	  (89)	  and	  RBP4	  (90)	  genes	  code	  for	  pro-­‐inflammatory	  proteins,	  
the	  down-­‐regulation	  of	  LBP	  and	  RBP4	  suggest	  a	  preventative,	  potentially	  beneficial	  
effect	  of	  soy	  isoflavones.	  Half	  of	  the	  genes	  expressed	  in	  this	  pathway	  were	  related	  to	  
cancer	  development	  and	  significantly	  up-­‐regulated,	  while	  the	  other	  half	  were	  related	  to	  
potential	  protective	  effects	  and	  were	  significantly	  down-­‐regulated.	  This	  suggests	  
conflicting	  effects	  of	  soy	  isoflavones,	  making	  it	  difficult	  to	  evaluate	  the	  benefit	  of	  soy	  
supplementation	  in	  prostate	  cancer.	  This	  pathway	  and	  these	  genes	  have	  not	  been	  
correlated	  with	  the	  effect	  of	  soy	  isoflavones.	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Normal	  tissue	  
The	  glutamate	  dependent	  acid	  resistance	  pathway	  was	  also	  highly	  significant.	  
The	  glutamate	  acid	  decarboxylase	  2	  (GAD2)	  gene	  was	  down-­‐regulated	  by	  soy	  
isoflavones	  in	  normal	  prostate	  tissue.	  The	  GAD2	  gene,	  along	  with	  the	  down-­‐regulated	  
gamma-­‐aminobutryic	  acid	  receptor	  4	  (GABRA4)	  gene,	  was	  also	  present	  in	  the	  GABA	  
receptor	  signaling	  pathway.	  Hudgens	  et	  al.	  found	  that	  estradiol	  stimulated	  GAD2	  
expression	  in	  rats,	  the	  gene	  that	  codes	  for	  the	  enzyme	  primarily	  responsible	  for	  GABA	  
synthesis	  (91).	  The	  structural	  similarity	  between	  soy	  isoflavones	  and	  estrogens	  may	  
explain	  how	  they	  affected	  the	  expression	  of	  GAD2	  in	  this	  study,	  though	  one	  would	  
expect	  up-­‐regulation	  instead	  of	  down-­‐regulation.	  The	  role	  of	  these	  pathways	  and	  these	  
genes	  in	  prostate	  cancer	  development	  and	  progression	  remains	  unknown.	  This	  pathway	  
and	  these	  genes	  have	  not	  been	  correlated	  with	  the	  effect	  of	  soy	  isoflavones.	  
	  
Overlapping	  pathways	  
The	  UDP-­‐glucuronosyltransferase	  2	  family,	  polypeptide	  B4	  (UGT2B4)	  gene	  was	  
up-­‐regulated	  by	  soy	  isoflavones	  in	  both	  normal	  and	  tumor	  tissues.	  This	  gene	  is	  a	  part	  of	  
the	  thyroid	  hormone	  metabolism	  III	  and	  nicotine	  degradation	  pathways,	  which	  have	  not	  
yet	  been	  correlated	  with	  prostate	  cancer.	  Enzymes	  from	  UGT2B	  family	  affect	  
metabolism	  and	  excretion	  of	  steroids	  (92).	  Though	  this	  gene	  has	  not	  been	  linked	  with	  
prostate	  cancer	  specifically,	  Lampe	  et	  al.	  (92)	  found	  that	  the	  prevalence	  of	  UGT2B4	  was	  
significantly	  higher	  in	  people	  of	  Asian	  descent	  compared	  with	  Caucasians,	  and	  that	  all	  
Asians	  were	  homozygous	  for	  UGT2B4	  compared	  with	  Caucasians,	  potentially	  explaining	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the	  soy	  isoflavone	  intake,	  Asian	  population,	  and	  reduced	  prostate	  cancer	  incidence	  link.	  
This	  pathway	  and	  this	  gene	  have	  not	  been	  correlated	  with	  the	  effect	  of	  soy	  isoflavones.	  
	  
Strengths	  and	  limitations	  
The	  majority	  of	  this	  study’s	  limitations	  originate	  from	  the	  retrospective	  study	  
design.	  The	  quantity	  and	  quality	  of	  the	  biospecimen	  inventory	  was	  affected	  due	  to	  lack	  
of	  control	  over	  data	  storage	  and	  collection.	  Because	  of	  this,	  the	  prostatectomy	  samples	  
available	  for	  RNA	  sequencing	  were	  limited	  to	  6,	  rather	  than	  the	  expected	  14	  
prostatectomy	  samples.	  As	  the	  samples	  were	  banked	  for	  several	  years	  prior	  to	  their	  
present	  use,	  the	  storage	  conditions	  and	  therefore	  the	  quality	  of	  the	  samples	  may	  have	  
been	  affected.	  Additionally,	  the	  amount	  of	  blood	  lost	  during	  surgery	  and	  the	  distribution	  
of	  epithelial	  and	  stromal	  tissues	  in	  the	  prostatectomy	  sample	  have	  been	  found	  to	  affect	  
the	  quality	  of	  the	  RNA	  (18).	  The	  parent	  study	  did	  not	  track	  these	  particular	  variables,	  but	  
quality	  control	  was	  conducted	  before	  sequencing,	  and	  all	  RNA	  samples	  had	  RNA	  
integrity	  numbers	  (RIN)	  over	  2.80,	  indicating	  good	  quality.	  	  
The	  choice	  of	  isoflavone	  supplement	  provided	  proportionally	  more	  daidzein	  than	  
isoflavone	  supplements	  derived	  from	  whole	  soybeans.	  Whole	  soy	  products	  provide	  an	  
average	  isoflavone	  distribution	  of	  50%	  genistein,	  40%	  daidzein,	  and	  10%	  glycitein,	  while	  
soy	  germ	  products	  provide	  15%	  genistein,	  40%	  daidzein,	  and	  40%	  glycitein.	  The	  majority	  
of	  reviewed	  studies	  focused	  on	  products	  derived	  from	  whole	  soy	  or	  on	  genistein	  
specifically,	  making	  it	  difficult	  to	  compare	  the	  findings.	  However,	  the	  supplement	  does	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represent	  a	  human	  physiological	  isoflavone	  dose	  so	  significant	  effects	  should	  be	  
reproducible	  in	  humans.	  	  
Although	  the	  study’s	  sample	  size	  was	  small,	  the	  reviewed	  RNA	  sequencing	  
human	  interventions	  ranged	  from	  3	  to	  16	  participants.	  A	  strength	  of	  the	  present	  study	  
was	  its	  use	  of	  normal/tumor	  tissue	  pairs,	  as	  few	  studies	  studied	  the	  transcriptomes	  of	  
human	  tissue	  and	  used	  cell	  lines	  or	  blood	  cells	  instead.	  The	  relatively	  short	  2	  to	  4	  week	  
dietary	  intervention	  period	  was	  originally	  thought	  to	  be	  a	  limitation,	  though	  the	  
majority	  of	  interventions	  employed	  in	  the	  reviewed	  studies	  induced	  a	  significant	  change	  
in	  the	  transcriptome	  of	  cells	  in	  as	  little	  as	  2	  weeks.	  The	  original	  protocol	  did	  not	  require	  
an	  extensive	  diet	  history,	  making	  it	  difficult	  to	  control	  for	  confounding	  dietary	  factors.	  	  
Human	  transcriptomic	  studies	  are	  few,	  especially	  when	  focusing	  specifically	  on	  
soy	  isoflavones	  and	  prostate	  cancer.	  No	  studies	  reviewed	  had	  investigated	  the	  
transcriptome	  of	  prostate	  cancer	  cells	  using	  RNA	  sequencing.	  Using	  NGS	  RNA	  seq	  
technology	  provides	  for	  much	  more	  detailed	  data.	  	  
	  
Conclusion	  
This	  study	  provided	  an	  opportunity	  to	  observe	  the	  effects	  of	  short-­‐term	  soy	  
supplementation	  on	  the	  transcriptome	  in	  a	  human	  model	  and	  found	  that	  many	  of	  the	  
top	  pathways	  expressed	  in	  normal	  and	  cancerous	  prostate	  tissue	  were	  related	  to	  cancer	  
processes	  and	  regulated	  by	  soy	  isoflavones.	  The	  data	  provided	  useful	  common	  pathway	  
maps	  for	  future	  understanding	  of	  the	  role	  of	  soy	  isoflavones	  in	  prostate	  cancer	  
prevention,	  development,	  and	  progression.	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Soy	  isoflavones	  differentially	  expressed	  128	  genes	  in	  cancerous	  prostate	  tissue	  
and	  166	  genes	  in	  normal	  prostate	  tissue.	  Twenty	  genes	  were	  expressed	  in	  both	  
cancerous	  and	  normal	  prostate	  tissue,	  two	  of	  which	  were	  differentially	  regulated	  by	  soy	  
isoflavones.	  Soy	  isoflavones	  affected	  tumor	  and	  normal	  cells	  differently.	  Some	  pathways	  
suggested	  a	  protective	  effect,	  such	  as	  the	  down-­‐regulation	  of	  genes	  involved	  in	  the	  
human	  embryonic	  stem	  cell	  pluripotency	  pathway,	  the	  complement	  system	  pathway,	  
the	  protein	  citrullination	  pathway,	  and	  the	  methylglyoxal	  degradation	  VI	  pathway.	  Other	  
pathways	  suggest	  harm,	  including	  the	  up-­‐regulation	  of	  genes	  involved	  in	  the	  extrinsic	  
and	  intrinsic	  prothrombin	  activation	  pathways	  as	  well	  as	  the	  IL-­‐17A	  pathway.	  The	  
following	  pathways	  are	  of	  unknown	  relevance:	  the	  acute	  phase	  response	  signaling	  
pathway,	  the	  UDP-­‐glucuronosyltransferase	  pathway,	  and	  the	  glutamate	  dependent	  acid	  
resistance	  pathway.	  	  
Previous	  soy	  isoflavone	  supplementation	  interventions	  in	  prostate	  cancer	  
patients	  have	  not	  affected	  PSA	  values,	  hormone	  profiles,	  or	  the	  incidence	  of	  
biochemical	  recurrence,	  but	  microarray	  and	  RNA	  sequencing	  data	  suggest	  genetic	  and	  
molecular	  changes.	  The	  clinical	  relevance	  of	  these	  findings	  are	  still	  uncertain.	  Further	  
studies	  are	  needed	  to	  elucidate	  the	  findings	  and	  contribute	  clinically	  applicable	  results.	  
Additionally,	  future	  studies	  that	  compare	  this	  study’s	  data	  with	  online	  data	  repositories	  
would	  be	  warranted.	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